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vAbstract
The present work compilation discusses the creation of improved molecular lymphoma
classifiers and studies the immunological properties of lymphoma antibodies.
Lymphatic system cells are grouped in B, T or natural killer cells according to their
functions. The B cell population is responsible for humoral immunity by secreting
antibodies and presenting antigen fragments in its surface. When malignantly transformed,
B cells can develop into what is described as B cell lymphoma.
Burkitt lymphoma (BL) is a rare type of B cell lymphoma characterised by its
hallmark chromosomal translocation [t(8;14)] involving the c-Myc oncogene and the
immunoglobulin heavy chain locus (IGH@). Burkitt lymphoma shares some
immunohistochemical (IHC), morphological and genetic characteristics with the most
frequent lymphoma form: diffuse large B cell lymphoma (DLBCL). Both diseases are
considered aggressive, presenting with severe symptoms and rapid growth. Therefore
distinguishing within and between the two diagnostic entities can, at times, be challenging.
In the past IHC tools were standardised to overcome the categorisation issue. With the
wake of gene expression profile assays lymphoma classification was adapted to newer
methods. The first chapter of this thesis presents two improved aggressive B cell
lymphoma classifiers based on a novel technology that does not require material
amplification, avoiding quantification bias and is able to count actual mRNA molecules to
infer genetic expression levels. On one side the classifier distinguishes molecular BL (mBL)
from non-BL and on the other the distinction is made between DLBCL subtypes. In
chapter two the former classifier is used to understand molecular labelling differences
between BCL2-expressing and non-expressing BL. The co-expression of MYC and BCL2
has been associated with poorer outcome in DLBCL. By assessing the molecular labelling
of BCL2-positive and -negative BL we determined that an expression of the anti-apoptotic
BCL2 protein is not enough to modify the labelling of mBL to another lymphoma subtype
and detect no clinical differences between BCL2-expressing and non-expressing cases.
Chapters three and four focus on the humoral immunity aspect of lymphoma B cells
and their B cell receptors (BcR). The BcR is a complex formed by a transmembranous
immunoglobulin (IG) and the Ig-/Ig- heterodimer facing the cytoplasm. The IG
molecule is in charge of antigen recognition through its variable domain. A wide range of
IG variability is achieved by the so called V(D)J recombination, a procedure that combines
gene segments in the IGH@. Lymphomas present a biased repertoire of IG gene
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recombinations distinct from normal B cells, a phenomenon attributed to antigenic drive.
In chapter three the IG rearrangement of B-cell lymphomas is reviewed, with a focus on
BL. Three V(D)J segments of BL monoclonal antibodies (mAbs) belonging to one same
biased subtype are characterised structurally in silico and studied for their mutation in the
antigen-binding site. By reverting the mutation to its original germline amino acid the
antigen-biding pocket is seen to vary in shape. Chapter four learns from these observations
and performs experimental procedures with phage display and nuclear magnetic resonance
techniques. Four peptides with variable binding affinities are discovered that bind to the
BL mAbs previously characterised and are homologous to various proteins of alimentary
and pathogenic origin.
Summarizing, this thesis presents an improved tool for BL and DLBCL
classification, which can be used for assessing basic science topics as well as avoiding
diagnostic pitfalls. The type of IG in tumoral BL cells and their antigen affinity is assessed,
pointing to an antigenic aetiology.
vii
Zusammenfassung
Die vorliegende Arbeit stellt eine Zusammenfassung von verbesserten molekularen
Lymphom Klassifikatoren und deren Studien über immunologische Eigenschaften von
Lymphom Antikörpern dar.
Die Zellen des lymphatischen Systems werden je nach Funktion in drei Gruppen
eingeteilt, B-Zellen, T-Zellen oder NK-Zellen (Natürliche Killerzellen). Die B-Zell
Population ist für die humorale Immunantwort verantwortlich. B-Zellen produzieren und
sekretieren Antikörper und präsentieren nach Antigenkontakt auch Fragmente auf der
Oberfläche. Bei einer bösartigen Entartung dieser Zellreihen entwickeln sich B-Zell-
Lymphome.
Das Burkitt Lymphom (BL) ist eine seltene Form des B-Zell-Lymphoms, welches
durch seine charakteristische Chromosomale Translokation [t(8;14)] mit Beteiligung des c-
Myc Onkogens und des IGH Lokus (IGH@) typisiert ist. Es hat zusätzlich auch
immunhistochemische (IHC), morphologische und genetische Eigenschaften wie andere,
häufigere Lymphome, z. B. das diffuse large B cell lymphoma (DLBCL). Beide
Erkrankungen sind sehr aggressiv und durch heftige, schlimme Symptome, sowie durch ein
schnelles Wachstum gekennzeichnet. Deshalb ist es manchmal eine Herausforderung
zwischen diesen beiden Entitäten zu unterscheiden. In der Vergangenheit wurden IHC
Methoden und Antikörperauswahl standardisiert, um dadurch eine bessere Kategorisierung
zu erreichen. Mit dem Beginn der Gen Expression Assays wurde die Lymphom
Klassifizierung an neuere Methoden angepasst. Das erste Kapitel dieser Promotionsschrift
zeigt zwei neue Klassifikatoren von aggressiven B-Zell-Lymphomen die durch die
Anwendung einer neuartiger Technologie entwickelt wurden, die keine Vervielfältigung
von Material benötigt, dadurch Amplifikationsprobleme vermeidet, in der Lage ist mRNA
Moleküle zu zählen, und genaue Rückschlüsse auf das genetische Expressions zulässt. Der
Klassifikator unterscheidet molekulare BL (mBL) von non-mBL und zeigt zusätzlich den
Unterschied zu DLBCL Subtypen. Im zweiten Kapitel wird beschrieben, wie der
Klassifikator verwendet wurde, um molekulare Kennzeichnungen zwischen BCL2
exprimierenden und nicht exprimierenden BL zu unterscheiden. Es ist bekannt, dass die
Co-Expression von MYC und BCL2 in DLBCLs mit einer schlechteren Prognose
verbunden ist. In unserer Studie sind keine klinischen Unterschiede zwischen den
untersuchten BCL2 exprimierenden und nicht exprimierenden Fällen erfunden worden. Bei
der Auswertung der molekularen Ergebnisse von BCL2 positiven und negativen BL
konnten wir allerdings feststellen, dass die Expression des anti-apoptotischen BCL2
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Proteins nicht ausreicht, um die Kennzeichnung eines mBL in einen anderen molekularen
Subtypen zu verändern.
Die Schwerpunkte in Kapitel drei und vier beziehen sich auf die humorale
Immunantwort bei B-Zell-Lymphomen und den B-Zell-Rezeptoren (BcR). Der BcR ist ein
aus einem transmembranären Immunglobulin (IG) und den Ig-alpha/Ig-beta Heterodimer
geformter Komplex. Das IG Molekül ist durch seine variable Domäne für die
Antigenerkennung hauptverantwortlich. Eine große Reichweite der IG Variabilität wird
durch die so genannten V(D)J Rekombination erreicht, ein Ablauf bei dem Gensegmente
im IGH@ neu kombiniert werden. Lymphome stellen ein biased Repertoire der IG-Gen
Rekombination dar, welche sich von normalen B-Zellen unterscheidet, ein Phänomen,
welches auf antigen drive zurückzuführen ist. In Kapitel drei wurde das IG Rearrangement
von B-Zell-Lymphomen, mit dem Schwerpunkt auf BL, untersucht. Immunoglobulin-Gen
V(D)J Segmente von drei BL monoklonalen AK (mAK) mit bestimmte Subtypen wurden
strukturell in silico charakterisiert und auf vorhandene Mutationen in der Antigen-
Bindungsstelle geprüft. Beim Zurückleiten auf die ursprüngliche Keimbahnsequenz der
Aminosäuren für die Antigen-Bindungstasche ergaben sich leicht veränderte Strukturen. In
Kapitel vier werden die experimentellen Verfahren und Durchführungen mit phage display
und nuclear magnetic resonance Technik beschrieben. Dabei wurden vier Peptide mit variablen
Bindungsaffinitäten entdeckt, die sich spezifisch an die in Kapitel drei erwähnten BL mAK
binden. Die Peptide sind homolog zu verschiedenen Proteinen des Verdauungstrakts
und/oder pathogenen Ursprungs.
Zusammenfassend liefert diese Promotionsschrift neue Hilfsmittel für die
differentielle BL/DLBCL Klassifikation, welche sowohl in der Grundlagenforschung als
auch für die Vermeidung von diagnostischen Fehleinschätzungen genutzt werden kann.
Der IG Typ und die entsprechende Affinität wurde in malignen BL Zellen bestimmt und
weist auf eine Antigen-vermittelte Ätiologie hin.
1General introduction
Cancer epidemiology in Europe
Cancer affects a considerable segment of the population. The latest large study for
cancer incidence and mortality reported a total of 355.7 cases per 100 000 inhabitants in
data from 2012 and a mortality rate of 1 754 600 in the same year, which accounts for more
than a quarter (26.3%) of all deaths of 2011 in the EU-28 countries [1].
Malignant neoplasms show different standardised mortality rates according to
gender, being those of men (370.3) significantly higher than those of women (207.1) [1].
Cancers are also of a varied nature and origin, with prostate and breast malignancies being
the most frequent in men and women respectively [2], but also include colorectal, lung,
lymphoid and hematopoietic cancers.
Lymphomas are classified as Hodgkin (17 600 new cases in Europe in 2012) and
non-Hodgkin lymphomas (NHL). A total of 93 500 new NHL cases were diagnosed in
Europe in 2012, making it the 11th most common cancer in the region [3]. Lymphomas are
a group of cancers originating in the lymphatic system cells, the lymphocytes. Mainly
involved in immunological functions, lymphocytes known to be of the B-, T- or natural
killer cell type depending on where they mature.
Thus, B-cell lymphomas are malignant neoplasms where the tumoral cell
component is of the B-cell lymphocyte population. They are named aggressive if their
symptoms are severe and tumor growth is rapid in contrast to the low grade types.
Up to one third of childhood neoplasms are NHL [4]. Burkitt lymphoma (BL)
makes up 40% of all paediatric NHL cases and accounts for 1-2% of all lymphomas in
adults [5,6] in the western world [7]. In the adult population, however, the most frequent
type of NHL is diffuse large B-cell lymphoma (DLBCL).
Burkitt lymphoma
Characteristics and typification
Burkitt lymphoma carries the name of its discoverer, who first described it in 1953 in
African children, although Sir Albert Cook wrote about similar clinical traits in children 66
years earlier. The three main types of BL are the endemic (eBL), sporadic (sBL) and the
immunodeficient-related variants. All three variants have relevant differences in its
presentation and geographical prevalence. The eBL variant is geographically present in
what is known as the malaria or equatorial belt and appears in the submandibular area of
suffering patients, mostly children and young adults [8]. The sBL variant is located
worldwide and appears mainly in the thorax region of children and young adults. The third
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variant is explained by the immunodeficiency of its suffering patients [9]. Without
treatment the lymphoma courses aggressively, having a tumour size doubling time of as
little as 24 hours.
The microscopical morphology of BL is characterized by the starry sky pattern,
with more than 90% of the tumoral cells being positive for the proliferation marker Ki67.
In some immunohistochemical and clinical characteristics BL can resemble those of
DLBCL. Hence, a clear line dividing both lymphoma entities is non-existent. A subgroup
of cases with characteristics shared between BL and DLBCL is recognised by the WHO
and names it intermediate subtype [10]. Within DLBCL there are three subgroups, namely
the activated B-cell (ABC), the germinal centre B-cell-like (GCB), and the unclassifiable
subtypes. They are prognostically relevant and their therapeutic regimens are distinctive
[11].
Moreover, considerable amounts of archival biopsy material are available in many
research and clinical centres. A need for adapting novel profiling techniques to paraffin-
embedded biopsies was detected and assessed in our group. The first two chapters of the
present thesis aims at improving BL and DLBCL classification while taking advantage of
the wide sample collection available in our facilities.
B-cell receptors
Burkitt lymphoma is defined molecularly by its hallmark translocation between
chromosome 8 and 14. The t(8;14) locates the c-Myc oncogene under control of the
immunoglobulin heavy chain locus (IGH@) promoter. This results in an overexpression of
the MYC protein and mistakes in the V(D)J gene segment assembly [12], responsible to
build the antigen-binding site of the B-cell receptors (BcR).
B-cell receptors are transmembranous complexes formed by an immunoglobulin
(IG) molecule and the intra-transmembranous heterodimer Ig-/Ig-. The latter
component of the BcR is involved in intracellular signal transduction. The IG molecule is
formed by two heavy and two light chains, named as such due to their length and
molecular weight. Each heavy chain binds to a light chain by one disulphide bond and the
two heavy chains contact each other via two more disulphide bonds in their hinge regions
(the central part of the Y). Each heavy and light chain contains a variable and a constant
domain, the latter being longer in heavy chains, explaining its bigger size. The variable
domain is made up of three regions, called variable (V), diversity (D, only in heavy chains)
and joining (J) gene segments. There are 77 V(D)J gene segments in the human IGH@,
while IGK@ and IGL@ (the light chain loci) present only V and J segments. One single
gene for each segment type is used to build a new variable domain in a genetic procedure
called V(D)J or somatic recombination. It occurs in the primary lymphatic organs- that is
3the bone marrow for B-lymphocytes. Briefly, the recombination activating genes RAG1
and RAG2 mediate the recombination procedure [13]. RAG1 binds to recombination
signal sequences located between each V, D and J segment, and RAG2 is then recruited to
form a RAG1/2 complex that will mediate a double-stranded DNA break. Firstly a D and
a J segment are randomly selected and joined by a non-homologous end-joining procedure,
forming one DJ coding joint and one signal joint or loop, containing the DNA excised
from between the two joined segments. The excised loop will be degraded. The same
procedure is repeated to join a V to a DJ segment. In case of a light chain recombination,
where there are no D segments, the only coding joint created is between a V and a J
segment.
Most importantly, IGs are able to recognise antigenic bodies by affinity binding to
their antigen-binding sites (ABS). These ABS are composed of complementarity
determining regions (CDR) within the variable domains of the IG heavy and light chains.
The great sequence variability of IGs is achieved by V(D)J recombination and somatic
hypermutation (SHM) of the CDRs [14]. Somatic hypermutation is a genetic alteration
mechanism by which mutations are introduced in specific regions of IG genes in order to
increase their sequence variability. The procedure is highly regulated by activation-induced
deaminase (AID), which transforms the cytosine nucleotides to uracil. The resulting uracil-
guanosine nucleotide pair is mutagenic, generating a thymidine in the forthcoming DNA
replication. By expressing a wide range of V(D)J segment combinations and enduring SHM
BcRs are known to be highly variable in their (appropriately named) variable domains.
Of note, the BcR array expressed in the surfaces of tumoral B-cells is significantly
different than normal B-cells. Such biased IG repertoire points to an antigenic drive and
the phenomenon has been detected in several lymphoma entities so far. The last two
chapters of this thesis focus on this matter with regards to B-cell lymphoma and more
particularly the BL framework.
Aims
This thesis combines the study of diagnostic and classificatory tools with the
immunological and onset analysis of BL.
 Improvement of existing gene expression profiling classifiers
 Exploitation of archival biopsy material
 Study of B-cell lymphoma cohorts
 Review immunoglobulin bias in lymphoma with focus on Burkitt lymphoma
 Determine Burkitt lymphoma antibody epitopes experimentally
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5Chapter 1
1.1 Introduction
Mature aggressive B-cell lymphomas currently present a double challenge when dealt with
conventional methodology: correct entity differentiation and molecular subtype
classification [1].
Differentiation between two clinical entities is useful to overcome potential
diagnostic pitfalls. This can be illustrated with the case of diffuse large B-cell lymphoma
(DLBCL) and Burkitt lymphoma (BL). Sharing histopathological features to DLBCL, BL is
at times a relevant differential diagnostic entity from the former. However, DLBCL and BL
classification is not discrete since a further subentity between the two lymphomas has been
characterised, establishing a molecular continuum. This subentity is defined by the World
Health Organisation (WHO) as “B-cell lymphoma, unclassifiable, with features
intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma” [2] and will be
further referred to as intermediate lymphomas. Morphologically, intermediates lie in the
grey zone between the classic starry sky appearance and monomorphic medium-sized cells
of BL, and the mostly large centroblasts (and sometimes immunoblasts) with broad
cytoplasm of DLBCL cells. The distinction would be mainly of academic relevance if it
weren’t for the fact that patient outcomes are inferior in BL treated with DLBCL regimes
instead of an appropriate BL chemotherapy [3–5]. Thus, establishing a correct diagnosis is
crucial for optimal therapy.
Molecular subclassification helps distinguish clinical subtypes that are not otherwise
easily detected by conventional immunohistochemical (IHC) methods.
In particular, DLBCL can be subclassified in activated B-cell-like type (ABC),
germinal centre B-cell-like type (GCB) and the unclassifiable subtype. These subdivisions
are relevant as they carry a prognostic value [6] and newly developed therapeutic regimes
target these subtype-specific pathomechanisms.
Figure 1.1: Clinical and genetic characteristics of ABC and GCB-like DLBCL [7].
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It is pivotal that pathologists and clinicians are able to differentiate between
aggressive B-cell lymphoma entities and within them, their molecular subtypes. Thus,
several efforts have been made in the past to transfer the molecular definitions of
lymphoma subtypes, based on fresh-frozen biopsies, into IHC classifiers using formalin-
fixed paraffin-embedded (FFPE) biopsies. A summary of previous aggressive B-cell
lymphoma classifications in IHC and gene expression profiling (GEP) follows.
Aggressive B-cell lymphoma classifiers - a background
Gene expression profiling has proven to be a very useful tool to understand cancer entities
as well as to determine their transcriptional convergences and divergences. Some classifier
approaches were based on molecular or GEP, well defining the molecular Burkitt
lymphomas (mBL, clinical BL identified molecularly), intermediate B-cell lymphomas
between DLBCL and mBL, GCB-like, ABC-like and unclassified DLBCL [4, 8-11]. Even a
combination of both IHC and GEP approaches [12] was created by screening their cases
with distinct IHC CD21 expression and then clustering them with a GCB/non-GCB gene
set.
All these studies used Affymetrix microarray technology and fresh-frozen materials,
due to the bad quality of FFPE-derived RNA of the time. Still, fresh-frozen biopsies are
not always readily available in diagnostic and research facilities. Furthermore, microarray
technology includes a reverse transcription and amplification steps, which can distort real
mRNA expression levels.
Since FFPE materials are more readily available, don’t need sophisticated storage
space and are easy to handle several research groups tried to establish IHC protocols for
lymphoma classification. One of the first IHC-based DLBCL classifier that tried to provide
pathology labs with an easy decision tree to distinguish molecular subtypes was the one
produced by Hans and colleagues [13] in 2004. It was based in tissue microarrays (TMA) of
FFPE biopsies and centred on the GCB – non-GCB distinction. Although this was a step
forward at the time the classifier was proven to be weak in assigning subgroups a
prognostic factor and was not able to distinguish between the ABC and the unclassified
subtypes within DLBCL.
Figure 1.2: Hans et al. decision tree for DLBCL classification[13].
7In 2006 an improved classifier by Muris et al. [14] introduced Bcl-2 as a decisive
marker. Group 1 was described to have a low clinical risk and group 2 (likely enclosing the
non-GCB subtype) presented a high clinical risk. The algorithm was stated to predict the
odds for complete remission and relapse. The different naming and slightly different
characterization of the groupings makes this classifier not directly comparable to their past
and future counterparts.
Figure 1.3: Muris et al. classifier tree [14].
Three years on, another publication tackled the IHC stratification of DLBCL. The
group from Choi et al [15] created a new algorithm based on 5 IHC markers by validating it
with a GEP tool. The complexity of this new approach allowed a distinction between ABC
and GCB subtypes for the first time. A prognostic group classification was not included in
the algorithm.
Figure 1.4: Choi et al classifier [15].
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These IHC classifiers have in common the omission of BL and thus the lack of the
intermediate group assignment. They also didn’t assess the unclassified DLBCL subtype
and comparison and replication efforts showed their relative unreliability [16].
RNA extraction techniques had lately improved by minimising degradation due to
crosslinking of macromolecules in the purification process. We thus set to generate a
molecular classifying tool for both BL and DLBCL subtypes from FFPE blocks, a more
accessible and obtainable material with a new multiplex gene expression technology [17].
This work is presented in sections 1.2 and 1.3.
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1.2 To the editor:
Molecular classification of mature aggressive B-cell lymphoma using
digital multiplexed gene expression on formalin-fixed paraffin-
embedded biopsy specimens
Neus Masqué-Soler1, Monika Szczepanowski1, Christian W. Kohler2, Rainer Spang2, and
Wolfram Klapper1.
1Department of Pathology, Haematopathology Section and Lymph Node Registry, University
Hospital Schleswig-Holstein, Campus Kiel/Christian-Albrecht University, Kiel, Germany.
2 Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
This piece was published in Blood, on the 12th September of 2013, Vol 122, Num 11 (1985-
1986).
The most frequent mature aggressive B-cell lymphomas are diffuse large B-cell lymphoma
(DLBCL) and Burkitt lymphoma (BL). Patients suffering from molecularly deﬁned BL
(mBL) but treated with a regimen developed for DLBCL show an unfavourable outcome
compared with mBL treated with chemotherapy regimens for BL [1]. Distinguishing BL
from DLBCL by conventional histopathology is challenging in lymphomas that have
features common to both diseases (aggressive B-cell lymphoma unclassiﬁable with features
of DLBCL and BL [intermediates]) [2]. Moreover, DLBCLs are a heterogeneous group of
lymphomas comprising distinct molecular subtypes: the activated B-cell–like (ABC), the
germinal center B-cell–like (GCB), and the unclassifiable subtype as defined by gene
expression profiling (GEP) [3]. Attempts to replace GEP with techniques applicable to
formalin-fixed paraffin-embedded (FFPE) tissue led to algorithms for
immunohistochemical staining (IHS) [4]. Disappointingly, the algorithms yielded
conﬂicting results with respect to their prognostic potential, raising concerns about their
validity [5]. Furthermore, IHS algorithms did not provide a fully resolved classiﬁcation:
they did not identify mBL nor did they separate ABC from unclassiﬁed DLBCLs [4].
We used digital multiplexed gene expression (DMGE) with FFPE-derived RNA to
classify aggressive B-cell lymphomas. Our assay comprised only 30 genes (10 for the
detection of mBL and 20 for the detection of ABC and GCB). We chose these genes by
reanalysis of the microarray data reported in a previous study [6]. A detailed description of
the methods is provided in the supplemental Materials on the Blood website. Thirty-nine
samples from mature aggressive B-cell lymphomas were analysed using DMGE (nCounter;
NanoString Technologies, Seattle, WA; see supplemental Materials for detailed methods) of
FFPE- and fresh-frozen–derived RNA. All cases were previously characterized by the
Molecular Mechanisms of Malignant Lymphoma [6] consortium using the Affymetrix
GeneChip technology (gold standard of classiﬁcation).
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Figure 1.5: Digital multiplexed gene expression of mature aggressive B-cell
lymphomas. (A) molecular classification of mature aggressive B-cell lymphomas as mBL, non-
mBL, and intermediates using FFPE-derived RNA. The expression of the genes is colour
A
B
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coded such that high expression is shown in yellow and low expression in blue. The molecular
labels assigned by the array using fresh-frozen RNA and DMGE (nCounter) assay using FFPE-
derived RNA are indicated as coloured labels in the top bars. (B) Molecular classification of
non-mBL using FFPE-derived RNA. The classification according to IHS (Hans), the array
using fresh-frozen RNA and the DMGE assay using FFPE-derived RNA are indicated as
coloured labels in the top bars.
For FFPE-derived RNA, the classiﬁcation of only 2 of 39 samples (5%) differed,
when comparing DMGE-based predictions with the gold standard (array) (Figure 1A). The
2 divergent classiﬁcations were 1 case of mBL that was classiﬁed as intermediate and 1 case
of an intermediate that was classiﬁed as mBL [both lymphomas carried a t(8;14)
translocation]. No major mistake (a classiﬁcation of a non-mBL as mBL or vice versa) was
observed. This performance is comparable with that of DMGE data from fresh-frozen
tissue blocks (supplemental Materials).Compared with the array, 5 of 31 (16%) non-
mBL/DLBCLs received different molecular classiﬁcations using DMGE and FFPE-
derived RNA (Figure 1B). All discrepancies comprised lymphomas that switched between
the unclassiﬁed and ABC or unclassiﬁed and GCB labels. Again, no major mistake (a
classiﬁcation of a GCB as an ABC or vice versa) was observed. In contrast, the Hans IHS
algorithm7 led to major mistakes (2 GCB classiﬁed as non-GCB and 1 ABC as GCB;
Figure 1B).
GEP-based molecular classiﬁcation of mature aggressive B-cell lymphomas is
possible with FFPE-derived RNA at a reasonable cost (<100 Euro) and within a
reasonable period of time (24 hours). To the best of our knowledge, this is the ﬁrst
molecular method for identifying mBL among mature aggressive B-cell lymphomas using
FFPE-derived RNA.
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1.3 Supplementary material to Molecular classification of mature aggressive B-
cell lymphoma using digital multiplexed gene expression on formalin-fixed
paraffin-embedded biopsy specimens.
1.3.1 Supplementary methods
RNA-extraction and assessment of quality
Formalin-fixed paraffin-embedded material was cut in five 10 µm-thick pieces per sample.
Extraction of RNA was done according to the manufacturer’s instructions (ExpressArt
FFPE Clear RNAready Kit, AmpTec, Hamburg, Germany). Fresh-frozen blocks’ RNA was
extracted as previously described [1]. To assess the RNA quality all 43 FFPE-extracted and
the 2 newly extracted fresh-frozen RNA material was analysed with the Agilent RNA 6000
Nano Chips (Agilent Technologies, Santa Clara, California, USA) following the product’s
protocol. As expected, the quality of the FFPE samples were considerably degraded due to
fixation steps but generally all samples yielded enough RNA with fragments at least longer
than 200 nucleotides. A further material quality control is present after RNA processing at
the nCounter instrument for digital multiplexed gene expression due to the company’s
recommendations (see below for summary).
Digital multiplexed gene expression (DMGE)
Straight after a RNA quality measurement and with a known RNA concentration for each
sample, 300ng were able to be hybridised with our custom-designed Reporter Probe (each
with a specific 5’-end colour code signal) and Capture Probe (marked with biotin at the 3’
end). After the overnight hybridisation the samples were ready to load to the Prep Station
where they were washed with a two-step magnetic bead-purification process and loaded in
the 12-well cartridges. Afterwards the cartridges were loaded to the Digital Analyzer (DA,
nCounter, NanoString Technologies Inc., Seattle, WA, USA). The DA resolution was set to
high, meaning that 280 fields of view (FOV) were counted per sample. A comma-
separated-value (.csv) file was obtained after processing. The first control on data-reliability
was done with the FOV-counter to FOV-count ratio, which had to be >80%. Secondly, an
acceptable binding density could not lie outside the 0.05-2.25 interval. Afterwards a data
normalisation was done: individually adding up the internal positive controls and finding an
average value in order to create a normalisation factor for each sample allowed for
cartridge-to-cartridge comparison. The third quality control was visible at this point, since
reliable samples had to show a normalisation factor between 0.3 and 3. Finally, through
each sample’s average internal negative control values, a background subtraction was
performed. After these correction steps, nCounter data of FFPE and fresh frozen samples
were normalized independently from each other using quantile normalization [2] and finally
log2 transformed afterwards.
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Study cohort
All cases were previously characterized by the Molecular Mechanisms of Malignant
Lymphoma (MMML [3]) consortium using the Affymetrix GeneChip® (U133A) technology
(referred to as the gold standard classification). We used the same original total RNA used
for arrays for 48/50 (96%) samples (11 mBL, 12 intermediates and 27 non-mBL, the latter
composed of 10 ABC, 8 GBC, 9 "unclassified"). For 2/50 (4%) cases the original RNA was
exhausted. For these cases total RNA was newly extracted from the same fresh-frozen
tissue blocks used previously for array based GEP. In addition, total RNA was isolated
from corresponding FFPE tissue blocks in 40 cases (ExpressArt FFPE Clear RNAready
Kit, AmpTec, Hamburg, Germany): 9 mBL, 8 intermediates, and 23 non-mBL, the latter
composed of 9 ABC, 8 GBC, and 6 unclassified. For 39 cases GEPs from both fresh-
frozen material and the FFPE tissue blocks were available (Supplementary Figure 1#).
Selection of genes and bioinformatics
A subset of 5/74 probe sets from the original mBL signature (representing the genes
SMARCA4, CD44, RNASEH2B, PRKAR2B, and CTSH) proved to be sufficient to
classify mBL and non-mBL cases correctly. However, we also found that the small number
of signature genes comes with a price. The robustness of the classification with respect to
measurement errors is reduced. We thus selected one back-up gene for all five genes. This
was always the gene on the microarray with the highest correlation to the signature gene
across all training samples (12). These 5 genes (TCF3, STAT3, NASP, PRDM10, and
BCL2A1) together with the 5 previous genes form the mBL set of the assay. In the same
way, we chose 10 genes from the GCB/ABC signature [4] and supplemented them with 10
back-up genes, giving us the ABC/GCB set of the assay. Supplementary table 1* gives a
complete list of the classifier’s 30 genes with their NCBI reference numbers.
With our final 30 gene assay we obtained GEP for 50 fresh-frozen samples from
mature aggressive B-cell lymphomas using DMGE. To obtain molecular classifications of
“mBL”, “intermediate”, and “non-mBL” from DMGE data, we first trained a linear
regression function to predict the mBL index [1] of lymphomas using the 10 genes of the
mBL set. We used least-angle regression [5] and predicted all mBL-index values in leave-
one-out cross-validation. We then calibrated two cut-off values C1 and C2 on the predicted
mBL-index values and labelled a case “mBL” if the predicted index was below C1. If it was
above C2 we labelled it “non-mBL”, and otherwise “intermediate”. This procedure was
repeated independently for frozen and FFPE derived data.
__________________________________________________________________________
# Currently figure 1.6
* Currently table 1.1
Note: More information on the Code Set gene selection can be found in section 1.4.1
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1.3.2 Supplementary figures
Figure 1.6*: Description of the study cohort.
__________________________________________________________________________
* Figure 1.6 (in original publication, “Supplementary figure 1”) shows the experiment
workflow and sample dimensions.  Orange boxes hold cohort specifications for the mBL –
non-mBL classifier and green boxes do so for the GCB-ABC classifier. A total of 39 sample
data was available from the same biopsy in FFPE and fresh-frozen material RNA. They were
classified with the mBL - non-mBL algorithm. Thirty samples were clustered with our GCB-
ABC classifier and compared between their FFPE and cryo biopsy counterparts. Data from the
Molecular Mechanisms of Malignant Lymphoma consortium (see section 1.2, reference 6) was
available from the fresh-frozen samples, which had been classified according to data from
Affymetrix’s GeneChip® processing.
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Figure 1.7: (A) Molecular classification of mature aggressive B-cell lymphomas as
mBL, non-mBL and intermediates using cryo-block (fresh frozen)-derived RNA. The
expression of the genes is displayed in a colour code with high expression in yellow and low
expression in blue. The molecular labels assigned by the array using fresh-frozen RNA and
DMGE (nCounter) assay using fresh frozen-derived RNA are indicated as coloured labels in
the top bars. (B) Molecular classification of non-mBL using fresh frozen-derived RNA. The
classification according to the immunohistochemical staining (Hans [6]), the array using fresh-
frozen RNA and DMGE assay using fresh frozen-derived RNA are indicated as coloured
labels in the top bars.
A
B
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1.3.3 Supplementary tables
Table 1.1*: Genes analysed.
__________________________________________________________________________
* Table 1.1 (originally “supplementary table 1” in publication) shows the signature
genes with their accession numbers. Core genes of each classifier are marked in red and in
black are back-up genes.
Endogenous
controls
Accession
number
GUSB NM_000181.1
EPHB3 NM_004443.3
INE1 NR_024616.1
EML2 NM_012155.2
mBL signature Accession number
BCL2A1 NM_004049.2
CD44 NM_001001392.1
CTSH NM_148979.2
NASP NM_172164.1
PRDM10 NM_020228.2
PRKAR2B NM_002736.2
RNASEH2B NM_001142279.1
SMARCA4 NM_003072.3
STAT3 NM_139276.2
TCF3 NM_003200.2
GCB/ABC signature Accession number
BATF NM_006399.3
C3orf37 NM_020187.2
CCND2 NM_001759.3
CPNE3 NM_003909.2
DBI NM_001079862.1
ENTPD1 NM_001098175.1
IGHM ENST00000390559.1
IGLJ3 ENST00000390324.1
IL16 NM_004513.4
ITPKB NM_002221.3
LRMP NM_006152.2
MME NM_000902.2
MYBL1 NM_001080416.2
PIM1 NM_002648.2
RAB7L1 NM_001135664.1
SH3BP5 NM_001018009.2
SKAP2 NM_003930.3
TBXA2R NM_001060.3
TNFRSF1B NM_001066.2
TPD52 NM_001025252.1
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mBL classifier
Table continued on next page
GEP
SAMPLE Array DMGE frozen DMGE FFPE
MPI‐043 mBL mBL mBL
MPI‐084 mBL mBL mBL
MPI‐347 non‐mBL non‐mBL non‐mBL
MPI‐407 intermediate intermediate intermediate
MPI‐528 mBL intermediate mBL
MPI‐584 non‐mBL non‐mBL non‐mBL
MPI‐586 mBL mBL mBL
MPI‐590 mBL intermediate mBL
MPI‐618 mBL mBL mBL
MPI‐619 intermediate intermediate mBL
MPI‐621 mBL mBL intermediate
MPI‐626 intermediate intermediate intermediate
MPI‐698 intermediate intermediate intermediate
MPI‐700 intermediate intermediate intermediate
MPI‐795 non‐mBL non‐mBL non‐mBL
MPI‐812 non‐mBL non‐mBL non‐mBL
MPI‐822 non‐mBL non‐mBL non‐mBL
MPI‐831 non‐mBL non‐mBL non‐mBL
MPI‐841 non‐mBL non‐mBL non‐mBL
MPI‐842 non‐mBL non‐mBL non‐mBL
MPI‐846 non‐mBL non‐mBL non‐mBL
MPI‐847 non‐mBL non‐mBL non‐mBL
MPI‐848 non‐mBL non‐mBL non‐mBL
MPI‐850 intermediate intermediate intermediate
MPI‐852 intermediate intermediate intermediate
MPI‐859 intermediate intermediate intermediate
MPI‐860 non‐mBL non‐mBL non‐mBL
MPI‐864 non‐mBL non‐mBL non‐mBL
MPI‐865 non‐mBL non‐mBL non‐mBL
MPI‐869 non‐mBL non‐mBL non‐mBL
MPI‐873 non‐mBL non‐mBL non‐mBL
MPI‐875 non‐mBL non‐mBL non‐mBL
MPI‐881 non‐mBL non‐mBL non‐mBL
MPI‐885 mBL mBL mBL
MPI‐895 mBL mBL mBL
MPI‐900 non‐mBL non‐mBL non‐mBL
MPI‐901 non‐mBL non‐mBL non‐mBL
MPI‐902 non‐mBL non‐mBL non‐mBL
MPI‐905 non‐mBL non‐mBL non‐mBL
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GCB-ABC classifier
Table 1.2*: Complete list of classifications according to array, IHS (Hans Algorithm
[6]), DMGE using cryo-derived RNA, DMGE using FFPE derived RNA. Lymphomas with
divergent classification between the assays are labelled in bold. Only lymphomas of the final
cohort for which both array and DMGE data were available are shown. DMGE: digital
multiplex gene expression.
__________________________________________________________________________
* Table 1.2 : Originally “Supplementary Table 2” in publication.
GEP
SAMPLE IHS (Hans) Array DMGE frozen DMGE FFPE
MPI-347 non-GCB ABC ABC ABC
MPI-407 GCB GCB GCB GCB
MPI-584 GCB GCB GCB GCB
MPI-619 GCB GCB GCB GCB
MPI-626 GCB GCB GCB GCB
MPI-698 GCB GCB GCB GCB
MPI-700 GCB GCB GCB GCB
MPI-795 non-GCB ABC unclassified unclassified
MPI-812 N/A ABC ABC unclassified
MPI-822 non-GCB ABC ABC ABC
MPI-831 N/A unclassified unclassified unclassified
MPI-841 N/A ABC ABC ABC
MPI-842 GCB ABC unclassified unclassified
MPI-846 non-GCB unclassified unclassified unclassified
MPI-847 non-GCB GCB GCB GCB
MPI-848 N/A unclassified GCB GCB
MPI-850 GCB GCB GCB GCB
MPI-852 GCB GCB GCB GCB
MPI-859 GCB GCB GCB GCB
MPI-860 N/A unclassified unclassified unclassified
MPI-864 non-GCB ABC ABC ABC
MPI-865 N/A ABC ABC ABC
MPI-869 GCB GCB GCB GCB
MPI-873 GCB GCB GCB GCB
MPI-875 GCB GCB GCB GCB
MPI-881 non-GCB ABC ABC ABC
MPI-900 GCB GCB unclassified unclassified
MPI-901 N/A GCB GCB GCB
MPI-902 non-GCB unclassified unclassified unclassified
MPI-905 N/A unclassified unclassified unclassified
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1.4 Additional data
The following materials are intended to be complementary to the above exposed contents
and are previously unpublished.
1.4.1 Material and Methods
nCounter technology
Previous methods used for gene expression studies included reverse-transcription and
amplification of the analytes. In the original NanoString technology [1] a pair of primer-like
probes is built per analysable gene. The probes are named capture and reporter probes.
Capture probes are made of (5’ to 3’): a 35-50 nucleotide-long sequence homologous to a
mRNA of interest, a repeats region, a biotin tag and a repeat sequence at its 3’ end
(common to all capture probes). Reporter probes are composed of (3’ to 5’): 35-50
nucleotides homologous to mRNA fragment, followed by an ssDNA backbone bound to
RNA coloured fragments. The coloured fragments build a colour tag that is specific for the
sequence that will be recognized by the probe pair. At the 5’ of the reporter probes there is
also a common repeat sequence to all reporter probes. The reporter and capture probes
plus their spiked-in control molecules are named Code Set. Six capture and reporter pair
probes are spiked-in for positive control purposes and eight probe pairs are present as
negative controls. Positive and negative controls are also useful for normalization purposes,
since they are present in known quantities in the Code Set.
The Code Set is hybridised overnight to the isolated mRNA. The capture and
reporter probes interact to and bind the homolog sequences found in the mRNA, forming
a tripartite molecule. After the hybridization the probe and mRNA mix is placed in the
Prep Station (PS), which in turn is loaded with reagent, materials and an acrylic glass
cartridge. Each cartridge has twelve lanes, one for each sample to be analysed and is
processed individually in the PS. Unhybridized probes are removed in the washing steps
through affinity purification. The samples are then loaded by the PS’s robot arm to the
streptavidin-coated lanes of the cartridge. The biotin molecules of the tripartite structures
stick to the cartridge lanes. In each lane the PS applies a 160 V/cm electric current so that
the bound molecules lay in the same direction. Finally, biotinylated anti-5’ oligonucleotides
are introduced in the lanes, binding to the 5’ repeats end of the reporter probes (purple
strand in figure 1.8-A and -B). This ensures that the tripartite molecules are immobilized
horizontally to the lane base. When the current is turned off the molecules lay in the same
direction with minimal crisscrossing.
After the samples are loaded in the PS to the cartridge, it is placed into the Digital
Analyzer (DA) which scans each lane to retrieve images of the coloured tags. Each
coloured tag is a reporter probe attached to a single specific mRNA molecule. The DA is
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equipped with a microscopic lens and automatically moves underneath the binding surface
of the cartridge through its fields of view (FOV). The more FOV are set up to be counted,
the longer it takes for the DA to finish a scan. There are 25, 100, 280 and 555 FOV with
GEN2 nCounter machines respectively named low, medium, high and max resolution
settings.
Figure 1.8: A: Code Set components, Capture and Reporter probes. B: Capture and
reporter probes schematized. mRNA is the linear molecule in green. After hybridization
tripartite molecules are formed. C: Schematic horizontal placement of the tripartite molecules.
D: Cartridge with its input and output wells per lane. E: Graphic representation of a cartridge’s
lane. Each lane has an input and an output well with a binding surface in between. The samples
are distributed in the middle segment of the lane or binding surface. The squares in the middle
segment represent the possible regions or fields of view (FOV) that each lane possesses. There
are a total of 555 FOV per lane and there are 4 colour channels per region, generating a
maximum of 2200 images per lane, or 26400 images per cartridge. Image source: NanoString.
After the scanning, the DA produces a .csv file after the scanning that can be
processed either with nCounter’s nSolver software or with a standard spreadsheet program.
Each output file contains the rough counts of each scan, including the spiked-in positive
and negative controls.
Custom Code Set composition and bioinformatics methodology
A few further remarks are made in the following lines to deepen the understanding of the
bioinformatics procedure of the initial Code Set construction.
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The 48 genes that assemble our custom Code Set are listed in table 1.3 and were
selected from existing signatures [3-6]. A selection of a subset of genes was performed for
either the mBL or the GCB-ABC classifier with the Least-Angle Regression (LARS) [2]
method. LARS is a statistical algorithm that performs variable selection by fitting linear
regression models on a given set of predictors. In essence, it is based on sequentially adding
the most correlated variables to build a model.
Table 1.3: Custom Code Set composition with a total of 48 genes, including mBL- and
DLBCL-target genes, and endogenous controls.
Samples from Hummel et al. [3] that had been previously classified with the
traditional microarrays were assigned an individual index (single numeric value). The index
value represents the distance from such sample to molecular label cut-off. The limit or cut-
off is specifically a 73-dimensional hyperplane, in our case, separating the mBL from the
non-mBL. The larger a sample’s index is, the further it is from the class-separating
hyperplane and thus the more defined its molecular diagnosis is. In the mBL gene selection
procedure, 73 probeIDs from Hummel et al., [3] were used to run in the LARS algorithm.
In a first step, a LARS model was learned on a training cohort, consisting of a subset
Code Set gene Accession number
BATF NM_006399.3
BCL2 NM_000657.2
BCL2A1 NM_004049.2
BCL6 NM_138931.1
BMP7 NM_001719.1
C3orf37 NM_020187.2
CCND2 NM_001759.3
CCR7 NM_001838.2
CD44 NM_001001392.1
CEBPA NM_004364.2
CPNE3 NM_003909.2
CTSH NM_148979.2
DBI NM_001079862.1
EML2 NM_012155.2
ENTPD1 NM_001098175.1
EPHB3 NM_004443.3
FN1 NM_212482.1
GUSB NM_000181.1
IGHM ENST00000390559.1
IGLJ3 ENST00000390324.1
IL16 NM_004513.4
INE1 NR_024616.1
IRF4 NM_002460.1
ITPKB NM_002221.3
Code Set gene Accession number
LMO2 NM_005574.3
LRMP NM_006152.2
MME NM_000902.2
MMP2 NM_004530.2
MYBL1 NM_001080416.2
MYC NM_002467.3
NASP NM_172164.1
Pecam1 (CD31) NM_000442.3
PIM1 NM_002648.2
PRDM10 NM_020228.2
PRKAR2B NM_002736.2
RAB7L1 NM_001135664.1
RNASEH2B NM_001142279.1
SCYA3 (CCL3) NM_002983.2
SH3BP5 NM_001018009.2
SKAP2 NM_003930.3
SMARCA4 NM_003072.3
STAT3 NM_139276.2
TBXA2R NM_001060.3
TCF3 NM_003200.2
TEK NM_000459.2
THBS1 NM_003246.2
TNFRSF1B NM_001066.2
TPD52 NM_001025252.1
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(n=113 samples; 25 mBL, 26 intermediate and 62 non-mBLs) from Hummel et al.,
generated with the old Affymetrix arrays. This model aims to relearn the index for each
sample with subsets of the initial 73 probeIDs only. Second, the model was used to predict
the individual mBL indexes on the full test cohort from Hummel et al. (n=220; 44, 48 and
128 mBL, intermediate and non-mBLs respectively). Prediction was performed by applying
the LARS model from the training stage with probeID subsets of different sizes starting
with 5 and ending with 20 genes. At each iteration step, an individual index per sample was
predicted and the maximum distance between mBL and non-mBL samples determined
respectively. The gene set that resulted in the maximum overall distance was composed of
5 genes for mBL/non-mBL classification.
The GCB-ABC gene selection was done similarly: Twenty-three probeIDs from the
same previous publication [3] were used to calculate the individual sample GCB-index on a
training set of 92 samples (63 GCBs and 29 ABCs). Following, a test set comprising a total
of 246 GCB and ABCs samples were run on a prediction response test using only 10/23
predictor genes. Care was taken to minimise the misclassification between GCB and ABCs.
Ultimately the gene selection from our initial 48-gene Code Set comprised 10 GCB-
ABC and 5 mBL genes. In addition, for each of these 10 GCB-ABC and 5 mBL genes a
further backup gene was chosen within our Code Set that maximised correlation to its
“partner” gene (see table 1.1). Backup genes are useful if data quality of the primary gene is
not sufficient, making the analysis more stable.
Two classifiers (from FFPE and frozen materials respectively) generated on the
Nanostring platform were learned and are referred to in sections 1.2 and 1.3. The classifier
learning procedure is described in section 1.3.1. Figure 1.6 schematizes the two cohorts
used for such purposes.
1.4.2 Results and Discussion
Array-nCounter labelling comparison
The comparison between our FFPE RNA-derived data and cryo RNA-derived data in
Affymetrix gave a Spearman correlation (rank based) of -0.82 and a total of 2/40 (5%)
samples with discrepant clustering (figure 1.9). One of the two cases had been classified
previously by the array technology as intermediate but as an mBL by ours. The second
misclassified case showed the opposite situation. Both classification shifts were minimal
(see heat map in figure 1.5, A), involving neighbouring subtypes. Moreover the two cases
carried a t(8;14), which is the hallmark translocation for BL, demonstrating that they
rightfully belonged to the group of mBL and intermediates (right side of the heat map).
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As well as the mBL classifier, the new FFPE-derived GCB-ABC labelling system
was juxtaposed with the gold standard classifier. Figure 1.10 plots 31 FFPE samples and
their cryo-preserved counterparts, analysed with our own custom nCounter Code Set and
in the Affymetrix array respectively. The rank based Spearman correlation reached 0.88,
with 5/31 (16%) of misclassifications. Again, as in the mBL classifier, the different labelling
was minor, affecting adjacent DLBCL subtypes. Three of the 5 lymphomas had been
classified as ABC subtype by the array and our algorithm gave them the unclassified label.
The remaining two cases had been one classified as GCB in the array and as unclassified
with our Code Set, and the last case vice versa.
Twenty-three samples of our 31 FFPE-cryo cohort had been also analysed
according to the Hans classifier [7] (see figure 1.5, B). The array fresh-frozen samples had
5/23 (22%) misclassifications to the Hans IHC system, containing 1 case from ABC to
GCB, two cases from unclassified to non-GCB and two cases from GCB to non-GCB.
Three major misclassifications (between non-GCB -or ABC- and GCB) are present. In
comparison, in the nCounter-Hans comparison, one can find 7/23 (30%) divergences,
being 2 of a major character (GCB in nCounter, and non-GCB in Hans).
Figure 1.9: mBL-index comparison of 40 FFPE-originated samples analysed in
nCounter (x axis) and their counterpart cryo RNA-derived samples analysed in Affymetrix (y
axis, as microarray in the graph). Cut-offs for each classifier label are shown (salmon to green
colour change).
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Figure 1.10: GCB/ABC classifier sample clustering representation. Minor
misclassifications between nCounter and array data are indicated with red dots. Cut-offs for
each classifier label are shown.
By comparing the discrepancies it is clear that greater differences are found
comparing the GEP classifiers to the IHC approach than by comparing the GEP classifiers
to each other. Between Affymetrix and nCounter results no major misclassifications were
generated, showing a robust differentiation of the mBL and DLBCL subtypes.
Several groups have established protocols for GEP on FFPE tissues using different
technologies including microarrays [7], whole genome cDNA-mediated Annealing,
Selection, 8extension, and Ligation (DASL) assay [9] or ribonuclease protection assays [10].
The technology used here provides several advantages in pathological practice. It does not
require reverse transcription and subsequent amplification of the nucleic acids, reducing
labour and simplifying standardization and automation. We further showed that a 30 gene
assay is sufficient to define mBL and distinguish DLBCL subtypes. In summary, our study
demonstrates that a GEP-based molecular classification of mature aggressive B-cell
lymphomas is robust on FFPE-derived RNA.
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Summary
The differential diagnosis between Burkitt lymphoma (BL) and diffuse large B-cell
lymphoma (DLBCL) can be challenging. BL has been reported to express less BCL2 than
DLBCL, but this issue has not been analysed systematically. BL expressing BCL2 can be
considered to be MYC/BCL2 co-expressors, a feature that is associated with poorer
outcome in DLBCL but that has not been correlated with outcome in BL so far. We
analysed the expression of BCL2 in 150 cases of conventionally diagnosed BL using two
different BCL2 antibodies. BCL2 expression was detected in 23% of the cases, though the
expression varied in intensity and number of positive cells. Using a subgroup of 43 cases
for which detailed clinical data were available, we did not detect any relevant differences in
clinical presentation and outcome between BCL2-positive and BCL2-negative BL. An
independent cohort of 17 BL with expression of BCL2 were analysed molecularly with 13
of 17 cases classified as molecularly defined BL using gene expression profiling on
formalin-fixed paraffin-embedded tissues. The four lymphomas diagnosed molecularly as
intermediates did not differ in clinical presentation and outcome from molecularly defined
BL.
Keywords: Nanostring, nCounter, classifier, Burkitt, diffuse large B-cell lymphoma, MYC
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2.1 Introduction
The differential diagnosis of Burkitt lymphoma (BL) versus diffuse large B-cell lymphoma
(DLBCL) can be challenging. In daily practice their diagnosis is based on morphological
assessment, immunophenotype and detection of translocations of the MYC and absence of
translocations involving the BCL2 or BCL6 gene by fluorescence in situ hybridization
(FISH) (conventionally diagnosed BL). The immunophenotype, which is assessed to
distinguish BL from DLBCL, frequently includes BCL2 expression [1–3]. The former
WHO classification published in 2001 stated that BCL2 is not expressed in BL [4].
However, gene expression profiling identified cases of molecularly defined BL (mBL) with
BCL2 expression not caused by translocations of the gene [5,6]. These findings led to a
new weighting of the immunophenotypic features of BL in the current WHO classification,
which describes BCL2 as being expressed in up to 20% of BL cases, predominantly with a
weak expression pattern [7].
BL expressing BCL2 must be distinguished from the group of lymphomas called
“B-cell lymphomas unclassified with features intermediate between BL and DLBCL”
(conventionally diagnosed intermediates, conventionally diagnosed intermediates), which
comprises a heterogeneous group of lymphomas. Conventionally diagnosed intermediate
lymphomas show at least some features reminiscent of BL, such as a monomorphic
cytological picture with small to medium-sized blasts, a starry sky pattern, high proliferation
and frequently translocations involving the MYC gene [7]. However, conventionally
diagnosed intermediate lymphomas often display immunophenotypic features such as
strong BCL2 expression or genetic features like BCL2 or BCL6 gene translocations that
preclude a BL diagnosis. The presence of both MYC and BCL2 or BCL6 translocations is
called “double hit” and is usually not compatible with the diagnosis of BL [8–10].
Intermediate lymphomas can also be identified by gene expression profiling
independent of morphology, immunophenotype and FISH data. Gene expression
profiling-based molecular intermediates (m-intermediates) are classified as conventionally
diagnosed BL or DLBCL by conventional diagnostics. A subgroup of m-intermediates lack
a genetic “double hit” constellation [6]. In children and adolescents translocations of BCL6
and BCL2, and thus “double hit” lymphomas, are exceedingly rare, but m-intermediates in
the young age group can be detected by gene expression profiling [11]. Similar to “double
hit” lymphomas, m-intermediates identified by gene expression profiling occasionally
express BCL2 protein [11]. Currently, gene expression profiling is not available for a
routine diagnosis, thus for diagnostic pathologists it is currently unclear whether strong
expression of BCL2 justifies the classification of a case with the morphological and
immunophenotypical features of a BL as an intermediate lymphoma.
In DLBCL not only the genetic “double hit” with MYC and BCL2 translocations
but also the co-expression of both proteins MYC and BCL2 (“co-expressor”) characterize
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a subgroup of DLBCL with an aggressive course [12–15]. In BL, high levels of MYC
protein expression is due to the MYC translocations [6]. Whether the co-expression with
BCL2 indicates inferior poorer outcome in BL has not yet been studied.
To gain a better understanding of the clinical implications, we systematically
analysed BCL2 expression in BL. To this end we screened a large cohort of conventionally
diagnosed BL for BCL2 expression using two antibodies that detect BCL2. We correlated
the BCL2 expression status with the clinical course in cases with available clinical data.
Moreover, we applied digital multiplexed gene expression profiling on formalin-fixed
paraffin-embedded (FFPE) tissue specimens from BCL2-positive BCL2-negative
conventionally diagnosed BL cases to determine whether they are classified as mBL.
2.2 Materials and methods
2.2.1 Patients and tissue specimens
BL cases from all age groups that were diagnosed between 2001 and 2014 were identified
within the files of the Lymph Node Registry Kiel. Cases with sufficient FFPE tissue were
arranged in a tissue microarray (TMA) with duplicate cores 0.6 mm in diameter for each
lymphoma. We included only lymphomas with morphological features compatible with the
diagnosis of conventionally diagnosed BL as judged on full tissue sections. The lymphomas
were composed of dense sheets of monomorphic small to medium-sized blasts with a
narrow rim of cytoplasm showing cohesive growth and a starry sky pattern in areas of good
tissue preservation. The TMA cohort comprised a total of 150 cases of conventionally
diagnosed BL from all age groups. A subgroup of cases with specimens of sufficient size
and a tumour content of at least 70% were selected for molecular analysis (n=17). Clinical
data were available for 43 cases.
2.2.2 Immunohistochemistry and fluorescence in situ hybridization (FISH)
Analysis of BCL2 expression was conducted using clone 100/D5 (DAKO, Glostrup,
Denmark) or clone E17 (Zytomed, Berlin, Germany)(Adam et al, 2013). Analysis of CD20,
CD10 and Ki67 was performed using an automated stainer (Leica, Wetzlar, Germany).
BCL2 immunohistochemistry results were scored by visual inspection in the following
categories: negative (no staining in lymphoma cells), 1-25% positive lymphoma cells, 26-
50% positive lymphoma cells, 51-75% positive lymphoma cells and >75% positive
lymphoma cells. The intensity of BCL2 staining was analysed relative to non-neoplastic T-
cells serving as an internal control as weak (weaker than T-cells) or strong (stronger or
equal to T-cells). Staining intensity of T-cells also served as a control for immunoreactivity
of the tissue. The Ki67 index was assessed in 5% steps, whereas CD20, CD10 and TdT
were reported as positive or negative. FISH was conducted as described recently [16].
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Break-apart probes for the MYC , BCL2 and BCL6 loci as well as IGH-MYC and IGH-
BCL2 fusion probes were applied (Abbott, Abbott Park, Illinois, USA) [17].
2.2.3 RNA extraction and digital multiplexed gene expression
FFPE material was cut into five 10 µm-thick sections per sample. Extraction of RNA was
done according to the manufacturer’s instructions (ExpressArt FFPE Clear RNAready Kit,
AmpTec, Hamburg, Germany), quantified and checked for quality (Agilent RNA 6000
Nano Chips, Agilent Technologies, Santa Clara, California, USA) as previously described
[18]. Gene expression analysis was performed using nCounter/Nanostring technology
following the previously published protocol [18]. In five specimens with previously
visualized BCL2 expression pattern on FFPE sections, BCL2-positive and -negative areas
were analogously labelled on unstained tissue sections, manually dissected and separately
processed for RNA extraction and gene expression.
2.3 Results
2.3.1 Incidence of BCL2 expression in conventionally diagnosed BL
We analysed 150 cases of conventionally diagnosed BL diagnosed by morphological and
immunophenotypical features as well as the presence of MYC translocations. All cases
were positive for CD20, CD10 and negative for TdT with a Ki67 index above 90%. All
lymphomas were shown by fluorescence in situ hybridization to harbour MYC (150/150,
100%) translocations but to lack BCL2 (0/141, 0%) or BCL6 (0/137, 0%) translocations.
TMAs containing our case cohort were stained by two antibodies directed against BCL2.
Applying the most widely used antibody clone 100/D5, 146 cases yielded an interpretable
result. No expression was detected in 113/146 cases (77%). BCL2 expression was detected
at various levels in 33/146 (23%) of the cases with interpretable results (1-25% positive
lymphoma cells in 16/146 (11%), 26-50% in 6/146 (4%), 51-75% in 6/146 (4%) and
>75% in 5/146 (3%)). The expression intensity was weak (weaker than non-neoplastic T-
cells as internal controls) in the majority of cases (Fig 1) and only two cases showed strong
staining intensity equal to or stronger than non-neoplastic T-cells (data not shown).
To analyse whether BCL2 protein expression might escape detection by the
frequently used antibody clone 100/D5, as reported for follicular lymphoma [19], the cases
were additionally analysed by the antibody clone E17. However, none of the conventionally
diagnosed BL that lacked BCL2 expression using the clone 100/D5 stained positive with
the clone E17 (0/104 of cases with interpretable results, Table 2.3, supplement).
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Figure 2.1: Variable expression of BCL2 in BL. Scattered cells comprising about 10%
of all lymphoma cells (A, corresponding to Case 9 in Table 2.1) and diffusely dispersed BCL2-
positive lymphoma cells comprising about 40% (B, corresponding to Case 12 in Table I).
Inserts with high magnifications with arrowheads indicating non-neoplastic T-cells and arrows
indicating BCL2-positive lymphoma cells. Original magnification 400x.
2.3.2 Pathological features of conventionally diagnosed BL showing expression of BCL2
A subgroup of 17 patients with conventionally diagnosed BL was further studied on full
tissue sections (7 of these patients were also part of the TMA cohort). The patients’ clinical
features were typical for BL and they were predominantly young (median age 11 years,
range 3-24 years) and male (Table 2.1). All but one patient presented with lymphomas with
no or limited bone marrow infiltration and they were frequently at a limited stage (Table
2.1). The lymphomas manifested predominantly at extranodal sites with 10/17 in the small
or large intestine or as an abdominal or ileocecal mass (Table 2.1).
Histopathology and genetics were compatible with the diagnosis of conventionally
diagnosed BL, with small to medium-sized blasts with a narrow rim of cytoplasm. A starry
sky pattern was detectable in the majority of cases, at least in areas with good tissue
preservation. A plasmacytic differentiation was not detectable. All lymphomas displayed
the conventionally diagnosed BL immunophenotype with expression of CD20 and CD10,
high proliferation as measured by the Ki67 index and absence of TdT expression (Table
2.1). Only 1/8 cases (13%) was positive for EBV by EBER in situ hybridization (data not
shown). The genetic features were compatible with the diagnosis conventionally diagnosed
BL too (Table 2.1). The BCL2-expressing cells were either diffusely dispersed over the
whole lymphoma/tumour or clustered in restricted areas while leaving other areas BCL2-
negative (Figure 2.2). In cases with spatially divergent BCL2 expression, the phenotype and
the morphology did not differ between BCL2-positive and BCL2-negative areas of the
lymphoma (Figure 2.2). Spatially divergent BCL2 expression occurred in 29% of the cases
analysed.
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2.3.3 BCL2-positive conventionally diagnosed BL show a molecular profile of mBL or m-
intermediate
In order to understand whether the expression of BCL2 in conventionally diagnosed BL
truly is a BL, we performed a gene expression analysis using RNA obtained from FFPE
tissues and digital multiplexed gene expression technology, as previously published [18].
Thirteen of 17 conventionally diagnosed BL (76%) were classified as mBL, confirming the
clinicopathological-cytogenetic diagnosis (Table 2.1). In five specimens the BCL2-positive
and negative areas of the conventionally diagnosed BL were manually dissected and
analysed separately for gene expression. All of these were classified as mBL in both the
BCL2-negative and the BCL2-positive areas of the tumour (Case 1, 2, 3, 4 and 11 in Table
2.1).
Figure 2.2: Example of a case of BL with differential spatial expression of BCL2. The
specimen was obtained from an ileocecal mass in a 12-year-old male child (Case 1 in Table I).
The tumour displays heterogeneous expression of BCL2 (A, overview; B and C high
magnification). Both areas with and without BCL2 expression show the typical morphology
and immunophenotype of BL. BCL2-positive areas: B, BCL2; D, haematoxylin and eosin; F,
CD20; G, CD10; H, Ki67. BCL2-negative areas: C, BCL2; E, haematoxylin and eosin; I, CD20;
J, CD10; K, Ki67. Original magnification 100x in A and 400x in B-K.
Interestingly, 4/17 conventionally diagnosed BL (24%) were classified as
lymphomas intermediate between mBL and non-mBL (m-intermediate, Case 5, 6, 13 and
16 in Table 2.1, Figure 2.3). All m-intermediate lymphomas showed typical features of
conventionally diagnosed BL. The patients were under the age of 16 and 3 patients
presented with an abdominal mass (Table 2.1). Although the morphology of these
lymphomas was ambiguous due to poor tissue quality (Figure 2.3), all lymphomas were
positive for t(8;14) and lacked BCL6 breaks. There were no BCL2 breaks in two cases with
available data. The patients were treated according to the protocols for BL and did not
suffer from a relapse.
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Figure 2.3: Two lymphomas diagnosed as BL by means of morphology,
immunophenotype and genetics that were classified as intermediates by gene expression
profiling. Panel A corresponds to Case 5 in Table I; panel B corresponds to Case 16 in Table I.
All panels are stained with haematoxylin and eosin. Original magnification 200x.
2.3.4 BCL2 expression in paediatric conventionally diagnosed BL is not associated with
unfavourable outcome
In DLBCL co-expression of BCL2 and MYC is associated with poorer outcome. In our
cohort of 13 mBL based on gene expression profiles and available clinical data the
outcome is excellent and none of the patients for whom a molecular diagnosis was
available in the current study showed a relapse (Table 2.1). We thus analysed a larger
number of conventionally diagnosed BL treated according to protocols of the NHL-BFM
study group. Forty three patients, for whom the BCL2 expression status based on whole
tissue section staining was available (including three patients that were analysed by gene
expression profiling), were registered in the NHL-BFM database, thus providing us with
complete clinical data. Seventeen of 43 cases of conventionally diagnosed BL (40%) were
reported to show BCL2 expression. There was no major difference in clinical variables
between the group with and the group without known BCL2 expression status, with the
exception that a lower number of cases with known BCL2-expression status had bone
marrow involvement and elevated lactate dehydrogenase (LDH) levels (Supplementary
Table 2.4,). A comparison of the clinical variables, gender, age, stage, bone marrow
involvement, central nervous system involvement, LDH, B-symptoms, risk groups and
event-free survival, did not reveal any difference between 26 BCL2-negative and 17 BCL2-
positive cases of conventionally diagnosed BL (Table 2.2).
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Table 2.2: Characteristics of BCL2-positive and –negative BL patients followed by the
BFM-NHL study group data. B-AL, Burkitt-acute leukaemia; BM, bone marrow; CNS, central
nervous system; LDH, lactate dehydrogenase; LR, likelihood ratio.
2.4 Discussion
BCL2 is a member of the BCL2 family of proteins, which are involved in a variety of
cellular processes and predominantly act in an anti-apoptotic manner [20]. BCL2 is a
promising therapeutic target in lymphomas that express the protein [21]. In this study we
show that BCL2 is expressed in a considerable number of conventionally diagnosed BL
cases. The percentage of BCL2-positive conventionally diagnosed BL cases in the NHL-
BFM database (39%) was higher than the percentage of conventionally diagnosed BL
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reported as positive in our tissue microarray study (23%). The difference might be due to
the fact that full slides were analysed for BCL2 expression for the NHL-BFM data, which
allows areas of local BCL2 reactivity to be detected that might escape identification using a
TMA. Translocations involving BCL2 as a cause of BCL2 expression were ruled out in our
study, confirming previous data [5,11,22]. Whether other genetic aberrations, such as
mutations in the promoter region or epigenetic mechanisms in BCL2-positive subclones of
conventionally diagnosed BL, cause the protein’s expression has not yet been elucidated. It
is worth mentioning that the widely used antibody clone 100/D5 (DAKO, Glostrup,
Denmark) is sufficiently sensitive to identify BCL2 expression in conventionally diagnosed
BL. In contrast to follicular lymphoma [19], mutations of BCL2 epitopes do not seem to
influence immunoreactivity despite the fact that mutations in BCL2 occasionally occur in
conventionally diagnosed BL [23]. It is important to mention that BCL2 staining suffers
from a high inter-observer variability [24].
The expression of BCL2 is associated with poorer survival in DLBCL, especially if
co-expressed with MYC protein [14,15]. As all BL cases express high levels of MYC [5,22],
the BCL2-positive BL are MYC and BCL2 co-expressors. Our findings show that, in
conventionally diagnosed BL or mBL, co-expression of MYC and BCL2 is not associated
with a poorer outcome. Certainly, the differences in therapeutic protocols might explain
the different prognostic impact of MYC-BCL2 co-expression. All conventionally diagnosed
BL and mBL cases in our study were paediatric patients who received intensive
chemotherapy according to paediatric protocols. The DLBCL for which the negative
prognostic impact of MYC-BCL2 co-expression has been demonstrated were mainly
treated with less aggressive immunochemotherapy using a CHOP [cyclophosphamide,
hydroxydaunorubicin (doxorubicin), vincristine, prednisolone]-based regimen [25].
Whether intensified chemotherapy might overcome the negative prognostic impact of
MYC-BCL2 coexpression in DLBCL is still uncertain. It is noteworthy that a recent study
of a young, high-risk cohort of DLBCL treated with intensified immunochemotherapy
identified biological risk factors that differ from cohorts of elderly patients with DLBCL
[26].
Using our recently developed gene expression-based classifier [18], we were able to
apply Nanostring technology to manually dissected areas of the lymphoma. BCL2-positive
and BCL2-negative areas of the same lymphomas were independently and consistently
classified as mBL, implying that the expression of BCL2 does not indicate a
‘transformation’ of BL towards an intermediate lymphoma. To our knowledge, this is the
first example of gene expression-based molecular diagnosis in independently analysed areas
of a lymphoma. The consistency of the results confirms the reliability of our multiplex
assay and suggests that the molecular diagnosis based on our classifier is not influenced by
intratumoural heterogeneity.
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We have previously shown that m-intermediates in children do not harbour a
genetic ‘double hit’ constellation and show more ‘Burkitt-ness’ than adult m-intermediates
[2,11]. This suggests that the majority of m-intermediates in children and young adults are,
in fact, BL, which escape classification as mBL due to minor divergence of gene expression
or simply the choice of the statistical cut-off in the current algorithms [11]. This study again
identified four m-intermediates among 17 lymphomas that were classified as conventionally
diagnosed BL on the basis of morphology and immunophenotype. However, the clinical,
pathological and genetic features of the m-intermediates, such as age, localization, site of
the lymphoma, morphology, immunophenotype, cytogenetics and outcome, do not differ
from mBL in this cohort of children and young adults. This finding raises questions as to
the potential advantage of molecular over conventional diagnosis for mature aggressive B-
cell lymphomas in children and adolescents. Obviously, m-intermediates in young patients
do not present a clinically or biologically relevant subgroup. As our cohort of molecularly
classified lymphomas is rather small, molecular diagnosis based on gene expression
profiling needs to be evaluated in larger cohorts of lymphomas in children and young
adults to understand its value as a diagnostic and prognostic tool.
Our data suggest that BCL2 expression is a feature detected to a variable extent in a
considerable number of cases of BL. It is important to mention, that even a high
expression intensity or a high number of BCL2 positive lymphoma cells does not preclude
the diagnosis of BL if all other features are compatible with this diagnosis, especially if
BCL2 translocations are absent. BCL2 expression in a lymphoma that clinically,
morphologically, immunophenotypically and genetically resembles BL is not sufficient to
diagnose an intermediate lymphoma, especially if the BCL2 expression is developed only in
a subgroup of lymphoma cells (as was the case in most of the specimens analysed in this
study).
In summary, more than 20% of lymphomas with the clinical, morphological,
immunophenotypical and genetic features of conventionally diagnosed BL express BCL2.
This expression is variable in extent and can occur diffusely or be restricted to certain areas
of the lymphoma. BCL2 expression in conventionally diagnosed BL is almost always
weaker than in non-neoplastic T-cells. Molecular diagnosis of BCL2-positive
conventionally diagnosed BL confirms the diagnosis in the vast majority of cases. The
clinical significance of m-intermediates in children is uncertain at the current time. BCL2
expression in conventionally diagnosed BL is not associated with poorer outcome in
paediatric patients. Diagnostic pathologists must be aware of the BCL2 expression pattern
in conventionally diagnosed BL.
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2.5 Supplementary materials to Clinical and pathological features of
Burkitt lymphoma showing expression of BCL2 – an analysis including
gene expression in formalin-fixed paraffin-embedded tissue
Supplementary Table 2.3: BCL2 expression for n=134 BL in the TMA cohort for which an
interpretable result was available for both BCL2 antibodies used in the study. The
immunohistochemistry score (see material and methods) for the Dako antibody is indicated by
each row. The number and percentage of cases and for Dako score in the second stain for E17
antibody is outlined in the columns.
E17 BCL2 antibody score
DAKO
BCL2
antibody
score
0 1 2 3 4
0 104/104 (100%) 0% 0% 0% 0%
1 13/15 (87%) 2/15 (13%) 0% 0% 0%
2 3/4 (75%) 0% 1/4 (25%) 0% 0%
3 1/6 (17%) 4/6 (67%) 1/6 (17%) 0% 0%
4 0% 0% 0% 3/5 (60%) 2/5 (40%)
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Supplementary Table 2.4: Patient characteristics of patients with versus patients without
known BCL2 status
Characteristics Patients not
analyzed (n=126)
Patients analyzed
(n=43)
P value
(Chi)
Gender male 113 89.7% 39 90.7%
female 13 10.3% 4 9.3% 0.85
Age < 10 73 58% 22 51%
10-14 40 31.7% 12 28%
> 14 13 10.3% 9 21% 0.20
Stage of
disease
I 3 2.6% 1 2.78%
II 21 18.4% 10 27.78%
III 57 50% 20 55.56%
IV 5 4.4% 1 2.78%
B-AL 28 24.6% 4 11.1%
n.a. 12 - 7 - 0.42
BM
involvement
yes 30 23.8% 4 9.3% 0.04
CNS
involvement
yes 13 10.3% 3 7% 0.52
LDH < 500 U/l 48 40.3% 25 61%
500-1000 U/l 25 21% 9 22%
> 1000 U/l 46 38.7% 7 17%
n.a. 7 - 2 - 0.03
B
symptoms
yes 31 24.6% 11 25.6% 0.90
Risk group R1 2 1.7% 0 0%
R2 41 35.7% 22 61.1%
R3 20 17.4% 5 13.9%
R4 52 45.2% 9 25%
n.a. 11 - 7 - 0.05
EFS 89+3% 90+5% 0.82 LR
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2.6 Outlook
The presentation of a new technology or protocol needs of several experiments and
approaches to validate it. Chapter 1 [1] presents a method to subtype aggressive B-cell
lymphomas using valuable archival FFPE material. On Chapter 2 [2] we apply the new BL
classifier to assess a previously unclassified group of BCL2-expressing BL, representing a
further validation step for the technology.
Our work has not been alone in trying to improve lymphoma classification. A
parallel DLBCL classifier was designed on the same technology and for FFPE materials in
2014 [3], named Lymph2Cx. A total of 15 genes and 5 endogenous genes were used (see
table 2.5). Four of the 20 genes overlapped our GCB-ABC and the Lymph2Cx classifier
(IRF4 was part of our custom Code Set but not selected as a prediction gene).
Unfortunately an algorithm comparison was not possible due to the unavailability of GEO
datasets of the Lymph2Cx data.
Table 2.5: Genes used in the Lymph2Cx assay. In bold are the overlapping genes with
our work.
In a further publication [4] the same group announced that the Lymph2Cx array
could assign prognostic indexes to the analysed samples, relative to their subtype or cell of
origin labelling (namely ABC, unclassified and GCB). Such developing could indicate that a
clinical application based on FFPE materials and multiplex GEP for aggressive B-cell
lymphomas could be available in the near future.
A broad study on nCounter technology reliability was published in 2015 [5] and
highlights the robustness of the platform by testing multiple variables such as batches of
Code Set, instruments, probe sequence design, among others.
However, by comparing Nanostring’s-generated data sets to genome scale data
(RNA-seq and Illumina arrays) some authors [6] postulate that for research purposes the
latter are more informative. It is clear that nCounter focuses on a discrete number of
analysable genes, whilst genome scale methods screen genetic phenomena, making it more
suitable for basic research. Even so the advantage of Nanostring technology’s rapid and
unbiased procedure cannot be easily discarded, because it allows for a straightforward
analysis of a known question (as disease subtyping). An example of an nCounter-based
clinical application is the company’s Prosigna™ Breast Cancer Gene Signature Assay, FDA
approved for the clinic.
TNFRSF13B PIM2 R3HDM1 TRIM56 MAML3
LIMD1 CYB5R2 WDR55 MME ITPKB
IRF4 RAB7L1 ISY1 SERPINA9 MYBL1
CREB3L2 CCDC50 UBXN4 ASB1 S1PR2
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Certainly, nCounter is not alone in the GEP approach for the classification of
FFPE material. Other systems for the molecular analysis of lymphoma have been
presented lately. One interesting method is the combination of quantitative PCR (qPCR)
and capillary electrophoresis separation [7]. With a total of 14 algorithm genes, 2 reference
genes and one internal control samples could be assigned to either the ABC or the GCB
DLBCL subtype. This assay goes back to the material amplification step of the original
gold standard arrays and should be taken with caution when generating new data to avoid
biasing errors.
In an era of many available molecular profiling tools the use of one with detriment
of another would be altogether scientifically damaging. To prevent this, a combination of
techniques could be helpful. Such experiments could be designed to firstly screen a set of
samples with high throughput techniques for relevant signature genes; afterwards selected
genes of interest could be shaped into a classification or prognostic tool (for example, with
GEP or qPCR approaches).
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Abstract
Immunoglobulin (IG) gene usage bias and stereotyped mutations in the same genes are
present in B-cell lymphoma. Studies in chronic lymphocytic leukaemia (CLL), mantle cell
lymphoma, splenic marginal zone lymphoma and lately in follicular and Burkitt lymphoma
(BL) have elucidated the most recurrent IG gene in each lymphoma entity. Stereotypy has
served to classify large cohorts in CLL and even create prognostic relevant groupings. The
cause of these stereotyped mutations is thought to be of antigenic origin, although none
relevant has been described for sporadic Burkitt lymphoma so far. We review the latest
works on IG bias and stereotyped mutations in lymphoma and compare it to two
unpublished BL data groups. Moreover, the frequently used VH4-39 segment in BL is
analysed for its stereotyped mutation structurally in three independent BL cases and
screened for superantigen binding. As the antigen drive hypothesis in lymphomagenesis
evolves, a comprehensive understanding in the structural and molecular antibody-antigen
interactions in each lymphoma entity is needed.
Keywords: Immunoglobulin gene usage, stereotyped mutations, Burkitt, B-cell lymphoma.
3.1 Introduction
Immune system B lymphocytes or B cells express B-cell receptors (BcR) on their surface.
BcRs are composed of a transmembranous immunoglobulin (IG) molecule that faces
extracellularly and an integral membrane heterodimer (CD79a and CD79b). The IG part of
the BcR is in charge of antigen recognition and it is composed of two identical heavy and
two identical light chains linked by disulfide bonds. Each chain has a variable and constant
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domain, being the former the antigen recognising part and the latter the effector and
isotype defining part. Four framework regions (FR) and three complementarity determining
regions (CDR) are distributed alternately throughout the variable domains. The three CDR
regions from a heavy chain form three loops that upon IG conformation are close to three
other loops from its corresponding light chain. Together, the six loops will form an antigen
binding site (ABS). Each IG molecule possesses two ABS since each IG is built by four IG
chains (two heavy and two light).
B cell receptors are able to specifically recognise antigens. By binding unknown
bodies an immunological reaction is generated that includes complement and effector cell
activation, aiming to control and eliminate a possible pathogen. To perform this function a
great variability of antigen recognition sequences need to be expressed in the CDRs. This
wide repertoire is achieved by V(D)J recombination. Diverse genes compose the variable
domain of the IG chains, named Variable (V), Diversity (D) and Joining (J) segments.
There are 44 V, 27 D and 6 J genes in the human IG heavy chain locus. Alternatively, light
chains lack D segments but also have multiple V and J genes. When combined, one gene of
each segment builds an IG chain. It is accepted that the IG repertoire in B cells is 1012
molecule-strong [1].
A biased usage of the immunoglobulin heavy chain variable region (IGHV) genes
in lymphoma has been reported previously, hypothesising an antigen drive or pathogen-
related cause. Although not all lymphomas show the same recurrent IG rearrangements
there are patterns to be found in each disease type.
The first hint of this phenomenon was detected in chronic lymphocytic leukaemia
(CLL) [2]. Particularly, half of the cases in CLL use the IGHV3-21 gene, frequently in
combination with the IGLV3-21 light chain gene. IGH gene rearrangement bias has also
been seen in mantle cell lymphoma (MCL) [3], by recurrent use of segments VH3-21, VH4-
34, VH1-8 and VH3-23. The same group also reported specific usage of IGHD or IGHJ
genes in combination with several IGHV sequences. In yet another lymphoma entity,
namely splenic marginal zone lymphoma (SMZL), up to 30% of the cases use IGHV1-2*04
[4,5]. Until recently there were no studies involving IG gene repertoire in Burkitt
lymphoma (BL). Newly, one group [6], pointed out an expression bias of the IGHV3 and
IGHV4 segments in this disease.
After the BcR has gone through the V(D)J recombination procedure an affinity
maturation process (via somatic hypermutation –SHM- and class switch recombination –
CSR-) adds further variability to the IG molecule. B cell receptor stereotypy defines
identical mutations detected in independent CDRs of B-cell clones. The probability of such
phenomena is very low (1/10-9 to 1/10-12) and it is not typical of physiological SHM.
Stereotyped mutations in BcRs are found in B-cell leukaemia and lymphomas with
rearranged and clonal BcR in which their variable heavy CDR sequences are restricted or
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not similar to healthy patients, where their sequence variability is greater. Although CDR
residues only account for 70 of the average 230 residues of the variable fragments [7], they
are crucial for antigen-binding [8].
So far, stereotyped or recurrent mutations present in CDR3 sequences have been
detected in CLL [2,9], MCL [3], SMZL [5] and BL [6,7]. The biased VH segments of CLL
patients also showed short restricted VH CDR3s [11]. Up to date it is considered that
almost one third of all CLL cases contain stereotyped VH CDR3 sequences. In MCL, 10%
of the 807 analysed cases bore stereotyped VH CDR3 sequences [3]. With long CDR3
regions and not a strong evidence of SHM, SMZL cases seem to have decisive stereotyped
mutations [4].
Biased uses of IG gene segments cannot be considered random events, as they
seldom occur accidentally. In addition, it has been repeatedly proven that the restricted
usage of the VH domain genes underlie the generation of stereotyped CDR3 motifs of the
VH [12], and thus it can be inferred that stereotypy of CDR motifs in lymphoma
populations is associated to IGH gene repertoire restriction.
This co-occurrence can be of clinical relevance: studies in CLL have proven that
patient stratification according to their stereotyped mutations could generate prognostic-
relevant clades [13]. However, the predilection for concrete VH segments above others in
one lymphoma cannot be horizontally translated to other entities, thus being "disease
biased". The same can be said for stereotyped mutations in the CDRs of lymphoma BcRs.
A need to collect and analyse other lymphoma entities BcRs in sufficient number to
elucidate repertoire and mutational patterns has emerged.
With long and detailed studies focusing on the 1D level of stereotyped mutations,
incursions in structural characterisation of the mutational effects in affected lymphoma
antibodies are lacking. A better understanding of the structural effects the mutational
changes have in the antigen-recognising pocket of the antibody might serve to elucidate the
nature of these lymphoma antibodies and their tumoral B-cell origin.
Here, we review the latest literature results in BL IG loci usage and mutation status.
Furthermore three cases of the most prominently stereotyped IGHV in BL are
characterised in their 3D structures by comparing their originally mutated CDR2 to their
unmutated germline sequences.
3.2 Materials and methods
3.2.1 IG gene repertoire analysis in B-cell lymphoma
Two unpublished studies to date and a recent publication are reviewed in the first part of
this work:
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Within the network project MMML (Molecular Mechanisms in Malignant
Lymphomas, Deutsche Krebshilfe, 70-3173-Tr3) a total of 60 sporadic BL (sBL) IGHV
rearrangements were amplified and sequenced [6] using the BIOMED-2 primers and
protocols [14]. The obtained sequenced data was run through the IMGT
http://www.imgt.org/) database.
Based on next generation sequencing (NGS) and as part of the International Cancer
Genome Consortium (ICGC-MMML-Seq, referred here as ICGC) project
(https://dcc.icgc.org/) the IG loci were RNA-sequenced [15] to assess IG segment usage
in different types of B-cell lymphoma [personal communication]. Subtypes of diffuse large
B-cell lymphoma (DLBCL) to follicular (FL) and Burkitt lymphomas were analysed.
A further study in BL from Baptista et al [7] was also considered for comparative
and validation purposes.
Statistical analysis was done in GraphPad Prism with two-way ANOVA test and a
significance level of P=0.05.
3.2.2 Original samples, cDNA extraction and sequencing
Samples R87264/95 (MPI-079), R87184/02 (MPI-589) and R82092/94 (MPI-621) were
obtained from fresh-frozen biopsies stored in the Lymph Node Registry, Kiel and had
been previously enrolled in the MMML study. From an initial 2µg of RNA, extracted from
frozen sections with RNeasy Mini Kit (Qiagen), cDNA was reverse transcribed following
the protocol for Invitrogen’s SuperScript™ First-Strand Synthesis System (Thermo Fisher
Scientific). The resulting material from the reverse transcription procedure was directly
amplified through PCR. For set up and reaction composition, see the Buffer and Reaction
list (Annex).
A total of 22 primers were tested to obtain the correct IG fragment in the three
cases analysed (see Primer Annex, Table P1). Primers were tested in combinations for VH
(forward) and JH (reverse), VL and JL, and VK with JK segments (Table P2 in Primer Annex).
Electrophoresis gels at 1% agarose were run for 30 min at 120V to separate the PCR
products. For each case a band containing the desired IG chain amplicon was generated,
cut and separated in microcentrifuge tubes. DNA was isolated from the agarose gel
fragments using the NuceloSpin Extract II kit (Macherey&Nagel), and the resulting DNA
concentration was measured with NanoDrop (Thermo Fisher Scientific).
With the cDNA a sequencing reaction was set up following ABI Prism’s guidelines
on DNA quantity for such reactions. The sequencing reaction was set as appears in the
Buffer and Reactions list (Appendix). The sequencing reaction purification was done using
NucleoSEQ columns (Macherey & Nagel) by following the company’s protocol.
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Afterwards the sequences were analysed with a Sanger sequencer from a 3500 ABIPrism
(Thermo Fischer Scientific) and they were compared to their germline sequences.
3.2.3 Immunoglobulin isotype assessment of the 3 BL-specific monoclonal antibodies
Primers were designed to be specific for each sample (forward) and the two variants,
secretory and transmembranous, of the constant IgH region (reverse) (see Table P3 in
Primer Annex) by guide of existing publications [14] and P01871 (IGHM_HUMAN),
isoforms P01871-1 and P01871-2 (UNIPROT: http://www.uniprot.org/). The previously
obtained cDNA was amplified to determine the original nature of the expressed Ig.
3.2.4 In silico structural analysis
General analysis of the sequenced IG genes from our patient material was obtained from
IMGT (http://www.imgt.org/IMGT_vquest/vquest) [17], a tool that confirmed their
productivity and assessed their germline identity.
In silico modelling was generated of the three BL mAbs for their respective heavy
and light chains. The sequences obtained from each case were translated with the
translation tool in ExPASy (http://web.expasy.org/translate/) and the resulting amino acid
(AA) data was fed to the Antibody section of the web-based tool Rosie
(http://rosie.rosettacommons.org/antibody) for modelling. The output from Rosie, a PDB
file, was in turn submitted to Paratome (http://www.ofranlab.org/paratome/) [18], a
bioinformatic online tool that predicts the ABS of any given antibody structure or sequence
[19]. Complementarity determining region estimations were retrieved from IMGT’s V-
QUEST  (http://www.imgt.org/IMGT_vquest/vquest) and Rosie. For CDR2 mutation
study the S>N stereotyped mutation was reverted and the resulting modelling was
compared to the previous PDB file with the mutation. The online structure alignment tool
RCSB PDB Protein Comparison Tool
(http://www.rcsb.org/pdb/workbench/workbench.do) was used for this purpose. All
modelling PDB files were visualised with Discovery Studio Visualizer 4.1 (Accelrys
Software Inc.).
3.3 Results
3.3.1 IG gene repertoire analysis in Burkitt lymphoma
The RNA of a cohort of 132 B-cell lymphomas within the ICGC consortium was deep
sequenced (RNA-seq) to infer the most prominently expressed IGH@ rearranged loci in
the tumour samples. The cohort contained DLBCL, intermediate, BL and FL cases. There
were only 29 different VH segments present in the most prominently expressed IGH alleles,
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with an overall bias towards IGHV3-23, 3-30, 3-48 and 4-34 (Figure 3.1). While the 3-23, 3-
48 and 4-34 rearrangements could be attributed to FL cases, there were also biases in other
lymphoma entities, being VH3-30, VH4-34 recurrent in BL.
Figure 3.1: IGHV rearrangement spectrum in B-cell lymphoma, ICGC.
Nineteen of the 132 lymphoma samples were diagnosed as BL. As three BL cases
had been previously included in the MMML study they are not further considered here,
making a total of 16 final BL. Their predominant IGHV segments were VH4 (43.8%, with
7/16 samples) and VH3 (37.5%, with 6/16 samples). More specifically, the most recurrent
subtypes were IGHV4-34 (4/16, 25%) and IGHV3-30 (2/16, 12.5%). Overall the 16 BL
cases had a clear bias towards IGHJ4 segment usage, being this segment present in 10/16
(62.5%) of the cases. For detailed subtype information see supplementary Table 3.5.
The unpublished work by Trautmann and colleagues within the MMML joint
project [6] amplified and analysed the productive VDJ rearrangements of 54 BL
(supplementary Table 3.7). Strikingly, a total of 42.6% (23/54) IGHV sequences belonged
to the IGHV4 subgroup, and 39% (21/54) to the IGHV3. Compared to the 54-BL of the
MMML cohort the IGH gene rearrangement distribution for the V region in ICGC is
similar (Figure 3.2, Table 3.1). Looking at patient age, IGHV subtype 4-34 and 4-39
presented a bias to paediatric cases, being significantly more frequent in underage patients
(7/11 and 5/6 respectively). With regard to the IGHV4-39 variant, a bias towards the
IGHJ3 gene usage was also seen, being present in 4/6 of the VH4-39 cases. In the ICGC
cohort the case presenting the VH4-39 segment showed an IGHJ4 gene.
In another study [7] with a total of 72 BL cell lines (35/72) and BL patient biopsies
(37/72) were screened for V segment usage. The most prevalent family rearrangements in
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the heavy chain IG gene were IGHV3 (47.9%) and IGHV4 (35.6%), with the other
families being comparatively underrepresented (Table 3.1). This group could also
demonstrate that the usage of the IGHV genes was statistically different to those of normal
B-cells and particularly the event of IGHV4-34 subtype usage was significantly higher to
that of non-tumoral cells. With a high mutational load of the series, Baptista et al
considered that practically all cases had gone through SHM. As previously reported [20,21]
IgM expression was confirmed and no bias towards kappa or lambda light chain was seen.
Table 3.1: IGHV rearrangement distribution in three independent BL cohorts.
While statistically comparing the most recurrent IGHV BL rearrangements in all
three cohorts (V3-23, V3-30, V4-34 and V4-39) the results were negative, showing no
significant differences in the frequency of the most recurrent allele recombinations. A
preference in light chain usage (lambda or kappa) was detected in none of the three groups
Figure 3.2: IGHV rearrangement frequency percentages in Burkitt lymphoma
corresponding to the ICGC, MMML and Baptista et al cohorts.
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IGHV1 4 6 11.1 6 7 9.6 1 1 6.3
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IGHV3 11 21 38.9 13 35 47.9 5 6 37.5
IGHV4 6 23 42.6 7 26 35.6 4 7 43.8
IGHV5 1 1 1.9 2 2 2.7 1 1 6.3
IGHV6 1 1 1.9 0 0 0.0 0 0 0.0
Total 54 72 16
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Interestingly, while stereotyped mutations in CDR3 were not detected, they were
found in the CDR1 and CDR2 (MMML cohort, [6]). Table 3.2 summarises the recurrent
AA changes observed in the IGHV4-34 and 4-39 subtypes. Some of the recurrent
mutations were localised in the framework regions (FR) but some were seen in the CDR1
for IGHV4-34 cases and in the CDR2 for IGHV4-39 cases.
Table 3.2: Stereotyped mutations in IGHV4-34 and IGHV4-39 (MMML, [6]). *Results
from Murray F et al. Blood 2008.
CDR-located mutations are of particular interest due to their being part of the ABS.
We focused on the serine-to-asparagine (S>N) AA change (AGC to AAC) in the CDR2,
which was detected in 4/6 (66%) of the IHGV4-39 samples and is also seen in CLL. Three
BL paediatric cases presenting both the IGHV4-39 rearrangement and the stereotyped
CDR2 S>N mutation at codon 64 from the MMML [6] study were recovered and further
analysed.
3.3.2 Clinical information
The three paediatric patients source for the RNA material and subsequently their mAb had
all been diagnosed with BL by a panel of pathologists within the MMML study and later
assigned their molecular Burkitt lymphoma label. The cases presented typical
morphological and immunohistochemical characteristics for BL, such as expression of
CD10, CD20, BCL6, Ki67 (more than 90%), and IgM as well as presenting the BL
hallmark translocation t(8;14). The three cases were negative for TdT, EBV and BCL2.
Being paediatric patients, all three were treated with the NHL-BFM protocol and none
suffered a relapse (see Supplementary Table 3.9 for clinical data).
IGHV4-34 sequences AAchange BL CLL*
IMGT-HCDR1, codon 36 G-to-D 5/11 27/135
IMGT-HFR3, codon 80 V-to-L 3/11 7/135
IMGT-HFR2, codon 40 S-to-T 3/11 43/135
IMGT-HFR2, codon 45 P-to-S 3/11 30/135
IMGT-HFR3, codon 69 P-to-S 2/11 1/135
IGHV4-39 sequences AAchange BL CLL
IMGT-HCDR2, codon 64 S-to-N 4/6 2/45
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3.3.3 BL mAbs characterisation
By sequencing the amplified IGH and IGK or IGL loci of the specific 3 paediatric patients
and analysing the sequences with the online IMGT/V-QUEST tool the prominent IG
rearrangement for each of the 3 BL samples could be determined (Table 3.3).
Table 3.3: IG heavy and light chain gene usage of the chosen BL patients. All three
rearrangements presented the stereotyped mutation in CDR2 from serine (Ser, with codon
AGC) to asparagine (Asn, with codon AAC) in codon 64.
All three cases showed the same V segment of the heavy chain (VH4-39), only with
case 621 having a distinct sub-variant (*07 instead of *01). The D segments were not
redundant but at the J segment case 079 and 621 converged again by using J3*01, having an
identical sub-variant. On the light chain side, case 079 and 621 displayed a predominant
lambda allele and case 589’s was a kappa. Two light chain alleles were sequenced in
preliminary amplifications of case 079, being named 079A (IGLV3-12*01) and 079B
(IGLV1-51*02). However, only 079B was successfully amplified and referred to as 079 for
further purposes.
The IGHM locus amplification yielded several bands in the electrophoresis gel due
to the IGHM primer structure and the fact that the amplification used part of the constant
region sequence. However, only the primer combinations with secretory primers gave
positive results. This confirmed that the type of Ig cloned is originally an IgHand of the
secretory type.
Figure 3.3: IGHM locus amplification electrophoresis gel. Odd-numbered lanes
contain cDNA material amplified with primers for the membranous region and even-
numbered lanes contain secretory-amplified IGHM. Lanes 1 and 2 represent case 079, lanes 3
and 4 case 589, and lanes 5 and 6 show case 621.
Germline sequence comparison or germline (GI) identity calculation of the three
IG cases helped to classify two of them (079 and 589) as mutated (<98% GI), with 93.47%
Heavy chains
CASE IGHV IGHD IGHJ
079 IGHV4-39*01 IGHD2-2*02 IGHJ3*01
589 IGHV4-39*01 IGHD6-13*01 IGHJ6*04
621 IGHV4-39*07 IGHD4-4*01 IGHJ3*01
Light chains
CASE IGLV IGLJ
079 IGLV3-12*01 IGLJ3*02IGLV1-51*02 IGLJ3*01
589 IGKV3-20*01 IGKJ2*01
621 IGLV1-47*02 IGLJ1*01
1 2         3          4         5         6 
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and 94.50% GI respectively; and one (621) as minimally mutated (98-99% GI), with a
98.97% GI. This could be a sign of ongoing SHM [5]. However, with lack of subclonal
analysis of our patient’s HCDR3 this cannot be fully confirmed.
Binding motives for staphylococcal protein A (SpA) and carbohydrate I/i are
scanned in our 3 mAb sequences since they have been postulated to be relevant
superantigens [21,22]. SpA binding motifs have been mainly described for germline
sequences of the IGHV3 family subtypes while the hydrophobic patch in heavy chain
framework region 1 (HFR1) of the IGHV4 family (germline) has been related to
carbohydrate I/i.
Table 3.4: Binding motifs for the SpA and carbohydrate I/i hydrophobic patch in the
cloned BL antibodies. Empty cells in the antibody rows show a match in the superantigen
binding sequences, which in turn are marked in bold letters in the superantigen rows.
In our 3 mAbs, all of the IGHV4-39 segment family, there should be no expected
conserved superantigen binding sites, however, there were up to 8/13, 7/13 and 9/13 of
the residues in respectively each case 079, 589 and 621. The conserved binding residues
were mainly concentrated in the HFR3 area.
3.2.4 In silico structural analysis
Both variable domains of the heavy and light chains were modelled in silico, containing the
three complementarity determining regions, which span throughout the V(D)J regions. The
resulting Paratome-defined ABS (Supplementary Figure 3.9) showed distinct pocket
volumes throughout the 3 BL mAbs. Case 079 had a mostly narrow and deep ABS pocket,
being 1.6nm x 0.6nm x 1.55nm (wide x long x deep). Being also slightly narrow, case 589
was not as deep and had the following dimensions: 1.65nm x 1.2nm x 0.9nm. Monoclonal
antibody 621 had a wider and shallower ABS, with 1.63nm x 1.62nm x 0.85nm in size.
Comparing the CDR areas estimated by IMGT and Rosie servers to the ABS
determination from Paratome [18] there were some discrepancies to be found. CDR and
ABS are not identical as it has depends on the numbering system used, modelling methods
and data available at analysis (Supplemental Figures 3.7 and 3.8). Of note, Paratome is able
to define Ag binding Paratome-unique residues, unidentified with previous CDR detection
HFR1 HCDR2 HFR3
Codon 7 16 18 20 24 25 26 65 67 72 74 75 77 79 90 92 93
SpA G S R/K K/I/T Y K G R T S Q N/G S
079 S S T S S S S K T
589 S S T S S S A S K S
621 S S T S T S S K
Carbohydrate I/i W A V Y
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methods, without losing CDR-relevant residues [19]. The differences in CDR and ABS are
mostly due to the approaches used in residue numbering. Since Kabat’s first approach in
defining CDRs [9], followed by Chothia’s contribution [24], to the more recent IMGT
numbering system [25], there have been many improvements on the subject. The latest
incursion in redefining the antibody-antigen (Ab-Ag) contact regions defines Antigen
Binding Regions (ABS) by analysing Ab-Ag complexes, showing that Ag binding residues
belong to structural consensus regions [19].
Figure 3.4: Variable regions of the 3 BL IgMs analysed. Continuous lines mark the
CDR sequences detected by IMGT and discontinuous lines mark the CDRs recognised by
Rosie. Letters in colour mark the ABR as detected by Paratome as coded in the figure legend.
A: 079B heavy chain, B: 079B light chain, C: 589 heavy chain, D: 589 light chain, E: 621 heavy
chain and F: 621 light chain.
To assess whether the stereotyped mutation in the CDR2 of our 3 BL mAbs
provoked a substantial change in the ABS structure, the stereotyped mutation from serine
to asparagine was reverted and the two modellings were compared with the structure
alignment tool RCSB PDB Protein Comparison Tool. The modelled comparisons of case
079 yielded 3 regions of structural difference, one including the mutated AA and two
regions not directly in contact. The smallest backbone shift occurred in the I29-Y33 AA,
belonging to the first ABS of the light chain. There were two more slightly larger backbone
shifts of 0.12nm in its maximum displacement between M162-T168 (ABS2 of the heavy
chain, where the CDR2 mutation is located) and S210-F218 (ABS3 of the heavy chain).
A
B
C
F
D
E
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Case 589 displayed a maximum of 0.133nm of backbone separation after mutation
reversion. There were four structural changes detected: between D137-Y144 in ABS1,
S166-Y170 in ABS2 and I210-V217 in ABS3 of the heavy chain and between G93-Y99 in
the ABS3 of the light chain. In case 621 there was a maximum backbone displacement of
0.233nm, with 3 main backbone angle shifts: in ABS1, comprising S141-W146, ABS2 in
S162-T169 and ABS3 in G210-D214 of the heavy chain.
Figure 3.5: Antibody backbone alignment of 079 (A), 589 (B) and 621 (C). The arrows
mark the main structural shifts.
A
B
C
0.5 nm
0.5 nm
0.5 nm
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Figure 3.6: 3D modelling of the three BL mAbs. Complementarity determining
regions are defined by Paratome and colour labelled accordingly. Case 079: A-B, case 589: C-D,
A B
DC
E F
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and case 621: E-F. Figures on the left are the strereotyped mutated antibodies as extracted
from patients’ cDNA. Right figures had their codon 64 mutation reverted. Arrows mark the
main structure differences upon CDR2 mutation reversion.
3.4 Discussion
Lymphoma cells, as their normal B cell counterparts, are dependent on their surface-
expressed BcRs for tonic survival signalling. As they originate from differentiated B cells,
this fact is not surprising but shows the importance of the BcR expression in lymphoma
cell populations [26].
By reviewing IGHV gene usage in Burkitt lymphoma it has been shown that the
most recurrent segment in this lymphoma entity is VH4-34 (in 18-25% of the cases). Table
3.5 summarises the most used segments detected in different B-cell lymphoma entities.
This particular segment is also biased in FL (ICGC, in preparation), MCL in 14.5% of cases
[3] CLL in variable frequencies [27] and DLBCL in 31% [40]. The second most prominent
IGHV gene in Burkitt lymphoma is VH3-30, being consistently seen in around 9% of the
cases, and also present in 8% of FL. Another IGHV gene with overrepresentation in BL is
also detected in other lymphoma populations in a biased fashion: VH3-23. This segment is
present in FL (22.5%) (ICGC, in preparation), MCL (7.5%) [3] and CLL (5-12%)
[13,27,28]. However, it has been demonstrated that gene VH3-23 is also frequently used by
normal CD5+ B cells [29,30]. With presence in 8.5% of the cases, gene VH4-39 is uniquely
biased in BL. Both IGHV4-34 and IGHV4-39 are used by only 3-5% of normal B cells [31]
and the same rearrangements were seen to be biased towards paediatric cases over adults
(MMML, [6]).
Table 3.5. Summary of biased IGHV usage in B-cell lymphoma. References are in
brackets for each column and entity. P.c: personal communication.
A B cell differentiation starts after exiting the bone marrow, having already gone
through IG loci recombination. The naïve B cells circulate the bloodstream, where they will
CLL % MCL % SMZL % FL % BL % DLBCL %
V3-21 11.7 V3-21 16.5 V1-2 24.9 V3-23 22.5 V4-34 21.1 V4-34 31
V1-69 7.2-11.9 V4-34 14.5 V4-34 12.8 V3-48 14.3 V3-30 9.1 V3-7 7.8
V4-34 11.9-18 V1-8 8 V3-23 8.1 V4-34 14.3 V4-39 8.5
V3-7 12.1 V3-23 7.5 V3-30 8.2 V3-23 6.7
V3-23 4.8-7-11.9 V3-11 8.2
V3-7 6.1
[10,12,27,29] [3] [4] [ICGC, p.c.] [6,7, ICGC, p.c.] [40]
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be exposed to antigens. They can either become regulatory B cells, short-lived plasma cells
(expressing IgM or IgG) or enter the germinal centre (GC) where they will undergo affinity
maturation through SHM, and CSR [32]. In the case of BL lymphocytes, the expression of
CD10 and BCL6, the mature phenotype of the tumoral B cells as well as intraclonal
diversity and acquisition of glycosylation sites [7] hints that they might have gone through
SHM. Ongoing SHM is further confirmed with the germline identity (GI) being lower than
100% in the 3 BL mAbs analysed in this work and elsewhere [7]. Burkitt lymphoma is
considered one of the GC-derived lymphomas together with FL and the GCB subtype of
DLBCL, due to the fact that their expression profiles resemble normal GC B cells [33].
IgM expressing B cells tend to induce the generation of mitogenic signals, not of
differentiation [33]. Taken together, BL cells might have been exposed to an antigen, and
having gone through an incomplete or monoallelic CSR process as supposed by their IgM
expression[34].
Moreover, BL cases expressing the VH4-39 gene have been described to possess a
mutation in codon 64 (CDR2), which is also seen, in much less frequency, in CLL [35].
Upon CDR2 mutation reversion we could detect a structural shift in all 3 antibody
backbones, not only restricted to the mutated area but also affecting other portions of the
ABS. Whether this mutation and the subsequent backbone shifts are enough to disturb a
hypothetical antigen binding will be addressed in Chapter 4.
The stereotyped mutations appearing in the CDRs of B cells in lymphoma have
been postulated to be a sign of antigen triggering of the disease, by proliferation stimulation
[12]. Could the biased repertoire of IG gene expression and the subsequent stereotyped
mutations be of ontogeny relevance in Burkitt lymphoma? The comparison to
carbohydrate I/i binding site produced no relevant conserved residues in the 3 analysed BL
antibodies. Yet, it has been previously demonstrated that the staphylococcal protein A
(SpA, widely used for antibody purification) has a Fab fragment specificity to the VH3
family that can “stimulate a large fraction of B cells, contributing to lymphocyte clonal
selection” [22]. In our 3 analysed BL antibodies there was a partially conserved SpA
binding site located in the CDR2 and HFR3. It has been noted that the localisation of SpA
binding residues are located in areas not touched by SHM, suggesting a superantigenic
interaction [35]. Even if the BL antibodies were of the V4 family, the SpA binding residues
were conserved to those of the VH3 family in the binding positions, explaining the cross-
family interaction.
Another possible antigenic driver in BL is the Epstein-Barr virus (EBV). In EBV+
BL there has been evidence of the virus driving BL pathogenesis by inducing B lymphocyte
proliferation through CD40 signal mimicking [35]. While a correlation with EBV infection
and Burkitt lymphoma in endemic cases has been shown to be 100%, sporadic BLs have a
much lower EBV coexisting infection (10%) [41] and their aetiology is not yet understood.
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Since there is no detected pathogen in BL cases the antigen driver for EBV- cases remains
unknown, leaving the antigenic hit and run hypothesis still open. In this light, a pathogen
that would no longer be present in a full blown BL could already have manipulated B cell
function, a mechanism by which B cells accumulate oncogenic characteristics [32]. B cells
do not only offer a reservoir for the pathogens, but they can also alter B cell maturation
and survival. A particular approach is that of antibody dilution by stimulating the
production of short-lived plasma cells that produce nonspecific antibodies, effectively
diluting the specific antibody concentration in the organism [32]. This mechanism,
combined with the fact that BL tumoral cells seem not to be fully matured and an antigen
promoting B cell overproliferation would further explain the IgM nature of the expressed B
cell antibodies. Thus, there is a risk that the secreted BL antibodies would have immature
and unspecific epitopes, making a causing antigen definition through epitope mapping a
difficult task.
Regarding aetiology, a risk factor prediction for BL negatively correlated a history
of allergy or asthma to the lymphoma occurrence in younger patients (below 50 years old)
[37]. The same study revealed an association of eczema to an elevated risk of BL in younger
patients and to a history of hepatitis C virus seropositivity in older patients. Another group
detected a negative association between atopic disease and non-Hodgkin lymphoma (NHL)
in a pooled data analysis [38], meaning a significant lower risk of  presenting NHL in a
population of asthma, hay fever and specific allergy (excluding eczema) sufferers. These
results reinforce a hit and run pathogen hypothesis or chronic immune activation for some
cases in the older age wave of sporadic BL and define an immature or partially
disfunctional immune system in younger BL patients.
To conclude, we review B-cell lymphoma IGH expression bias and describe the 3D
ABS structures from 3 BL mAbs with stereotyped CDR2 mutations. The triggering
pathogenic effects summed to the already described mutations in BL explain the final
appearance of the lymphoma as we know it [39]. However, many fronts remain open in the
initial BL agent’s, autologous or exogen, discovery.
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Web tool references:
AbYsis: http://www.bioinf.org.uk/abysis/about/definitions/definitions.html
IMGT V-QUEST: http://www.imgt.org/IMGT_vquest/vquest
UNIPROT: http://www.uniprot.org/
Translate tool: http://web.expasy.org/translate/
Rosetta Antibody Protocol: http://rosie.rosettacommons.org/antibody
Paratome: http://www.ofranlab.org/paratome/
RCSB PDB Protein Comparison Tool:  http://www.rcsb.org
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ICGC cohort
Heavy Light
V gene D gene J gene V gene J gene
1 IGHV3-23 IGHD3-3 IGHJ4 IGKV3-20 IGKJ1 IGK
2 IGHV3-30 IGHD6-19 IGHJ2 IGKV1D-13 IGKJ3 IGK
3 IGHV4-39 IGHD7-27 IGHJ3 IGLV1-51 IGLJ2 IGL
4 IGHV1-46 IGHD3-10 IGHJ4 IGKV4-1 IGKJ2 IGK
5 IGHV4-34 IGHD3-3 IGHJ5 IGLV1-40 IGLJ1 IGL
6 IGHV4-31 IGHD3-22 IGHJ6 IGLV2-14 IGKJ1 IGK
7 IGHV3-30 IGHD3-16 IGHJ2 IGLV1-40 IGLJ3 IGL
8 IGHV2-26 IGHD2-2 IGHJ6 IGKV1-5 IGKJ1 IGK
9 IGHV3-53 IGHD3-9 IGHJ4 IGKV2-24 IGKJ2 IGK
10 IGHV4-34 IGHD3-10 IGHJ6 IGLV1-47 IGLJ3 IGL
11 IGHV4-61 IGHD3-3 IGHJ5 IGKV3-20 IGKJ1 IGK
12 IGHV4-34 IGHD3-22 IGHJ4 IGLV1-40 IGLJ3 IGL
13 IGHV4-34 IGHD1-26 IGHJ4 IGKV1-12 IGKJ2 IGK
14 IGHV1-46 IGHD1-26 IGHJ5 IGLV2-14 IGLJ3 IGL
15 IGHV3-74 IGHD2-15 IGHJ4 IGKV2D-28 IGKJ4 IGK
16 IGHV3-30 IGHD2-2 IGHJ4 IGLV1-40 IGKJ1 IGL
17 IGHV3-48 IGHD3-22 IGHJ4 IGKV2-40 IGKJ2 IGK
18 IGHV4-39 IGHD3-22 IGHJ4 IGLV1-51 IGLJ3 IGL
19 IGHV5-51 IGHD5-24 IGHJ4 IGKV3-20 IGKJ1 IGK
3.5 Supplementary data to Immunoglobulin rearrangement bias and
stereotyped mutations in Burkitt lymphoma
Supplementary Table 3.6: List of VDJ rearrangements for the main gene of the
heavy and light chain detected in Burkitt lymphoma RNA-seq cases. Cases 2, 3 and 14 had
been previously included in the MMML study.
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Supplementary Table 3.7: IGHV rearrangements detected in three study cohorts for
Burkitt lymphoma.
LOCUS MMML ICGC Baptista et al
n % n % n %
IGHV1-18 2 3.70 1 1.39
IGHV1-2 1 1.85 1 1.39
IGHV1-24 1 1.39
IGHV1-46 1 6.25 1 1.39
IGHV1-58 1 1.85
IGHV1-69 1 1.39
IGHV1-8 2 3.70 2 2.78
IGHV2-26 1 6.25
IGHV2-5 2 3.70 1 1.39
IGHV2-70 1 1.39
IGHV3-11 2 2.78
IGHV3-15 3 5.56 2 2.78
IGHV3-21 2 3.70 4 5.56
IGHV3-23 3 5.56 1 6.25 6 8.33
IGHV3-30 5 9.26 2 12.50 7 9.72
IGHV3-30-3 1 1.85 1 1.39
IGHV3-33 1 1.39
IGHV3-43 1 1.39
IGHV3-48 1 1.85 1 6.25 5 6.94
IGHV3-49 1 1.85
IGHV3-53 1 1.85 1 6.25 1 1.39
IGHV3-64 1 1.85
IGHV3-66 2 2.78
IGHV3-7 1 1.85 1 1.39
IGHV3-74 1 1.85 1 6.25 2 2.78
IGHV3-9 1 1.85
IGHV4-30 1 1.85
IGHV4-31 1 1.85 1 6.25 1 1.39
IGHV4-34 11 20.37 4 25.00 13 18.06
IGHV4-39 6 11.11 1 6.25 6 8.33
IGHV4-4 1 1.85 1 1.39
IGHV4-59 3 5.56 5 6.94
IGHV4-61 1 6.25
IGHV5-51 1 1.85 1 6.25 1 1.39
IGHV5-a 1 1.39
IGHV6-1 1 1.85
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Supplementary Table 3.8: Rearrangements found in 54 BL cases. MMML.
IGHV GENE n %
IGHV1-18 2 3.70
IGHV1-2 1 1.85
IGHV1-58 1 1.85
IGHV1-8 2 3.70
IGHV2-5 2 3.70
IGHV3-15 3 5.56
IGHV3-21 2 3.70
IGHV3-23 3 5.56
IGHV3-30 4 7.41
IGHV3-30-3 2 3.70
IGHV3-48 1 1.85
IGHV3-49 1 1.85
IGHV3-53 1 1.85
IGHV3-64 1 1.85
IGHV3-7 1 1.85
IGHV3-74 1 1.85
IGHV3-9 1 1.85
IGHV4-30-4 1 1.85
IGHV4-31 1 1.85
IGHV4-34 11 20.37
IGHV4-39 6 11.11
IGHV4-4 1 1.85
IGHV4-59 3 5.56
IGHV5-51 1 1.85
IGHV6-1 1 1.85
Total 54 100
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Supplementary Table 3.9: Patient’s clinical data. Ref. diagnostic: reference diagnostic,
sBL: sporadic Burkitt lymphoma, nos: not otherwise specified, Mol. diagnostic: molecular
diagnostic, mBL: molecular Burkitt lymphoma, n.a.: not available, k: kappa light chain, l:
lambda light chain, Intraabd.: Intraabdominal, LN: lymph node, Staging: Murphy staging, FU
time: follow up time.
079 589 621
Gender Female Male Male
Ref. diagnostic sBL High-grade nos BL-like
Mol. diagnostic mBL mBL mBL
CD20 + + +
CD10 + + +
BCL2 - - -
BCL6 + + +
KI67 90% 100% 95%
MUM1 + - -
TdT - - -
t(8:14) + + +
T cells 5% n.a. n.a.
Light chain k k l
Localisation Intraabd. LN Left maxillary Cervical LN
Hepatomegaly - - -
Splegnomegaly + - -
EBV - - -
IgM n.a. + +
Staging II IV II
Treatment NHL-BFM 95 NHL-BFM 95 NHL-BFM 90
FU time (days) 3538 911 4936
Relapse No No No
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Supplementary Figure 3.7: Overall overlap of the CDRs to the detected Paratome
ABS. The overlap differences are consistent between mAbs. There are similarities across
antibodies but differences in the consensus level between regions. Antigen binding site 3 in the
light chains correlates very well with the CDR regions detected by both IMGT and Rosie. The
least similar comparison is seen in the ABS2 in the light chain. Overall there is generally more
than 50% overlap in all regions.
Supplementary Figure 3.8: Length of the 3 BL antibody CDR and ABS. This graph
shows the length variation through different CDR and ABS annotating methods. The
annotations from IMGT are marked with a left-down to right-top diagonal, the ones made by
Rosie are marked with opposite diagonal lines and the bars with points on them represent the
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ABS region lengths. They are grouped by the region and antibody, so the differences between
numbering techniques can be compared. Overall CDR2 seems to be the less homolog
numbering in the heavy and light chains. CDR1 has also some significant discordances, mainly
in the light chains.
Supplementary Figure 3.9: Top views of the ABS definition by Paratome. A-B: 079,
C-D: 589 and E-F: 621. Ribbon (left) and spacefill (right) ABS representation
B
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Abstract
Sporadic Burkitt lymphoma (BL) aetiology is still eluding discovery. Several B-cell
lymphomas have been related to auto or superantigenic drive or pathogen influence. While
antigenic screening is demanding and can result in unspecific matches, we choose an
antibody side approach to determine possible antigenic epitopes. We analyse three
paediatric BL antibodies from patients expressing the same biased immunoglobulin gene
family. By using phage display techniques and in silico modelling methods we describe BL
binding peptides. Better understanding of lymphomagenesis can help improve prevention
and treatment procedures for these diseases.
Keywords: Burkitt lymphoma, antigenic drive, antibody stereotypy.
4.1 Introduction
Burkitt lymphoma (BL) is a non-Hodgkin lymphoma of mature B-cells considered as
aggressive. It affects a paediatric to young adult population with a later middle-aged patient
wave. Patient age is a factor upon treatment decision [1,2] but also defines some pathogenic
characteristics. The hallmark translocation between chromosomes 8 and 14, involving the
C-MYC oncogene and the immunoglobulin heavy chain locus (IGH@) is common in both
age subgroups. Yet, up to 31% of paediatric diffuse large B-cell lymphoma (DLBCL) cases
were reclassified as molecular BL in recent gene expression profiling studies [3]. Paediatric
BL also expresses the IGHV4-34 and IGHV4-39 rearrangements more frequently than
adult BL, the same types that have been seen to carry stereotyped mutations (see Chapter 3
of this thesis). Moreover, epidemiologic studies have demonstrated a negative correlation
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between allergy (and other over-activating immunological diseases) and BL [7]. The same
study concluded that adult and paediatric BL might be aetiologically different.
Of the three main types of BL (endemic –eBL-, sporadic –sBL- and
immunodeficiency-associated), the sporadic version is the one where a possible pathogenic
aetiology is still eluding discovery. The endemic variant is present in the equatorial or
malaria belt zones, where it is strongly associated to the Epstein-Barr virus (EBV)
infection. The same broad geographical distribution is shared by Plasmodium falciparum
infection rates [4] but a much clearer causal relationship is found with EBV association.
The third variant is explained by the immunodeficiency of its suffering patients and, again,
by mostly co-occurring with EBV infection [5].
Even though the similarities between BL subtypes are subtle, some of their
characteristics point to interesting questions. Why is the location of sBL and eBL restricted
mostly to abdominal and maxillary areas respectively? Indeed, an exposure to the Euphorbia
sp. plant has been linked to activate EBV replication [6], which would explain antigenic
pressure in eBL. As the appendix is the analogous sBL location of maxillary eBL it has
been postulated that the intestinal Peyer patches could play an important role in early
pathogenic stages of sBL. Peyer patches are lymphoid tissue aggregates of the small
intestine mucosa, where sBL arises.
Yet, sBL pathogenic aetiology is unknown. With little to none infectious agents
found to correlate with the disease (EBV infection co-occurs in only 10% of sBL),
extraneous or autologous superantigens such as protein A of Staphylococcus aureus (SpA) and
blood antigen I/i could be a possible explanation. These same superantigens have been
seen to bind CLL antibodies [8] and are now postulated to play a role in the lymphoma
onset.
The biased immunoglobulin (IG) repertoire and stereotyped mutations found in BL
could be a mark of antigen drive [9] as postulated for CLL [8,10]. We chose a set of three
antibody sequences of the IGHV4-39 family expressed in paediatric BL patients. By
producing them in vitro we could analyse their putative epitopes and thus infer possible
pathogenically relevant antigens.
With a better understanding of lymphoma aetiology new approaches in prevention
[11] and treatment could result in less malignancy events and better treatment options.
4.2 Materials and methods
4.2.1 Original samples and cDNA
Samples and cDNA generation were processed as previously [Chapter 3, Section 3.2.2].
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4.2.2 Vector cloning
Vector pCR2.1 from the Topo TA cloning kit was used (Thermo Fisher Scientific) to
amplify the immunoglobulin sequences needed in TOP 10 E.coli competent cells (Thermo
Fisher Scientific) following the company’s manual. After clone amplification and plasmid
extraction the plasmids were sequenced, controlled and amplified via PCR.
The vectors to be used for mammalian cell transfection, were amplified in One
Shot TOP10 Chemically Competent E.coli (Thermo Fisher Scientific), their DNA
extracted with PureLink® Quick Plasmid Miniprep Kit (Thermo Fisher Scientific), and
measured with NanoDrop and fotometer. The vectors were modified in order to make
insertion to the transfection vector (pFUSE) easier.
To know the quantity of each vector to be used in each ligation reaction a molarity
ratio had to be calculated. The vectors were ligated and used to transform OneShot
Chemically Competent Cells (Thermo Fisher Scientific) according to the company’s
guidelines. The transformed bacteria were amplified, their DNA extracted and sequenced.
Finally the multiple cloning sites were deleted out of the pFUSE vectors.
Full protocols can be found in the Supplementary Methods section.
4.2.3 Transfection experiments and protein purification
HEK-293 cells (ACC305, DSMZ) were cultured in complete medium (RPMI, 10% FBC,
S/P) at 37°C, and 5% CO2 and used for transfection. Transfection tests were made with a
GFP-containing plasmid (pmaxGFP®, Lonza) and to assess the following methods:
lipofection with TransIT (Mirus) and Lipofectamine 2000 (Thermo Fisher Scientific), and
electroporation with Amaxa’s Nucleofector (Lonza) following the manufacturer’s
protocols. Cell viability and transfection performance were assessed via DAPI-stained
cytospins.
Further transfection tests were tested (H:L:pAdvantage): 1:4:1, 2:3:1, 1:4, 1:4Ø, in
complete RPMI medium [10% Ultra Low IgG FBS (Thermo Fisher Scientific), without
antibiotics]. Cells and supernatants were collected for protein purification.
Cell pellets were processed for protein extraction, and IgG purification was carried
out for all supernatants. IgG fractions were dialysed and concentrated. All supernatants and
protein extracts were measured for protein concentration. For extended protocols please
see the Supplementary Methods and Buffer list section.
4.2.4 Western blots
Reducing Western blots were made with protein extracts and supernatants from the
transfected HEK-293 cells. Native Western blots were performed for the 1:4:1 and 72h
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ratio and protein G-purified supernatants except for case 079A due to lack of detectable
protein in the supernatants, for such case protein extracts were used.
Detailed protocols can be found in the Supplementary Methods and Buffer list
section.
4.2.5 Cell blocks and IHC stainings
The cyto block (or cell block) protocol aims at fixing the cultured cells and embedding
them in paraffin. Cell blocks were generated from all the transient transfection variations
(079B, 589, 621 and mock transfection with empty vectors) and from other lymphoma cell
lines: L428 (Hodgkin lymphoma), BL-2 and EB-1 (BL), Oci-ly7 and Rck-8 (diffuse large B-
cell lymphoma, DLBCL) and MLMA (hairy cell lymphoma). All cell block slides were cut at
5µm thickness and stained with the supernatants of a 72h-old transfection, including the
supernatant of the empty vector transfection as control. To confirm IG expression the
transfected cell blocks were also stained with an anti IgG2a antibody (Invitrogen) and an
anti-IgL antibody (Abcam).
HEK-293 transfected cells were grown on sterile coverslips, which were attached to
glass slides and fixed with acetone. After allowing drying they were stained with the
purified IgG fractions of all transfection variants to screen for auto or cross reactivity.
Each coverslip was stained with a total of 50µl of approximately 350µg/ml concentrated
antibody (17.5µg of antibody per slide). Control stainings were made with anti-mouse IgG2a
antibody (Thermo Fisher Scientific) at 1:100 dilution.
Three brain biopsies from DLBCL and Peyer patches present in six formalin-fixed
paraffin embedded (FFPE) biopsies were stained with supernatants obtained from the
transient transfections.
In cryo preserved material we could stain the original patient’s biopsies with their
newly generated BL mAbs, including cross-combinations between patient mAbs, and with
,  (lambda) and (kappa) chain antibodies. An unrelated appendix, one small intestine
and one tonsil biopsy were also stained with the transfection supernatants.
All stainings included a secondary antibody control. Staining protocols can be
found in the Supplementary Material and Methods.
4.2.6 Phage display
Phage display is established with PhD12 library (NewEngland Biolabs). For full method
specifications refer to the Supplementary Material and Methods section. For each mAb two
phage display experiments were performed as repeats. Each experiment was followed by an
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enzyme-linked immunosorbent assay (ELISA), where the reactivity between the mAbs and
the selected phages was tested. The resulting positive wells after the ELISA were extracted
for DNA and further sequenced. Some negative wells were processed as well as controls.
Sequencing reactions were performed with the M13 96-primer from the PhD12 kit. Phage
DNA sequences were reviewed and the peptide coding regions were translated in silico
(Expassy, http://web.expasy.org/translate/) to obtain the peptide each sequence codes for.
All sequences found are listed in the Supplementary Table 4.2.
Recurrent peptides were selected to be ordered in a synthetic primer facility
(Eurogentec, Belgium). All peptides were labelled with CONH2 in the C-terminus to mimic
internal peptide structure. Aliquotes of the same peptides with biotin marking were used
for ELISAs. A linker (Ahx, an inert six carbon linear aminohexanoic chain) between the
peptide sequence and the biotin mark was used to minimise possible folding interferences.
Random peptide QSHWFVPWQDRW was generated by randomising the most recurrent
peptide sequence VHWDFRQWWQPS to serve as a negative control in binding assays.
4.2.7 In silico docking and structural analysis
The online tool pBLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) was
used to perform alignments. For phage protein-peptide alignments the threshold was set to
100 and the option for short alignment optimisation was activated. Other online resources
are also used, such as: ExPASy (http://web.expasy.org/translate/) for nucleotide-to-amino
acid translation, and IMGT/V-QUEST
(http://www.imgt.org/IMGT_vquest/share/textes/) for productivity, structure and
sequence determination of our antibody sequences.
All peptides identified in the phage display technique were analysed for selection
advantages and / or randomness through information indexes by the info program
(http://www.northeastern.edu/xray/downloads/info-program/) [12]. Two files were
submitted: an unselected phage display result containing random peptide sequences and the
sequences obtained with a selective procedure. The program was able to assign a random
probability number to each peptide sequence. The probability was then transformed to an
associated information parameter. The greater the information content measure, the more
probable is that the sequence was detected due to a real target binding. A further control
step was done by submitting the 12mer peptide sequences to the MimoDB
(http://immunet.cn/mimodb/) [13] database, where peptides were checked for known
motives or sequences, and thus for possible contaminations of the phage display
experiments. The sequences were also screened for other known motives by reviewing
published works [14,15]. Peptide sequences are screened for DNA and protein motifs with
the MEME Suite, version 4.10.2 (http://meme-suite.org/)
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Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) was used to align the
various sequences obtained to each other and to other published Burkitt lymphoma-related
epitopes.
Rosetta (http://rosie.rosettacommons.org/antibody) [16] was used to model the 3
BL mAbs. The resulting .pdb files were fed to CABSdock
(http://biocomp.chem.uw.edu.pl/CABSdock), a web-based tool [17] to model the three
BL mAbs binding to the main peptides found with a recurrence in the phage display
experiments. The contact cut-off for the analysed peptide-antibody contacts was set at 4.5
Å. CABSdock groups modelling trajectories by hierarchical clustering. The models are
divided into 10 groups according to their structure similarities. For each cluster an average
sample is chosen by the program as the representative model. Clusters were evaluated for
their density, which is the number of elements divided by average cluster root mean square
deviation (RMSD). The average distance of the C atoms in all models of a cluster defines
RMSD. Thus, the greater a cluster density is, the more homogenous its model components
are. Therefore cluster density and binding site per peptide were taken into account upon
model reviewing. To evaluate realistic binding sites models where only one chain was
interacting with the peptide were excluded, as well as models where interactions were
located opposite from the ABS.
Two visualising software packages were used to interpret the .pdf output files of the
different modelling experiments: The PyMOL Molecular Graphics System, Version 1.7.4.5
(Schrödinger, LLC) and Discovery Studio Version 4.1 (Accelrys, Biovia). PyMOL was also
used to mark the conserved binding residues for the superantigen staphylococcal protein A
(SpA).
4.2.8 mAb-peptide ELISAs
To prove that the synthetic peptides bound in a specific way to the mAbs an affinity
ELISA per interaction was done. Cases 079 and 589 were hybridised with peptides VH, GL
and QS, while case 621 was tested with peptides GL and QS. For protocol specifications
refer to Supplemental Material and Methods.
4.2.9 Nuclear Magnetic Resonance
Purified mAbs binding to synthetic peptides were analysed with NMR [18]. For detailed
methodology see Supplemental Material and Methods. Broadly, mAb and peptide solutions
were irradiated to selectively saturate mAb resonances. The principle is based in irradiating
the mAb within the peptide solution to liberate a small part of the peptide, should the latter
be bound to the mAb. The disruption can be detected by comparing the pre- and post-
irradiation spectra with saturation transfer difference (STD) experiments.
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4.2.10 Statistical tests
Statistical experiments were carried out with the transfection experiment data. One-way
ANOVA (Kruskal-Wallis test) was done to compare the three different methods in cell
viability and positivity. Two-tailed Mann Whitney tests were done to compare effectiveness
in pairs of transfection methods against each other as well as region of preference in
peptide-to-antibody binding. For ABS-FR binding comparisons Mann Whitney tests were
performed for the mutated and the germline populations independently. The confidence
interval was always 95% and software used was GraphPad Prism, version 5.03.
4.3 Results
4.3.1 Lipofection transfection is more efficient than electroporation
Three different transient transfection reagents were tested in the mammalian cell line
HEK-293 T (Figure 4.1). There were statistical differences in the transfection efficacy
between both the lipofection and the electroporation method: Amaxa vs TransIT p=
0.0022, Amaxa-Lipofectamine p=0.0411, Lipofectamine-TransIT p=0.6991. When
comparing all three methods for cell viability there were no significant differences observed
(p=0.9897), while there were differences in positively transfected cell quantity, or efficacy
(p=0.0148).
Figure 4.1: Transient transfection comparison of the three protocols assessed.
Expression of IG was confirmed with SDS- and native PAGE (Supplementary
Figure 4.11) from both protein extracts and transfection supernatants of HEK-293 cells.
While case 079A was producing IG it was not being secreted and the light chain
*
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production was considerably less than the other cases. Cases 079B, 589 and 621 could
secrete IG as it could be detected in their supernatants. The most productive ratio and
incubation time was chosen to be 1:4:1 after 72h of transfection after Western blot and
protein concentration measurement.
4.3.2 Burkitt lymphoma antibodies show cross- and self-recognition in
immunohistochemistry
Heavy and light chain production was further proven with cell block staining of the
transfected HEK-293 cells. All tested blocks were positive for both the heavy and light
chain expression, with the exception of the empty-plasmid transfected cells (data not
shown). Original cryo material was positive for IgM in the three cases, case 079 and 621
expressed  and 589 showed  expression. When stained with the transfection
supernatants the 3 BL patient original material showed a cross-positivity on the biopsy
material from cases 589 and 621 when stained with supernatant from the 589 transfection
(Figure 4.2).
None of the analysed cell line blocks of four different lymphoma entities presented
binding when stained with the transfection supernatants of either case. However, there was
some cytoplasmic positivity detected in the transfected HEK-293 cell blocks when stained
with their own and the other cases’ transfection supernatants. Untransfected cell blocks
remained negative when stained with transfection supernatants of all three cases
(Supplementary Figure 4.12).
Figure 4.2. HE stainings of the original cryo BL biopsies are represented in the first
row. Underneath each HE image the corresponding case stained with supernatant of the 589
transfection is represented. All images are at 10x.
589 621079
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Figure 4.3. Rows represent the purified IgG antibodies used to stain the
corresponding coverslips containing fixed transfected cells (columns). Al pictures at 20x.
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IgG2a
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The transfected HEK-293 cells grown in coverslips and stained with transfection
supernatants showed cross-reactivity between the three BL mAbs clearer (Figure 4.3). All
three mAb presented cross- and self-reactivity when applied to the transfected cells in the
coverslips in variable levels throughout. Of note, the transfection supernatants stained cells
that had been only transfected with an empty vector, only containing a mouse constant
region (Figure 4.3,  plasmid column). Cells that had been transfected with no plasmid
(mock control) showed no positivity when stained with any of the 3 purified mAbs. Anti-
IgG2a staining showed antibody presence in membrane and cytoplasm.
The transfection supernatants were used to stain other tissues like gastrointestinal
biopsies (6 Peyer patches in FFPE, 1 fresh-frozen appendix, and 1 fresh-frozen small
intestine), one tonsil in fresh-frozen state and 3 brain biopsies corresponding to two
different patients. The gastrointestinal biopsies of Peyer Patches showed some unspecific
nuclear reactivity with 621 (Supplementary Results, Figure 4.13), also present in villi
epithelia in the same sample. Otherwise, no Peyer patch lymphocytes were specifically
recognised by any of our 3 mAbs. While the fresh-frozen tonsils, appendix and small
intestine showed some unspecific positivity, it was only when stained with the 589
supernatant and in the small intestine sample where it was deemed specific by our
pathology reviewer.  The reactivity seen in the small intestine biopsy was located in
neuronal cells (Figure 4.4, A). To confirm the nervous cell affinity of the 589 mAb three
brain DLBCL cases were stained with the 3 mAb supernatants. Again only sample 589
showed affinity to the tissues (Figure 4.4, B).
Figure 4.4. 589 transfection supernatant staining of different cryo preparations. A: Small
intestine cryo section. The main image is at 10x and the framed detail framed is at 20x. B: Brain
biopsies of DLBCL patients. All images are at 10x.
A B
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4.3.3 Recurrently interacting peptides to Burkitt lymphoma antibodies
A total of 104 sequences were read throughout the 6 phage display experiments, amounting
to a total of 59 different peptide sequences. The majority of the sequenced phages were
chosen out of positive ELISA wells (82/104, 79%, Figure 4.5, A) but the phages in 22
negative wells (21%) were also sequenced to control due to signals being weak.
Supplementary Table 4.2 and Figure 4.14 summarize all peptides translated from the 104
sequencing reactions performed.
Target-speciﬁc binders are molecules that bind specifically to the antigen-
recognising part of a particular antibody. Target-unrelated peptides (TUP) bind to other
antibody regions instead, such as their constant fragments, or to elements of the screening
system (plates, streptavidin, protein G, etc.). On that note, the resulting phage display
12mer sequences were screened for known motives such as plastic binders and selective
advantage sequences by reviewing literature on the matter [14,15]. Motive SSL, a TUP, was
found within the peptide sequences, such as SGVSSLRGNDVR and HTSSLWHLFRST.
Peptide SGVSSLRGNDVR was interestingly sequenced out of a negative ELISA well,
while peptide HTSSLWHLFRST had a low recurrence, having being detected once in a
negative and once in a positive ELISA well. Plastic binder motives were also detected in
the overall 12mer sequences, mainly those containing a tryptophan (W) pair, separated by
one, two or three random amino acids. Specifically, motives with two W separated by one
(WXW) or two (WXXW) different amino acids were found in six independent sequences
(Supplementary Table 4.2).
The total 59 different sequences collected in the six phage display rounds were
screened with BLAST for phage protein detection. The peptide sequences were also
specifically BLASTed against the nine M13 phage proteins to control for biased phage
selection. Of concern were the phage coating proteins or presented in its exterior (proteins
III, VI, VII, VIII and IX). Only the alignment to proteins I, III and IV gave matches of
any kind. While proteins I and IV gave short hits (5 or less amino acids in common and
non-consecutive), protein III presented two interesting alignments to peptides
FIPFDPMSMRWE and DPFWSHPCVLSW. Although the latter only appears once and
is not further considered peptide FIPFDPMSMRWE is one of the recurrent ones, possibly
being its selection due to phage binding, even if only partially.
Information content of only the positive ELISA sequences from the phage display
experiments were generated (Figure 4.5, B) with the INFO software, which estimates the
likelihood of random occurrence of given sequences. It yielded a normal distribution and
overall a high average information content, pointing to a correct and specific phage display
screening. Contamination though the different phage display runs was thus ruled out. A
further control procedure was performed with MimoDB database, which aims to be a
virtual tool for phage display experiment control. Its database consists of peptide sequences
87
with known targets. At the time of analysis Version 4.3 contained 22418 peptide sequences,
2463 mimotope sets, as well as unique peptides, targets, templates  and libraries. No
sequences retrieved in the phage display experiments for the 3 BL mAbs gave back a
known peptide of relevance.
Figure 4.5. A: Peptide sequences retrieved from positive post-phage display ELISAs.
B: Information content distribution of the peptides found in positive ELISA wells. The
resulting histogram is normalised to 100 peptides.
All 59 peptide sequences were clustered in ClustalOmega including those found by
another group studying BL cell line epitopes [19]. The resulting multiple sequence
alignment showed no relevant similarities, either in sequence or amino acid properties (not
shown). Another alignment is performed with only the most recurrent peptides found with
interaction to the 3 analysed BL mAbs (Figure 4.6) and it is coloured by ClustalOmega’s
amino acid coding. The small and hydrophobic residues are marked with red colour (Als,
Val, Phe, Pro, Met, Ile, Leu, and Trp). In blue are the acidic amino acids (Asp and Glu) and
in magenta the basic ones (Arg and Lys). Finally, glycine and the amino acids containing
amine, hydroxyl and sulfhydryl groups are labelled in green (Ser, Thr, Tyr, His, Cys, Asn
and Gln). After domain reviewing of all peptide sequences with the MEME tool
(http://meme-suite.org/) no conclusive results were produced, with only a vague DNA
motif and several infrequent amino acid domains detected (a representation can be found
in Supplementary Figure 4.15, A and B).
A
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Sequence Occurrence 079 589 621
1 VHWDFRQWWQPS 12  
2 GNNPLHVHHDKR 8 
3 FIPFDPMSMRWE 4  
4 GLHTSATNLYLH 4   
Random1 QSHWFVPWQDRW -
A B
C
D E
Figure 4.6. Peptide sequence alignments and bindings A: Peptide alignments and B:
cladogram of recurrent putative epitopes of BL, named “cell-“ [19]. Numbers 1-7 mark the
most recurrent peptides in the phage display experiments performed in this study. C: All
synthetic peptides tested either in NMR or affinity binding in ELISA and their occurrence in
the phage display experiments. Peptide named random1 is the randomised peptide from
number 1, used as control. D and E: Specific binding for peptide-589 ELISA results for
peptides VH and GL respectively.
The four most recurrent peptides that were not suspected of having suffered a
selection bias (number 1-4 in Figure 4.6, C) were analysed in pBLAST with non-redundant
protein sequence databases (including PDB, SwissProt, PIR and PRF). As the peptides are
only 12 amino acids in length the E value had to be taken as a broad estimate of match
significance. Randomised peptide QSHWFVPWQDRW (QS) showed BLAST results of E
value >100 after already the fourth hit, therefore in the subsequent analysed peptides 100
was taken as an ultimate maximum for hits to be considered. In the case of peptide
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VHWDFRQWWQPS (VH) there was a predominance of putative human pathogens like
Enterobacteriaceae, Pseudomonadaceae, Streptomycetaceae, Mycobacteriaceae,
Lactobacillaceae, Aeromonadaceae and Vibrionaceae, all with an <50 E value
(Supplementary Table 4.3). The majority of hits represented cytoplasmic proteins (data not
shown). There were hits for specific proteins of the regular melon (Cucumis melo), the cotton
plant (Gossypium raimondii) and the common housefly (Musca domestica). Results for peptide
GNNPLHVHHDKR yielded high E values (>81) from the first hit (Supplementary Table
4.4). However, nuclear and cytosolic proteins of known human pathogens appeared in the
list, such as Microbacterum sp., Cedecea sp. (Enterobacteriaceae), Streptococcus sp., Streptomyces sp.
and Candida albicans. For peptide FIPFDPMSMRWE proteins present in gastrointestinal
pathogens and parasites such as Gammaproteobacteria, Trypanosoma cruzi, Fusobacterium
varium and Leptospira sp. were matched with <60 E values, however overall higher than
those of the VH peptide (Supplementary Table 4.5). Of note, the F-box/kelch-repeat
protein of tomato (Solanum lycopersicum) and the alcohol dehydrogenase of the castor oil
plant (Ricinus communis) were also within the most relevant hits.
Peptide GLHTSATNLYLH (GL) was commonly detected in all three mAbs. It was
the third most recurrent peptide sequenced throughout the six phage display experiments
and its BLAST output contained mostly proteins of alimentary-related products, such as
sugarcane (bZIP transcription factor 29), millet (basic leucine zipper 9-like), corn, and
apple (Supplementary Table 4.6). The proteins related to human pathogens had E values
higher than 200 and included Mycobacterium, Firmicutes, Acetinobacter and Clostridium spp..
Strikingly, peptide GL was also detected in a MCL sample from an independent laboratory
(personal communication). When aligning the MCL IG sequence to those of the 3 BLs
between 45-48% identity percentage in their heavy chains and a 68-83% similarity through
the light chains was seen. Belonging to a different IGHV family (V5), converging residues
between the MCL and the 3 BL mAb sequences were mostly located in the FR rather than
their CDRs (data not shown).
To further prove the binding of the mAbs to the VH and GL peptides ELISAs
were performed. Each antibody was tested with both peptides and the QS control, except
for antibody 621, which didn’t produce VH sequences in the phage display experiments
(Supplementary Figure 4.15, C-D). Binding was weak but an increasing signal for specific
binding could be detected with higher antibody molarity in all peptide-mAb tested
combinations. Of note, peptide GL produced complete binding curve when combined to
antibody 589 (Figure 4.6, E).
4.3.4 Structural 3D modelling of specific peptides and superantigen SpA to BL antibodies
Binding or docking models were generated with the online tool CABSdock. Each docking
assessment yielded a total of 10 possible models, which were evaluated for ABS or FR
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binding and cluster density. Upon three-dimensional modelling of the 3 clones mAb there
was a trend of some antibody to bind tested peptides more frequently either in ABS or in
FR. Cases 079 and 621 mostly bound peptides in their ABS, while mAb 589 contacted
them most frequently in its FRs. Comparing 13 recurrent bindings (079-VH, 079-GL, 079-
SG, 589-VH, 589-DW, 589-FI, 589-GL, 589-AD, 621-DW, 621-FI, 621-GN, 621-GL and
621-SG) no preference was seen to either binding ABS or FR peptide-wise.
A localisation analysis of the structurally conserved motifs for staphylococcal
protein A (SpA) present in our 3 BL mAbs was performed (Supplementary Figure 4.16).
They were localised mainly in the heavy chain FR3 of all 3 mAbs.
4.3.5 NMR assessment of peptide-antibody binding
Nuclear magnetic resonance is able to characterize peptide sequences with the use of
several resonance spectra. In our case we characterized each peptide tested for binding and
thus we were able to specify which amino acid was interacting with the mAb in the test.
Supplementary Table 4.7 summarizes all interactions attributed to the peptide amino acids
when bound to each mAb. Moreover, by resonance properties observed in the
characterisation (2D COSY and NOESY) experiments of peptide GL a tendency to form a
-turn between the T7N8L9 (Amino_acidposition_in_peptide) portion was seen. The same molecule
showed spatial interactions between residues A6T7N8 and between Y10L11. Peptide GL,
thus, seems to have a light structural tendency, possibly belonging to a conformational, as
opposed to a linear, epitope.
Analysis of the peptide-mAb binding with nuclear magnetic resonance could
confirm some results seen in the ELISA experiments. Saturation transfer difference plots
confirmed binding of the GL peptide with all three studied BL mAbs (Figure 4.7). Peptide
GN with mAbs 079 and 589, as expected, didn’t show binding; while binding to mAb 621
could not be confirmed. Binding of peptide FI to mAbs 589 and 621 resulted with low
signals in the peptide aromatic residues, but consistent binding throughout the peptide
length could not be confirmed with NMR in neither (Supplementary Figure 4.17, B, C).
Peptide VH was seen to be unstable in H2O solution by showing degenerated proton
spectra after ON storage. Accordingly, fresh solutions were prepared before each analysis.
VH binding to mAb 079, albeit weak, was confirmed; but to mAb 589 it was not (see
Supplementary Figure 4.17, A). However, the unstable characteristic of this peptide in its
linear form could be a sign for a nonlinear or conformational epitope containing part or all
VH residues.
Peptide QS, formed by the same scrambled residues of peptide VH was tested with
mAb 589 (Supplementary Figure 4.17, D). Some saturation was observed in the aromatic
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group region, possibly due to the irradiation transmission or some residues interacting to
the mAb unspecifically.
Figure 4.7. In red, STD spectra of peptide GL with A: 079, B: 589 and C: 621 mAbs
after irradiation at 5952 or 7110Hz are shown. For each STD graph a proton spectrum (blue) is
represented underneath, showing the amide, aromatic groups of the side chains (between 6-
9ppm) and aliphatic groups (containing C and methyl groups) of the analysed peptide
(between 0-5ppm).
4.3.6 BcR CDR2 stereotyped mutation is relevant in recurrent peptide binding
The three studied BL antibodies contained a stereotyped CDR2 mutation in codon 64. It is
unclear, but suspected, whether unique and recurring mutations in lymphoma signal a role
of antigens in its pathogenesis. To assess if the S>N mutation in CDR2 was determinant in
antigen-binding peptide sequences obtained through phage display experiments were
docked in silico using CABSdock. For each antibody a mutated (containing asparagine) and
germline (with serine) version in codon 64 were docked to several phage display peptides.
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For each peptide-mAb studied interaction (079-VH, 079-GL, 079-SG, 589-VH, 589-DW,
589-FI, 589-GL, 589-AD, 621-DW, 621-FI, 621-GN, 621-GL and 621-SG) the number of
detected ABS and FR interactions was measured and statistical differences were calculated
between the mutated and the germline populations. Only in the ABS binding comparison
the difference was statistically significant between the mutated and the germline groups
(p=0.017), showing that there was indeed an effect in reverting the stereotyped mutation to
its germline sequence original (Figure 4.8).
Figure 4.8. Number of times the sequences of the three BL mAbs have bound
relevant phage display peptides in their ABS (A) or outside (B) of it.
The mutation reversion effect translated in different in silico binding of the mAbs to
the peptide sequences selected by phage display. Comparison between the amount of
peptide binding to the mAb (number of amino acids contacting the antibody or number of
contacts between peptide and antibody) between the CDR2 mutated sequences and the
models containing the germline codon 64 found no statistical differences (p=0.368 and
p=0.731 respectively, not shown). This shows that while there was no evidence that the
binding of the peptide to the mAb was weakened or strengthened by the CDR2 mutation
the areas where the peptides made contact were preferably the ABS for the mutated in
comparison to the ones carrying the germline amino acid.
4.4 Discussion
In our IHC analysis an inter-sample cross- and auto-reactivity was detected by at least one
of the produced mAbs from the most productive transfection technique. The monoclonal
antibody (mAb) from sample 589 presented auto-reactivity on the original biopsy slides
when stained with the transfection supernatants and also stained the original patient cryo
material of case 621. The same mAb had specificity for neuronal tissue of the intestine and
the brain. There was a more broad interaction of all 3 BL mAbs, which reacted against cells
transfected with a vector containing their own IG sequence and against the other two
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cases. This cross-reactivity seen in acetone-fixed transfected HEK cells was not only
restricted to cells with full-insert plasmids, but was also seen in cells that had been
transfected with a vector containing only the mouse constant region. However, HEK-293
cells that were mock transfected (with no plasmid) were not stained with any mAb
supernatant. Most probably, thus, the mAbs were either reacting against themselves and/or
against the mouse IG constant region present in the culture supernatant, suggesting broad
antibody affinity or lack of antibody maturation.
The peptides encountered in phage display experiments showed two types of
possible antigen origin: pathogenic or alimentary. While peptide GNNPLHVHHDKR was
only homologous to proteins of known human pathogens, peptides VHWDFRQWWQPS
and FIPFDPMSMRWE hit both pathogen and alimentary-related proteins. The third most
recurrent peptide found in all 6 phage display experiments with the BL mAbs was
GLHTSATNLYLH. Not only was this peptide also present in independent MCL phage
display experiments, but its matching proteins were mostly alimentary. As epidemiological
studies have demonstrated there is a negative correlation between the risk of suffering BL
and having allergy [7]. The fact that one transversal possible epitope (namely peptide GL)
had sequence homologies with nutritional elements could signal an undeveloped food
allergy or intolerance.
Moreover, conserved residues between the BL and MCL mAbs recognising GL are
located in the FR region. Since FRs are less affected by somatic hypermutation events [20]
this was expected, but it could also be a sign of FR binding, and therefore unspecific or
inmature mAb recognition. Another sign of possible unspecific FR binding is the
localisation of Staphylococcus aureus protein A (SpA) binding motifs in the 3 BL mAbs. SpA
has been related to IGHV3 and V4 family binding, stimulating the survival of those B-cells
expressing them [9,21].  The special property of these IG rearrangements would consist in
superantigen binding through subgroup-specific residues outside the usual ABS [22].
A previously was the case with biased IG gene repertoire, stereotyped mutation
studies are also lead by chronic lymphocytic leukemia (CLL) study groups [22,23] but not
much is known for BL. Our 3 studied BL cases were chosen due to containing the same
stereotyped S>N mutation in codon 64 of the CDR2 region. Having detected putative
antigenic peptides for all 3 mAbs through phage display, docking experiments were
performed to assess if the CDR2 mutation affected peptide binding. Mutation reversion
from the patient’s original arginine to the germline serine showed significant differences in
the location of peptide binding in silico, being the mutated antibody version more efficient
in ABS binding than the germline version. Since tethering of an antigen to the antibody
ABS is considered to be a sign of specific binding, the validity of the peptide sequences
discovered by phage display is reinforced.
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Furthermore, the stereotyped mutation present in the 3 BL mAbs could be a sign
of an antigenic exposure prior to lymphomagenesis. However, not a sign towards a
recurrent motif throughout different BL samples and cell lines was found (see phage
display epitope clustering and MEME results). There doesn’t seem to be a clear linear or
structural pattern by aligning the sequences found by us and other groups working with
Burkitt lymphoma materials. In the immunohistochemical stainings we were able to show
cross-reactivity between the three studied BL samples but also cross-tissue affinity of at
least one mAb sample. This heterogeneous reactivity can be explained by the existence of a
nonlinear epitope (or several mimotopes) or even an unspecific autoreactive mAb nature.
The entropic or sticky binding site would make defining single epitopes difficult. That
being said, an initial triggering event for the three studied BL cases doesn’t seem to have
been related to autoreactivity per se, since no human proteins resulted from the BLAST
screening of the phage display sequences. Even in such a small sample experiment it can
already be pointed out that BL mAbs can recognise peptides with homology to different
origin proteins, which would advocate for a unspecific or inmature nature of BL BcRs. The
multiple antigenic pseudo-affinity phenomenon is seen in also CLL [8], where many
antigens have been postulated to be related to the lymphoma pathogenesis. From
autogenous potential antigens such as non-muscle myosin heavy chain IIA present in
apoptotic bodies [24], or the i and I blood carbohydrates [25], to exogenous molecules like
fungal polysaccharides [26] and viral infections such as Hepatitis C virus [27], CLL has a
wide array of antigenic candidates. Thus, like CLL, BL could also have in antigens a key
component in its pathogenesis.
With several protein-origins as antigenic candidates for the analysed BL mAbs there
probably was not a single organism driving or carrying the hit-and-run event prior to their
lymphoma onset.
What remains to be fully understood is the missing link between antigenic contact
and B-cell malignancy. Several studies have focused to elucidate the molecular causes
behind B-cell lymphoma [28,29] and Burkitt lymphoma in particular [30,31]. A very
interesting development was that of Muppidi et al. regarding mechanisms by which a
signalling disruption of the membrane receptor G13 pathway promotes loss of
confinement in germinal center of B cells, leading to dissemination within the LN, lymph
and blood. This is due to loss of function mutations of the receptor itself (GNA13,
encoded by G13), of its coupling receptors P2RY8 and S1PR2, and of its effector
ARHGEF1 [32]. Furthermore, Peyer’s patches involvement in early BL has been seen in a
new and promising mouse model for the disease [33]. We could not show reactivity to
heterologous Peyer’s patches with our mAbs but a screening for such human tissues with
antigenic markers would be an interesting test.
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As investigations on BcR signalling and nature develop [34] we gain insight in how
pathogenic events may unfold. Yet, a full picture that shows the main hypothesis from
antigenic hit-and-run to B-cell activation, linked to secondary mutagenic events leading to
lymphomagenesis is still unpainted. What seems clear until now is that the characteristics
and signalling function of the BcR in lymphoma are pivotal to both understand ontogeny
and improve treatment options.
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Web tool references:
Translate tool: http://web.expasy.org/translate/
INFO software: http://www.northeastern.edu/xray/downloads/info-program/
MimoDB: http://immunet.cn/mimodb/
Clustal Omega: http://www.ebi.ac.uk/Tools/msa/clustalo/
MEME Suite: http://meme-suite.org/
CABS-dock: http://biocomp.chem.uw.edu.pl/CABSdock
Rosetta Antibody Protocol: http://rosie.rosettacommons.org/antibody
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4.5 Supplementary data to Putative antigenic epitopes of CDR2 stereotyped-
mutated Burkitt lymphoma antibodies
4.5.1 Supplementary Material and Methods
 Vector cloning for plasmid expansion
Vector pCR2.1 from the Topo TA cloning kit is used (Thermo Fisher Scientific) to amplify
the immunoglobulin sequences needed, a procedure that already ads the poly-A tails
needed for the cloning. When the plasmids are transformed to TOP 10 E.coli competent
cells (Thermo Fisher Scientific) following the company’s manual they are spread to LB
agarKan plates to grow overnight (ON) at 37°C.
After the ON incubation the plates are placed at 4°C for further clone amplification.
Three milliliters of LBKan medium is used to generate minipreps that will contain 1 picked
colony. Per case and chain 7 minipreps are generated and incubated ON at 37°C. The
minipreps are centrifuged for 10minutes at 5000g and the supernatant is discarded. The
resulting pellets are frozen at -20°C. Bacterial pellets are purified using peqGOLD Plasmid
Miniprep Kit II (PeqLab) following the company’s guidelines. Plasmid DNA concentration
is measured with NanoDrop.
To control for the correct insert introduction to the vector an enzymatic digestion is
prepared as appears in the Buffer and Reactions List. The reaction is maintained at 37°C
for 2h and then an electrophoresis gel at 1% agarose is run for 20 minutes at 120V with the
restriction digestion material. Tubes containing clones with a reliable band pattern are
chosen and sequencing reactions are prepared with the M13 forward and reverse primers
(TOPO® TA Cloning Kit, Thermo Fisher Scientific). The sequencing reaction products
are cleaned and sequenced as before. After an extensive sequence analysis the original
sequences previously sequenced by another group are compared to the recent ones. The
sequences are blasted to the IgBlast (http://www.ncbi.nlm.nih.gov/igblast/) and
IMGT/V-QUEST (http://www.imgt.org/IMGT_vquest/share/textes/) databases to be
checked for productivity and compared to their germline sequences. The samples that
show no sequence changes are chosen as reference material for the future.
The pCR2.1 TOPO TA cloning products are amplified via PCR. A gel
electrophoresis at 1% agarose is done for size control. The right bands are cut and DNA is
isolated from them with NucleoSpin® Gel and PCR Clean-up kit (Macherey & Nagel).
DNA concentrations are measured with NanoDrop.
 Vector cloning for transfection preparation
The vectors to be used for mammalian cell transfection, pFUSE2-CLIg-mI1 and pFUSE-
CHIg-mG2a, are amplified in One Shot TOP10 Chemically Competent E.coli (Thermo
Fisher Scientific), extracted with PureLink® Quick Plasmid Miniprep Kit (Thermo Fisher
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Scientific), and their DNA concentration measured with NanoDrop and fotometer. In
order to control the clones a restriction reaction using EcoRI for 2h at 37°C and a
subsequent 1% agarose gel electrophoresis is done.
To make insertion to pFUSE vector easier extra restriction sites and overhangs
(Supplementary Figure 4.9) are cloned inside the insert sequences. Overhangs are 6nt long
and are generated randomly. Some nucleotides are added to complete codons at the 3' end
of some sequences, to avoid frame shifts in the mouse constant region of the vector.
Primers used are listed in Table P4 of the Primer Annex.
Supplementary Figure 4.9. pFUSE vector modification strategy to obtain new
restriction sites in the sequences of interest.
The modified inserts are controlled with an electrophoresis gel and the extracted
bands are purified with the NuceloSpin Extract II kit (Macherey & Nagel). Then, a
digestion with the appropriate restriction enzymes is performed at 37°C ON (heavy chains
with EcoRI and NheI and light chains with EcoRI) to prepare the inserts to be attached to
their vector. After digestion the inserts are purified with the QIA Quick PCR Purification
Kit (QIAgen).
On the vector side, the receiving pFUSE vectors are digested as their inserts. The
digested vectors are dephosphorylated at 37°C for 30 minutes. The dephosphorylated
vector is cleaned with a phenol-chloroform protocol: the dephosphorylated samples are
brought to 200µl volume with distilled water and a further 200µl of
phenol:chloroform:isoamyl alcohol (25:24:1) is added. The mixture is vortexed and
centrifuged for 10 minutes at 14000 rpm. The resulting upper phase is brought to a fresh
tube, to which 600µl of 100% EtOH is added. After mixing, 20µl of 3M sodium acetate
(pH5.2) is added to the mix and all is vortexed before centrifuging it again for 15 minutes
at 14000 rpm. The supernatant is discarded, leaving the pellet to be washed with 500µl of
70% EtOH. Finally, the pellet is left to dry and 30µl of distilled water is added to the tubes
to resuspend the resulting DNA.
Heavy chain
Light chain
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Then, samples are controlled via gel electrophoresis and their DNA concentration is
measured in Qubit (Thermo Fisher Scientific). The quantity of each vector to be used in
each ligation reaction is calculated with the following formula:Insert quantity (ng) = Vector quantity (ng)  Insert size (Kb)Vector size (Kb) Molar ratio (insert: vector)
The molar ratio used is 1:3 (insert:vector) and the vector quantity is 40ng. The
ligation reaction is performed at 16°C for 2 hours with T4 ligase and its buffer (New
England Biolabs). And right after the ligated products are transformed to OneShot
Chemically Competent Cells (Thermo Fisher Scientific) according to the companys
guidelines.
The transformed cells are plated to either Zeocine (heavy chain pFUSE) or
Blasticidin (light chain pFUSE) LB plates. In further minipreps and maxiprep specifications
the right antibiotic is used in each respective case. Per case a total of 5 clones are selected
and brought to minipreps as previously described. After the ON incubation plasmids are
extracted with peqGOLD Plasmid Miniprep Kit II (PeqLab) and plasmid concentration is
measured in Qubit (Thermo Fisher Scientific). Once again, an enzyme restriction with
EcoRI and NheI as described above and gel electrophoresis is done for controlling
purposes.
Right clones are chosen by sequencing and the use of consensus sequencing primers
for both heavy and light chains. The primers bind up to the vector’s original sequence, so
that all insert is readable (see primers in Table P5 of the Primer Annex). The sequencing
procedure is carried out as previously. After assessing the sequences the mini preps that are
equal to the original samples are chosen.
To amplify the plasmids an OneShot TOP10 (Thermo Fisher Scientific) reaction is
done for each heavy and light chain. Backup glycerol stocks (25% final glycerol
concentration) are stored per sample. They are amplified with minipreps ON and in maxi
preps afterwards.
Since the multiple cloning site (MCS) of the pFUSE vectors is quite large and it is
located between the variable and the constant region (see vector maps in Annex) it is
mutated away to avoid antibody conformation problems. In case of the light chain vector it
is both mutated and digested due to its length. Primers used are listed in Table P6 of the
Primer Annex. The mutations are carried out by following the QuikChangeII protocol
(Agilent Technologies). After, the DpnI digestion (1 hour at 37°C) ensures that the
template material, which is methylated, is degraded leaving only the amplification product.
Then TOP10 cells are transformed following the provider’s manual. Minipreps, glycerol
stocks and plasmid isolation follow as described before. DNA concentration is measured
with Qubit® dsDNA BR Assay Kit (Thermo Fisher Scientific), and sequencing reactions
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are prepared. Control sequencing reactions are done as described above and maxipreps are
stored per case.
 Transfection experiments
HEK-293 cells (ACC305, DSMZ) are cultured in complete medium (RPMI, 10% FBC,
S/P) at 37°C and 5% CO2 before transfection. In order to decide with transient
transfection is most suitable a comparative set-up is made where a GFP-containing plasmid
(pmaxGFP®, Lonza) is transfected to 6-well plates containing HEK-293 cells. Three extra
wells are taken as control, with empty plasmid (pFUSE). Three methods are compared:
lipofection with TransIT (Mirus) and Lipofectamine 2000 (Thermo Fisher Scientific), and
electroporation with Amaxa’s Nucleofector (Lonza) following the manufacturer’s
protocols.
For the comparative assessment the supernatants of the three transfections are
collected 24, 31, 47, 54, 72 and 78h after transfection. A fraction of the collected cells is
used to assess its viability and the rest to generate cytospins. Cytospins are done by washing
the cells off of the well surface with 1ml of 1xPBS. According to the cell density between
250µl and 500µl is applied to each funnel in a Cytospin3 machine (Shandon) to generate at
least 2 cytospins per culture well. Loading of the cytospin machine is done according to the
company’s guidelines. The cells are centrifuged at 1000rpm for 5 minutes. The resulting
cytospin slides are left to dry ON and stored at -80°C before DAPI staining. With an
Axioplan 2 fluorescent microscope (Zeiss) pictures of the cytospin slides are made and
analysed using the TissueQuest v3.0 (TissueGnostics) image analysis program.
Further transfection tests are designed to assess the best molarity ratio between the
heavy chain, light chain and the pAdvantage plasmids. Molarity calculation for vector
quantities has to be taken into account upon doing transfections. Three ratios are tested
(H:L:pAdvantage): 1:4:1, 2:3:1, 1:4, 1:4Ø. The transfections of cases 079A, 079B, 589 and
621 are done with complete RPMI medium [10% Ultra Low IgG FBS (Thermo Fisher
Scientific), without antibiotics]. Six 6-well plates are used to test different plasmid ratios
and collection times in triplicates. After collecting the supernatants the cells of two wells
from each triplicate are resuspended with 1ml of culture medium and further processed
into cytoblocks. The remaining well of the triplicates is resuspended in 1ml of culture
medium, centrifuged at 1000rpm for 2min, its supernatant is discarded and the remaining
pellet is then placed in liquid N2 and later at -80°C for storage for protein extraction.
Transfection is scaled up to reach significantly higher protein quantities for all cases.
 Protein extraction and purification
Protein extraction is performed to the available cell pellets (cases 079A, 079B and 621): for
each well of collected cells 200µl of lysis buffer (see Buffer and Reactions List) and 30 µl of
the cOmplete protease inhibitor (Roche) is mixed until the cell pellet is resuspended. The
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mixtures are incubated on ice for 30 minutes and centrifuged at 14000rpm and 4°C for 10
minutes. The resulting supernatant is pipetted in a clean microtube and freeze-shocked in
liquid N2. Finally the protein extracts can be stored at -20 or -80°C.
IgG purification with protein (MAb Trap Kit, GE Healthcare) is carried out for all
cases’ supernatants following the suppier’s guidelines. On upscaled transfections the MAb
Trap 1ml columns are substituted with the 5ml HiTrap columns (GE Healthcare). Buffers
used are listed in the Buffer and Reactions List.
After independently purifying the secreted Ig from the transient transfection
experiments the fractions that result with higher absorvance at 260nm (but lower than 0.01
at 320nm) on a fotometer are brought together. Dialysis in 5 litres of 1x PBS throughout
24h with a minimum of 2 buffer changes is followed. Afterwards the purified IgGs are
concentrated with Amicon® Ultra-4 Centrifugal Filter Units 30k (Merck-Millipore).
All supernatants and protein extracts are measured with the Qubit Protein Assay Kit
(Thermo Fisher Scientific) for protein concentration measurement.
 Western blots
Reducing Western blots are made with NuPAGE® Novex® 4-12% Bis-Tris Protein Gels
(Thermo Fisher Scientific) with protein extracts and supernatants from the transfected
HEK-293 cells. On the gels the MultiMark® Colored Standard (Thermo Fisher Scientific)
is used as ladder, with NuPAGE MES as running buffer (Thermo Fisher Scientific). Gels
are pre-run for 20 minutes at 40V after rinsing the wells with running buffer without
samples. Samples are complemented with the 1x loading dye and denatured for 5 minutes
at 95°C before being loaded to the gel. IgG2a mouse isotype control (BioLegend) is used as
a positive control on a 1:10 dilution. Membrane transfer is carried out in cold conditions
for 1h or ON at either 100 or 20V respectively on Amersham Hybond-P PVDF
membranes (GE Healthcare). Simply Blue SafeStain (Thermo Fisher Scientific) is used to
ensure product transferred, following the supplier’s guidelines. Membrane blocking is done
in blocking buffer (see Buffer and Reactions List) during 1h at RT with light shaking.
Blocking is followed by a wash in 1xTBST during 5 minutes and 2h incubation with 1:5000
in blocking buffer of the primary antibody (except at 1:2500 for the anti-bovine antibody).
Next, three washes of 15 minutes each in 1xTBST and the secondary antibody incubation
(at 1:10000) for 45 minutes in blocking buffer is done. Two more washes in 1xTBST and
one in 1xTBS at 15 minutes each follow. Membranes are then processed with Amersham
ECL Prime Western Blotting Detection Reagent (GE Healthcare) according to the
company’s guidelines. Stripping of the PVDF membrane is done with 100ml of the
stripping buffer and 700µl of -mercaptoethanol (see Buffer and Reactions List) at 50°C
for 30 minutes with light shaking. The membrane is subsequently washed three times for
10 minutes with 1xTBST.
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Native Western blots are performed for the 1:4:1 and 72h ratio and proteinG-
purified supernatants except for case 079A where no protein is being detected in the
supernatants, for such case the protein extracts are used. The protocol used is the one
supplied by NativePAGE™ Novex® 4-16% Bis-Tris Protein Gels (Thermo Fisher
Scientific). Materials used are listed in the Materials table. Specifically, Light Blue Cathode
Buffer (containing a 0.002% of G-250 Coomassie) is used in the runs and is prepared as
described in the company’s protocol. The native gels are run at 150V for 120 minutes, at
RT. After the gel run the Coomassie staining protocol in the manual is performed,
followed by the Western blotting per se. The transference is done with the transfer buffer
used for the denaturing Westerns, without methanol at 75V for 1h, starting at 130mA and
finishing at 100mA. After blotting the membrane is stained with the Ponceau S solution for
control. The membrane is blocked and stained as detailed in the denaturing version.
 Cyto blocks
The cells are detached from the plate after 1xPBS wash and centrifuged for 10 minutes at
2000rpm. The resulting supernatant is discarded while the pellet is resuspended with 2ml of
4% formaldehyde. This fixation step is left 15 minutes at RT and it is centrifuged for 1
minute at 2000rpm. Then, the supernatant is discarded and 3 drops of protein glycerol and
2ml of 96% isopropanol are added to the pellet. The mixture is centrifuged for 5 minutes at
2000rpm. The pellet is scraped with a spatula and placed in a filter paper in a tissue capsule.
The fixed material is then processed as standard biopsy material and embedded in a
paraffin block.
 Staining protocols
Staining protocol for FFPE immunology
The formalin-fxed paraffin-embedded (FFPE) slides are left to dry after cutting at
37°C ON. They are then incubated in xylol for 20 minutes and afterwards apply
shortly the slides in 3 different cuvettes of xylol sequentially. The slides are then placed
through an alcohol line (100% three times, 96% two times and 70% once). The
endogenous peroxidase is blocked by incubating the slides in for 10 minutes in a
methanol H2O2 solution. The next step will unmask the antigen through 3 minutes
pressure-cooking of the slides in citrate buffer (Merck), pH 6.0.
The slides are then washed in regular water and in WB. After washing between
150µl of the 1:10 transfection supernatant is applied to each slide, and left for 1h at RT
covered to avoid drying out. The antibody CD20 (Dako) is used in the control slides at
1:600. The slides are washed in regular water three times and once in WB.
The secondary antibody (ab97245 or ab74316, Abcam) is applied at a 1:200
dilution in PBS, 150µl to each slide and left to incubate for 30 minutes in a wet
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chamber to hinder drying out. The slides are washed as previously. Next, a total of
100µl of Dako-DAB is applied to each slide and left to react for 5-7 minutes or until
the brown colour develops. Then the slides are washed with regular water. The
materials are stained with Mayer's hemalaun solution (Merck) at 1:4 dilution, washed
with regular water and left for 10 minutes in a clean water cuvette. The slides are
passed through an alcohol line (70%, 1x; 96%, 2x; and 100%, 3x) and 2 times with a
100% solution of alcohol-xylol (1:1). Finally, submerge the slides 4 times in xylol and
cover with Pertex (Medite).
All materials and providers are listed in the Material List.
Staining for fresh-frozen material, cytospins and cell coverslips
The fresh material and cytospins are fixed for 10minutes in acetone and left to dry.
They are washed with wash buffer (WB).
The target (10x) is prepared at 1:50 dilution, ON at RT or 1h at 95°C. Slides are
pre-processed with the target (Dako) either 7 minutes at 95°C or 3 minutes at RT.
After incubation, the slides are washed with WB.
After this step the protocol is valid also for the coverslips containing cultured
cells, although the washing is for this material more delicate, by use of a pipette and
always washed with WB.
The slides are incubated for 1h with the transfection supernatant (1:10) and
washed as previously. The primary antibody enhancer is applied in 3-4 drops per slide
and left to incubate 20 minutes. Washed with WB, three times with regular water (not
for coverslips) and one further time with WB, the slides receive each 3-4 drops of AP
polymer to each slide and are washed as before. The colour developing is performed
by applying 100µl of the appropriate reagent of the Lab Vision™ UltraVision™ kit to
the slides, and they are left to incubate 10 minutes. They are washed once with regular
water (except for coverslips, in WB) and stained with Mayer's hemalaun solution
(Merck) in 1:4 dilution for 3-6 minutes. After staining, the slides are washed with
regular water for 10 minutes, this time for all types of slides, but carefully and with a
pipette for the coverslips.
At this stage the coverslips are ready to be left to dry before covering them with
Aquatex (Merck) and protected with a further coverslip on top. The rest of the
materials will be further processed in an alcohol line (30%, 70%, 95%, 95% and
100%), once submerged in xylol and covered in Pertex (Medite).
All materials and providers are listed in the Material List.
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DAPI staining
Leave cryo slides or cytospins to dry and place 10 minutes in acetone to fix the
tissue. Let dry and submerge in PBS. In each slide apply 100µl of DAPI, 1:5000,
during 2 minutes. Wash 3 times in PBS and cover with mounting medium, a coverslip
and seal with transparent nail polish.
All materials and providers are listed in the Material List.
 Phage display
Phage display is established with PhD12 library (NewEngland Biolabs). Each run is done
separately to avoid cross-contamination from different antibodies and the reagents are all
prepared afresh per experiment. The purified IgGs are biotinylated using and following the
manual of EZ-Link™ Micro Sulfo-NHS-LC-Biotinylation Kit (Thermo Fisher Scientific).
Once biotinylated they are desalted through the Zeba Spin Desalting Columns within the
EZ-Link kit. Protein concentration is measured in Qubit (Thermo Fisher Scientific).
The K12 strain of Escherichia coli (ER2738) is used for phage amplification and
maintenance. Selection is done on IPTG/Xgal agar plates and bacteria are grown in LBTet.
A panning round is followed by an amplification round with their respective titrations.
Each titration is used to control for the appropriate number of phages present in the
eluates. Two rounds of panning and amplification are done before the 3rd panning, where
its titration will be used to independently amplify selected clones.
Specifically a panning round consists of preparing one 20ml LB culture of ER2738
from a plate in an Erlenmeyer and a 50ml-Falcon with 5ml of LBTet of ER2738 from a
plate (not older than a week). The E.coli cultures are placed in the incubator, at 37°C,
shaking and at 200rpm until the Erlenmeyer reaches an OD of 0,01-0,05 and the Falcon
tube 0,5. A 96-well panning plate (Nunc Immobilizer Streptavidin F96 Clear, Thermo
Fisher Scientific) is sealed and 4 wells are opened. The 4 wells are activated with 350ml of
1xDPBS each, they are washed with a pipette and fresh 1xDPBS is applied and left for 15
minutes. The panning mix contains 0,1µg of the biotinylated protein, 1µg of IgG2a mouse
isotype control, 20µl of the phage library (to reach 2x1011 phages) and the necessary volume
of 1xDPBS to reach 400µl. The mixture is kept on ice. Under a fume hood the DPBS is
discarded and 100µl/well of the panning mix is applied to each of the 4 wells and left to
incubate at RT for 10 minutes. One microliter of biotin is applied per well and incubated a
further 5 minutes at RT. The liquid is discarded and the plate is slapped down to cellulose
tissues to dry the wells. The used wells are washed five times with 1xTBST and the plate is
slapped face-down to some clean tissues each time. The bound phages are eluted by
pipetting 100µl of triethylamine (100mM) per well and left 10 minutes at RT with light
shaking. After the incubation the liquid is placed in a microtube that will quickly receive a
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further 200µl of 1M TrisHCl (pH9) to neutralize the acidic eluate. The tube with the
panning eluate is vortexed and placed on ice.
When the Erlenmeyer culture reaches an OD of 0,01-0,05 the phage eluate can be
inoculated for amplification. A small quantity of the panning eluate is kept for titration.
Infected bacterial culture is left in the incubator at 37°C for 4.5h shaking at 200rpm so that
the phages can be reproduced. After the amplification time is over the 20ml culture is
poured into a 50ml-Falcon. The culture is centrifuged during 15 minutes at 4000g at 4°C
and the supernatant is transferred to a clean tube and re-spinned, while the pellet is
discarded. The resulting upper 80% of the supernatant is transferred into a new tube,
where 1/6 volume of 20% PEG/2.5M NaCl is added. This solution will precipitate the
phages at 4°C ON.
When the Falcon tube reaches an OD of 0.5 the output titration can be done in the
range of 10-104. The titration protocol from the phage library manual is followed.
The next day the titration results are evaluated by counting the blue plaques in each
culture plate to calculate the plaque forming units per microlitre (pfu/µl). The amount of
transparent plaques (if any) has also to be taken into account, since that indicates wild type
phages and thus contamination. Only plates with 100 or more plaques can be assessed. The
ON PEG mixture is centrifuged at 4000g for 30 minutes at 4°C. The supernatant is
discarded and the tube is re-spinned shortly to remove the remaining supernatant with a
pipette. The phage pellet is resuspended in 1ml of TBS and placed in a microtube. The
tube is centrifuged at 14000rpm for 5 minutes at 4°C to pellet residual cells. The phage-
containing supernatant is then pipetted to a clean microtube and 1/6 of its volume of 20%
PEG/2 .5 M NaCl is added to it to precipitate the phages. The tube is incubated on ice for
15-60 minutes and then centrifuged at 14000rpm for 10 minutes at 4°C. The supernatant is
discarded, the tube re-spinned briefly and the remaining supernatant is removed by
pipetting. Two-hundred microliters of TBS are used to re-suspend the phage pellet and
finally the mixture is centrifuged for another 1 minute. The supernatant is placed in a
microcentrifuge tube and can be stored a maximum of 3 weeks at 4°C. This purified
amplification is titrated taking into account the panning titration. The supplier guidelines
are taken into account at this point. Normally 5 titration dilutions are made and left to
incubate at 37°C ON.
The second panning and amplification are done as the first round but with more
stringent washing of the panning step: 10 washes with TBST (0.05% tween).
The third panning round is done as the two previous but with 20 washes of TBST
(0.05% tween) and without a subsequent amplification. On the titration the plates with an
expected suitable plaque number will be duplicated in order to have enough plaques to pick
and amplify.
ELISA plates (Nunc maxisorp) are washed with sterile PBS and then coated with the
appropriate purified antibody. An antibody solution at 10µg/ml is generated in carbonate
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buffer (see Buffer and Reactions List). The plate is left covered at 4°C ON. Two ELISA
plates are prepared per phage display round and antibody: one with the antibody of interest
and another with a mouse IgG2a isotype control (ab18414, Abcam), in the same conditions.
The following day an amplification plate is prepared. A 1:100 dilution in sufficient
volume is generated out of an ON ER2738 culture grown in 10ml of LBTet at 37°C. When
the OD of the diluted bacterial culture reaches 0.1 some 220µl of the culture are pipetted
to each ELISA plate well. No bacteria are placed in the last 3 wells of the last row. Next, a
plaque is picked from the titration plates, not older than 3 days, and inoculated to each well
with E.coli. The plate is incubated at 37°C, shaking at 200rpm for 4h. After the incubation
time the plate is centrifuged at 4000rpm for 5 minutes and 50µl of the upper supernatant is
transferred to the washed ELISA plate. The upper 80% of the remaining volume is stored
on a clean standard plate.
After the ON incubation of the ELISA plates the liquid is blotted out of the wells
and the plates are washed. A wash round consists of a submersion of the plate in washing
buffer (see Buffer and Reactions List), decantation and blotting repeated four times. Then,
400µl of blocking buffer is pipetted to the plate and left at RT until the amplification plate
is ready. Another wash is performed and 50µl of the supernatant from the last
amplification is applied to the respective wells. In the last 3 wells a total of two positive and
one negative control are established. The first positive control and instead of the bacterial
culture contains 30µl of the purification of 2nd amplification round and the second positive
control receives 50µl of the 3rd panning elution. The negative control has only fresh LB
medium. The ELISA plate is sealed and incubated at RT for 1.5h with light shaking. A
further wash is performed and the detection antibody is applied to each well with a quantity
of 100µl and 1:5000 ratio in blocking buffer. The second positive control receives anti-
mouse-HRP in the same conditions instead. The plate is sealed and incubated 1h at RT
with light shaking. After one last wash the developing of the plate can be carried out
following the 1-Step™ Ultra TMB-ELISA Substrate Solution supplier’s instructions
(Thermo Fisher Scientific). Readings are taken at 650nm before stopping the development
and at 450nm after adding the H2SO4. The reference reading is the latter. Both antibody
and its corresponding anti-IgG2a mouse isotype control plate are processed in parallel in the
same day.
After the last amplification of the selected phages and the subsequent ELISA assay
the positive ELISA and a number of negative samples are selected on the amplified phages
plate and a DNA extraction of the existing phages is performed. Forty µl of PEG is added
to each tube containing phage in solution. Tubes are left at RT for 15 minutes and
afterwards centrifuged at 14000rpm for 10 minutes at 4°C. The generated supernatants are
discarded and the tubes re-spinned briefly. The resulting pellets are re-suspended in 20µl of
iodide buffer (see Buffer and Reactions List) and the tubes are tapped vigorously. Next,
50µl of ethanol is added to each tube and incubated for 15 minutes at RT. The samples are
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centrifuged at 14000rpm for 10 minutes at 4°C and their supernatants are discarded. A
100µl of cold ethanol (kept at -20°C) is added to each resulting pellet and then centrifuged
as before once again. Supernatants are discarded and pellets are left to dry. Finally, phage
DNA pellets are re-suspended in 15µl of TE buffer and measured in the NanoDrop
(Thermo Fisher Scientific) for DNA concentration estimation.
Sequencing reactions are performed with the M13 96-primer from the PhD12 kit
(New England Biolabs, sequence: 5’-CCCTCATAGTTAGCGTAACG-3’). Forty
nanograms of phage DNA are used per sequencing reaction, which is performed as
previously described but with 1µM of 96-primer. Sequence reaction purification is
performed as before and read in the ABI 3500 Sanger machine.
 mAb-peptide ELISAs
Biotinylated synthetic peptides (Eurogentec) are re-suspended in ddH2O to generate
1mg/ml concentrations. NeutrAvidin-coated 96-well plates (Thermo Fisher Scientific) are
washed three times with wash buffer (WB, see Buffer and Reactions List).
Supplementary Table 4.1. Positive and negative controls performed in the peptide-
mAb ELISAs with their respective mAb application (primary Ab) and use or absence of the
detection Ab.
After adjusting the pH to reach 6-7 the peptides are allowed to coat the plates in
1xPBS ON at 4°C. A total of 100µl of peptide at a 30µg/ml concentration is pipetted in
each corresponding well. Control (VHWDFRQWWQPS randomized, named QS) and test
peptides are placed in the same plate to be able to compare and subtract unspecific binding
(represented by the random peptide). All seven mAb dilutions are tested in duplicates, from
0.35uM to 84pM, separated by 1:4 dilution steps. The following controls are applied: a
positive control, and 5 negative controls (see Supplementary Table SX for their
specifications).
After the ON incubation of the peptides the plates are washed with WB three times
and they are blocked with 300µl of 1xTBS/3% milk powder at RT for 2 hours. Plates are
washed three times again with WB before 150µl of each mAb dilution step is pipetted to
each corresponding well in the plate. An incubation at RT for 30 minutes is followed by
another wash and the detection antibodies are applied at 100µl per well. The detecting
antibody HRP-anti-mouse (Jackson ImmunoResearch) is used at a 1:1000 in WB and HRP-
Coating peptide mAb Detection Ab
Control + Y Y Y,HRP-streptavidin
Control -1 Y Y N
Control -2 Y N N
Control -3 N Y, 079 Y, HRP-anti-mouse
Control -4 N Y, 589 Y, HRP-anti-mouse
Control -5 N Y, 621 Y, HRP-anti-mouse
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streptavidin is used at a 1:4000in 1xPBS. Plates are incubated in the dark with light shaking
for 30 minutes and then washed two times with WB and the last time with 1xTBS.
Developing of the signals is done as previously detailed.
To evaluate binding the results from the plate wells containing peptide QS are used
as unspecific binding and GraphPad’s protocol for Two sites Specific binding is followed
to generate graphical results.
 Nuclear magnetic resonance
Two milligram of peptide were dissolved in 550µl of distilled H2O and 50µl of D2O
(containing a small amount of DSS for calibration purposes). Once the solution was fully
resolved pH was adjusted to 5-6 by adding NaOD at 0.01N (5-10µl). The NMR equipment
used was a Brunker Avance 600 MHz spectrometer, with triple channel cryoprobe head.
Firstly, peptide proton nuclear magnetic resonances were assigned by double quantum
filtered COSY (correlation spectroscopy), 2D-NOESY (nuclear Overhauser effect
spectroscopy) and 2D-TOCSY (total correlation spectroscopy) experiments. Mixing times
of TOCSY were 60ms and 300ms for NOESY. Measurements were carried out at 280°K
(6.85°C) and 300°K (RT). Excitation sculpting with gradients was used for the water
suppression in all experiments and results were visualised with the TopSpin 3.2 (Bruker)
software.
Once peptides were deemed pure approximately 500pmol of mAb was added to the
2500µM peptide solution, making an end molarity of 0.8µM. The molar ratio used in the
mAb: peptide experiments was thus 1:3000. The mAb and peptide solution was irradiated
at +11.85ppm (7110Hz) and -0.9ppm (-540Hz) to selectively saturate the mAb resonances.
Gauss pulses for 12.5ms were used, without delay, 4s of saturation and 2s of acquisition
time. All STDs were either carried out at 1200, 2500 or 4800 scans for need of extra
resolution.
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4.5.2 Supplementary Results
 mAb production
The pFUSE plasmids (see Chapter 3) were used for the heavy and light chain sequence
transfections. Additionally an adjuvant plasmid (pAdvantage, Promega) was also used to
improve protein production. Two molar ratios between the three transfection plasmids
were tested, namely 1:4:1 and 2:3:1, representing “heavy chain : light chain : pAdvantage”.
An extra combination with empty plasmids (that is, plasmids without insert cloned in them)
was used, with the molecular ratio of 1:4:1, and labelled 1:4:1. Three collection time
points were also considered to detect the most effective production time, at 24, 48 and 72h
after transfection. The selected ratio and time point for supernatant collection was 1:4:1,
72h post transfection (Supplementary Figure 4.10).
When dealing with 079A, which included variant IGLV3-12*01 and IGLJ3*02 in the
light chain it was seen that while the protein extraction material contained a heavy chain
product the secreted, the light chain band was very weak. In the direct comparison of the
transfection supernatant products between case 079A (IGLV3-12*01 and IGLJ3*02) and
case 079B (IGLV1-51*02 and IGLJ3*01) it was seen that only cells transfected with case
079B secreted a heavy and light chain peptide (Supplementary Figure 4.11, C).
Supplementary Figure 4.10. Ratio and collection time experiment for case 589 in
triplicates. I.C.: isotype control,: size marker, : empty pFUSE plasmid supernatant, H:
heavy chain, L: light chain.
Further SDS-PAGE blots were done to check for minimal quantities of bovine
proteins that could be present in purified fractions of the mAbs. When loading the gel with
BSA the IgG heavy and light detecting antibodies do not react to it (not shown). Also, the
loading of complete medium from a mock transfection (with ultra-low IgG FBS) shows
that while in the Ponceau staining there is a band see in the medium-loaded well, the IgG
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detecting antibodies do generate a signal in the same lane, so there is no risk of false-
positive band detection.
Supplementary Figure 4.11. A-C, SDS-PAGE of A: 079A protein extraction of the
three different plasmid ratios; B: 621 in protein extraction of the three different plasmid ratios
tested: 1:4:1, 2:3:1 and 1:4:1 (with empty plasmids); C: 079A and 079B transfection
A
B
C
D
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supernatants, with pAdvantage on a ratio of 1:4:1 (H:L:pAdvantage) and 72h post transfection.
D: Native-PAGE the 079A protein extraction and 079B, 589 and 621 transfection
supernatants. The red square marks where the band for the recombinant IgG shoud be. The
arrows mark the lanes with the supernatant or protein extract materials. a, b, c: triplicates; I.C.:
isotype control,: size marker, : empty pFUSE plasmid supernatant, : no plasmid
supernatant, H: heavy chain, L: light chain.
 Burkitt lymphoma antibodies show cross- and self-recognition
Supplementary Figure 4.12. HEK-293 cells transfected with the 3 constructs (heavy
and light and adjuvant pAdvantage plasmids), embedded in paraffin blocks. A-C: cells
transfected with 079, D-F: cells transfected with 589, G-I: cells transfected with 621, J-L:
untransfected cells, M: untransfected cells stained with their own supernatant. The first image
row represents slides stained with supernatant of the 079 transfection, the second of the 589
transfection and the third row of images are cells stained with the 621 transfection supernatant.
All pictures are at 20x.
A D
B
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Peyer patches positivity was seen in one antibody of the 3 mAbs. However, it was
deemed not specific due to it staining also epithelial villi and showing a slight nuclear
specificity (Supplementary Figure 4.13).
Supplementary Figure 4.13. Intestinal biopsy showing a Peyer patch area. The same
biopsy is stained with antibody-containing supernatant from cells transfected with constructs
A: 079B, B: 589, C: 621 and D: no construct (mock control). All pictures are at 10x.
 Recurrent interacting peptides to Burkitt lymphoma antibodies
Two sets of phage display experiments were run per mAb. In the first round of phage
display the corresponding ELISA plate was only coated with the antibody of interest.
Sequences obtained with this procedure are marked in grey (Suplementary Figure 4.14) and
labelled as “uncontrolled”. On the repeated round of phage display two ELISA plates per
experiment were coated: one with the mAb of interest and another with an IgG2a antibody
(isotype control, ab18414, Abcam) to compare the positivity. The phages generated in the
last amplification round were distributed to the two plates and ELISA was performed as
described above. Well positivities were then assigned relative to the mAb (a well is only
positive in the mAb plate), the IgG2a mouse antibody (a well is only positive in the IgG2a
plate, yellow in Supplementary Figure 4.14).
Of the 104 sequences analysed 59 different peptides were detected. Some sequences
came from ELISA wells that didn’t develop colour above background. Within these
sequences there were some recurrent peptides that had shown positivity in the other two
antibodies and are marked with the same symbol across Supplementary Figure 4.14.
A B
C D
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Supplementary Figure 4.14. All sequences read in the six phage display experiments.
Sequences found in positive ELISA wells are in red (for the mAb plate) and yellow (for the
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IgG2a plate). Results from negative ELISA wells are in black. The sequences found in the first
round of phage display, where the second parallel ELISA with the IgG2a coating was not
performed are represented in grey.
Table continued on the next page
In positive, of which
Sequences Inpositive
In
negative
Ab
plate
Unattri-
butable
IgG
plate Unknown
Possible
binding to
1 VHWDFRQWWQPS 12 1 5 6
2 GNNPLHVHHDKR 8 1 3 3 2
3 GLHTSATNLYLH 4 2 3 1
4 ADWYHWRSHSSS 4 2 1 1 plastic
5 FIPFDPMSMRWE 4 1 1 3
6 SGVYKVAYDWQH 3 2 1 1 1
7 DWSSWVYRDPQT 3 1 3 plastic
8 QVGGMKRHTMDG 2 1 1
9 HVTSIFDWVGSW 2 2 plastic
10 FGNDHRFTQSST 2 2
11 HSWWSFKDALNW 2 1 1
12 DPIKHLEDQAST 1 1
13 SGDDWSTARTWH 1 1
14 SGIVDPPMSYPN 1 1
15 VARNNAWLDFTT 1 1
16 GDPGRKEAADLV 1 1
17 HPHDYNDLTSPF 1 1
18 GIATMPPTFSKQ 1 1
19 STPGCCAHDHFR 1 1
20 AYPQKFNNNFMS 1 1
21 DPFWSHPCVLSW 1 1
22 RDYHPRDHTATW 1 1 1
23 DCHDQSLLRWRK 1 1
24 KASGSPSGFWPS 1 1 1
25 APFDLEHFRPWY 1 1
26 DLILLNGGSQQX 1 1
27 QVNGLGERSQQM 1 1
28 ADLPAKSWTYMY 1 1
29 VDPGLTAHLMVE 1 1
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Supplementary Table 4.2. All sequences read in the six phage display experiments.
Results from exclusively negative ELISA wells are in red. Residues that account for target-
unspecific binding are in bold letters, and the rightmost column gives details to which type of
binding was detected. The sequences found in the first round of phage display, where the
second parallel ELISA with the IgG2a coating was not performed are represented in the
column labelled “Unknown”.
30 VHGLKYPSNSRQ 1 1
31 QGLWSWDMHYRY 1 1 plastic
32 FFPLTFPWTYYD 1 1
33 LDCRPDDLRVCS 1 1
34 RSKNSQMTQYQT 1 1
35 HHLRIPYALDQT 1 1
36 CARRTPHDGGSF 1 1
37 AGVALGWPGPHP 1 1
38 STPIFAEATARS 1 1
39 DRWVARDPASIF 1 1
40 HTSSLWHLFRST 1 1 1 unspecific
41 GWXSWVIGMQQH 1 1 plastic
42 TFTESPVNVTRV 1 1
43 QCSDDFTSECMW 1 1
44 FSWSMVMPWPTA 1 1
45 DSYPLRHYLYSV 1 1
46 KTVVPMKPYTLI 1 1
47 HYSWSWIAYSPG 1 1 plastic
48 VEXXQXPIXPXW 1
49 SLGAAGARVTTV 1 plastic
50 FQKDGVGPRYAL 1
51 HYPFMLPVLFIP 1
52 HSPQYWVHHWRG 1 plastic
53 TVDGSRTPLRSM 1
54 VAARTGEIYVPW 1
55 SVLEYNKMAQVA 1
56 HTSVLLLLFRST 1
57 ELEFVGV-GSAD 1
58 SMTVTLTIV-KS 1
59 SGVSSLRGNDVR 1 unspecific
TOTAL 104
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Supplementary Figure 4.15. DNA (A) and protein (B) motifs found within the 59
different phage display-obtained sequences. Motif A, albeit weak, was found in 58/59 (98%)
samples. The following motifs detected were only found in 2 and 3 sequences. Protein motif B
was found in 3/59 (5%) samples. Peptide-mAb binding analysis was performed by ELISA for
peptides VH and GL and scrambled peptide QS as the unspecific binding control C: Specific
binding of mAb 079 to peptide VH. D: Specific binding of mAb 079 to peptide GL. E:
Specific binding of mAb 621 to peptide GL.
A B
C D
E
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Supplementary Table 4.3. Main proteins hit by peptide VH in pBLAST.
Description Organism E value Accession Characteristics
1 ParB-like protein Providenciaalcalifaciens R90-1475 0.73 EUD09004.1
2 transcriptional regulator Providenciaalcalifaciens Dmel2 0.74 EKT62626.1
3 hypothetical proteinPTSG_05644 Salpingoeca rosetta 1.4 XP_004993512.1 Choanoflagellate
4 putative ADP-ribosylation/crystallin J1
Cronobacter phage
S13 4.7 AIA64848.1 Phage
5 methionyl tRNAsynthetase, cytoplasmic
Hymenolepis
microstoma 6.8 CDS25457.1
Intestinal dwelling parasite in the bile duct and small
intestines of mice and rats, rarely infects humans
6 RND transporter Pseudomonas sp.LAIL14HWK12:I7 9.2 WP_027594488.1
The best studied species include P. aeruginosa in its
role as an opportunistic human pathogen
7 putative methionine-tRNA synthetase Schistosoma mansoni 9.2 CCD78761.1 Significant parasite of humans, a trematode
8 PREDICTED: methionine--tRNA ligase, cytoplasmic Musca domestica 9.4 XP_005182375.1 Housefly
9
particulate methane
monooxygenase protein
A
Crenothrix polyspora 11 ABC59824.1
Filamentous bacteria which utilize iron in their
metabolism, and cause staining, plugging and taste
and odor problems in water systems.
10 hypothetical protein Streptomyces sp.NRRL B-24484 12 WP_030262153.1
Found predominantly in soil and decaying
vegetation. They are infrequent pathogens, though
infections in humans, such as mycetoma, can be
caused by S. somaliensis  and S. sudanensis
11 diguanylate cyclase Mycobacterium sp.MCS 12 ABG06477.1
Includes pathogens known to cause serious diseases
in mammals, including tuberculosis and the classic
Hansen's strain of leprosy.
12
planctomycete
cytochrome C domain
protein
Rhodopirellula sp.
SWK7 13 WP_009103602.1 Marine bacterium
13 beta-lactamase Enterobacter cloacae 15 WP_044858668.1and others
Member of the normal gut flora of many humans and
is not usually a primary pathogen. It is sometimes
associated with urinary tract and respiratory tract
infections.
14 NDP-glucosedehydratase Streptomyces sp. 275 16 AAR23325.1
Found predominantly in soil and decaying
vegetation. They are infrequent pathogens, though
infections in humans, such as mycetoma, can be
caused by S. somaliensis  and S. sudanensis
15 hypothetical protein Burkholderia glathei 16 WP_035939563.1KDR39482.1 Gram- soil bacterium. Pathogen for Asian Rice
16 beta-lactamase Enterobacter sp. 17 WP_042717670.1and others
Several strains of these bacteria are pathogenic and
cause opportunistic
infections in immunocompromised hosts
17 NDP-4-6-dehydratase Streptomyces sp. 275 17 AGG12562.1
Found predominantly in soil and decaying
vegetation. They are infrequent pathogens, though
infections in humans, such as mycetoma, can be
caused by S. somaliensis  and S. sudanensis
18 beta-lactamase
Enterobacter ludwigii
Enterobacter
asburiae
17
WP_040017771.1
KJP74682.1 and
others
Close to E.cloacae  but separate strains from clinical
specimens. Hospital-acquired infections
19 beta-lactamase Enterobacter mori 17 WP_041951418.1 Plant pathogen
20 general substratetransporter
Ophiostoma piceae
UAMH 11346 17 EPE06190.1 Fungus
21 OPT family smalloligopeptide transporter
Mortierella verticillata
NRRL 6337 17 KFH66298.1
Soil fungi. Mortierella wolfii (only), causes bovine
abortion, pneumonia and systemic mycosis
22 putativeglycosyltransferase Rubidibacter lacunae 23 WP_022604159.1
Unicellular, phycoerythrin-containing
cyanobacterium
23 hypothetical proteinB456_005G0190002 Gossypium raimondii 23 KJB27967.1 Cotton plant
24
PREDICTED: protein
trichome birefringence-
like 3
Cucumis melo 23 XP_008464204.1 Melon
25 hypothetical protein Lactobacillusfabifermentans 24 WP_024625239.1
Often involved in food fermentation. Lactobacillus
has been reported to be the causative pathogen in
many types of infection
26 hypothetical proteinB456_005G018900 Gossypium raimondii 24 KJB27963.1 Cotton plant
Associated with diarrhea in children and travelers. It
is found in the gastrointestinal tract.
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Supplementary Table 4.4. Main proteins hit by peptide GN in pBLAST.
Description Organism E value Accession Characteristics
1 hypothetical protein Actinoplanes sp. N902-109 81
WP_041833668.1
AGL16941.1 Produce pharmaceutically important compounds 
2 PREDICTED: contactin-6 Eptesicus fuscus 83 XP_008153220.1 Big brown bat
3 DNA-binding protein Microbacteriumketosireducens 101
WP_045276536.1
WP_018170430.1 Found in human clinical specimens
4 glucose-6-phosphate 1-dehydrogenase
Corynebacterium
maris 151 WP_020934819.1 Marine bacterium
5 hypothetical proteinHMPREF0623_0441
Pediococcus
acidilactici DSM 20284 171 EFL96390.1 Homofermentative bacterium
6 transcriptional regulator Lactobacillusfarciminis 184 WP_010020995.1 Potential for bacteriocin and antibiotic assay
7 methyltransferase Cedecea neteri 189 WP_039296343.1 Isolated in clinical specimens
8 hypothetical protein Nitratireductoraquibiodomus 190 WP_036540293.1
alpha-proteobacterium from the marine
denitrification
9 hypothetical protein Alcaligenes faecalis 194 WP_035272769.1
10 cupin Alcaligenes faecalis 196 WP_042481935.1
11 hypothetical protein Pseudomonasthermotolerans 199 WP_040640672.1 Not known to be pathogenic
12 HIT family hydrolase Streptococcus oralis 202 WP_033630192.1
Commensal bacteria (belongs to the Mitis group
which contains the human pathogen S. pneumoniae),
and is found in the human oral cavity. Opportunist
pathogen
13 MULTISPECIES:hypothetical protein Streptomyces 203 WP_030357946.1 Infections in humans can be caused
14 hypothetical proteinACD_77C00140G0015 uncultured bacterium 204 EKD32280.1
15 HIT family hydrolase Streptococcus infantis 204 WP_033685884.1and others Belongs to the Mitis group. Opportunist.
16 hypothetical proteins Candida albicans 205 KGR12292.1 andothers
Fungus. Opportunistic oral and genital infections in
humans
17 histidine triad protein Streptococcus infantisSK1076 205 EGL88114.1 Belongs to the Mitis group. Opportunist.
18 major facilitatortransporter
Nocardioides sp.
URHA0032 206 WP_028636268.1 Vibrio cholerae control
19 asparagine synthase Streptomyces sp.NRRL F-5727 206 WP_031010442.1 Infections in humans can be caused
20 HIT family hydrolase Streptococcus mitis 209 WP_004252756.1 Inhabits the human mouth
21 HIT family hydrolase Streptococcus peroris 209 WP_006145489.1 Belongs to the Mitis group. Opportunist. Clinicalspecimens
22 hypothetical proteinSK141_0919 Streptococcus oralis 209 KEQ46442.1
Commensal bacteria (belongs to the Mitis group
which contains the human pathogen S. pneumoniae),
and is found in the human oral cavity. Opportunist
pathogen
23 histidine triad protein Streptococcus sp.SK643 209 EIF39158.1 Infections in humans can be caused
24 hypothetical proteinDesmer_2846
Desulfosporosinus
meridiei DSM 13257 265 AFQ44752.1 Sulfate-reducing bacteria, found in soil
25 DeoR faimlytranscriptional regulator
Pseudomonas
fluorescens 275 WP_042732208.1 Pathogenesis not known
26 predicted protein
Thalassiosira
pseudonana
CCMP1335
277 XP_002291965.1 Marine centric diatom
Commonly found in the environment. Oportunist
infections and generally considered nonpathogenic
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Supplementary Table 4.5. Main proteins hit by peptide FI in pBLAST.
Description Organism E value Accession Characteristics
1 stage V sporulationprotein AF Tuberibacillus calidus 1.9 WP_027724421.1 Soil bacteria
2 hypothetical proteinB456_007G065400 Gossypium raimondii 12 KJB40466.1 Cotton
3 alcohol dehydrogenase Burkholderia glathei 12 WP_035934187.1 Asian rice pathogen. Other species are humanpathogens
4 hypothetical protein Gammaproteobacteria bacterium MFB021 17 WP_035470415.1 Pathogenic species within the group
5 hypothetical proteinMGU_06668
Metarhizium
guizhouense ARSEF
977
17 KID86235.1 Fungus
6 2'-5' RNA ligase Selenomonas sp.FC4001 21 WP_037352693.1 Gastrointestinal bacteria. Pathogenicity not proven
7 chlorophyll a/b-bindingprotein
Coccomyxa
subellipsoidea C-169 22 XP_005644739.1 Microalgae
8 histidine kinase Micromonospora sp.ATCC 39149 23 WP_007071575.1 Bacterium used to fight fungal infections in plants
9 metal ABC transporterATPase
Endozoicomonas
numazuensis 24 WP_034833803.1 Bacteria isolated from marine sponges
10 hypothetical proteinPIIN_01893
Piriformospora indica
DSM 11827 24 CCA68026.1 Cultivable Plant-Growth-Promoting Root Endophyte
11 PREDICTED: F-box/kelch-repeat protein At1g22040 Solanum lycopersicum 32 XP_004230575.1 Tomato
12 hypothetical protein Rhodopirellulamaiorica 32 WP_008700650.1 Marine bacterium
13 hypothetical proteinH696_00155 Fonticula alba 42 XP_009492265.1 Slime mold
14 Alcohol dehydrogenase,putative Ricinus communis 43 XP_002537752.1 Castor oil plant
15 hypothetical protein Trypanosoma cruzistrain CL Brener 45
XP_809502.1
XP_804727.1
Parasitic euglenoid protozoan. Causes Chagas’ disease
and sleeping sickness
16 hypothetical protein Pseudomonasamygdali 46 WP_010207465.1 Almond tree pathogen
17 hypothetical protein Fusobacteriumvarium 55 WP_005948124.1
Localized in the colonic mucosa of patients with
ulcerative colitis 
18 co-chaperone GrpE Leptospira kirschneri 56 WP_020762800.1and others
The species is pathogenic and can cause leptospirosis,
most commonly in pigs
19 co-chaperone GrpE Leptospira santarosai 56 WP_020766940.1 Pathogenic
20 co-chaperone GrpE Leptospirainterrogans 57
WP_017854508.1
and others
21 protein GrpE Leptospirainterrogans 57
WP_000829531.1
WP_000852393.1
22 co-chaperone GrpE Leptospiraborgpetersenii 57 WP_002748244.1 Humans are accidental hosts. Leptospirosis
23 abhydrolase domain-containing protein 4 Clonorchis sinensis 59 GAA32290.2 Chinese liver fluke. Parasites human livers.
24 hypothetical protein Lactobacillus crispatus 60 WP_035163946.1 Beneficial micro biota species
25 hypothetical proteinT265_10435 Opisthorchis viverrini 60 XP_009175071.1 Southeast Asian liver fluke. Causes opisthorchiasis.
26 hypothetical protein Fusobacteriumulcerans 60 WP_008695352.1 Cause tropical ulcers.
Humans are accidental hosts
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Supplementary Table 4.6. Main proteins hit by peptide GL in pBLAST.
Description Organism E value Accession Characteristics
1 hypothetical protein Hymenobacternorwichensis 1.7 WP_022823267.1
Newly defined bacteria isolated from the air in
Norwich, England
2
PREDICTED:
uncharacterized protein
LOC103374163
Stegastes partitus 30 XP_008302425.1 Fish
3 hypothetical protein Oceanobacillusiheyensis 33 WP_011064616.1 Isolated from deep sea sediment
4 hypothetical protein Oceanobacillus kimchii 33 WP_017795246.1 N/A
5 hypothetical proteinSAMD00019534_081110
Acytostelium
subglobosum LB1 51 GAM24936.1 Slime mold
6 hypothetical proteinPsta_1654
Pirellula staleyi DSM
6068 105 ADB16329.1 Water bacterium
7 putative ATPase (AAA+superfamily) Spirochaeta africana 110 WP_014455122.1 Non-pathogenic
8 hypothetical proteinDFA_02459
Dictyostelium
fasciculatum 111 XP_004366844.1 Soil-living amoeba. Slime mold
9 bZIP transcription factor29
Saccharum hybrid
cultivar CoC 671 136 AHZ96966.1 Sugarcane
10 hypothetical proteinCAPTEDRAFT_84087 Capitella teleta 147 ELU15435.1 Polychaete worm
11 hypothetical proteinPGTG_12583
Puccinia graminis f.
sp. tritici CRL 75-36-
700-3
148 XP_003332555.1 Plant pathogen. Fungi. Possible allergen.
12 PREDICTED: basic leucinezipper 9-like Setaria italica 148
XP_004951741.1
XP_004951740.1
XP_004951739.1
and others
Millet (cultured plant)
13
PREDICTED:
uncharacterized protein
LOC100192650 isoform X1
Zea mays 148 XP_008681056.1NP_001131334.1
14 BZO2H2 Zea mays 148 ACG31513.1
15 hypothetical proteinSEPMUDRAFT_76258
Sphaerulina musiva
SO2202 152 EMF16749.1 Fungi. Plant pathogen
16 hypothetical proteinACD_75C02113G0003 uncultured bacterium 153 EKD34949.1 N/A
17
PREDICTED:
uncharacterized protein
LOC103449949
Malus domestica 187 XP_008387494.1 Apple
18 hypothetical protein Nocardia jiangxiensis 196 WP_040823595.1 Soil actinomycetes. Some Nocardia cause infectionsin humans.
19 GTP cyclohydrolase Streptomycescellulosae 196 WP_030663047.1 Inhibits Gram positive bacteria 
20 aminoglycosidephosphotransferase
Mycobacterium sp.
JLS 203
WP_011855250.1
WP_011559205.1
Includes pathogens known to cause tuberculosis
and the Hansen's strain of leprosy.
21
restriction modification
system DNA specificity
domain protein
Desulfitobacterium
hafniense DCB-2 204 ACL21964.1 Environmental bacteria
22 hypothetical proteinL798_03101
Zootermopsis
nevadensis 207 KDR07320.1 Termite 
23 predicted protein Fibroporia radiculosa 208 CCM03831.1 Fungus
24 flagellar motor proteinMotB
Microbulbifer
variabilis 210 WP_040628820.1 Bacteria that produce anticancer antibiotics
25
glycoside/pentoside/hex
uronide:cation symporter
GPH family
Firmicutes bacterium
CAG:882 279 WP_022369591.1 Some are pathogenic
26 hypothetical proteinBAUCODRAFT_78015
Baudoinia
compniacensis UAMH
10762
280 XP_007680480.1 Sac fungus 
Corn
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Supplementary Figure 4.16. Burkitt lymphoma mAbs 3D frontal and lateral
representation. Heavy (blue) and light (yellow) chains, ABS (grey) and SpA (red) binding
residues are represented for A: case 079, B: case 589 and C: case 621. Left pictures are from the
ABS perspective and right pictures are lateral to the heavy chain.
A
B
C
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Supplementary Figure 4.17. A: Peptide VH with mAb 079, B: Peptide FI with mAbs
589 and C: 621, D: Peptide QS with mAb 589.
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By nuclear magnetic resonance the amino acids that had contacted the mAbs in
each test could be determined. Below is a summary of all contacts detected.
Table is continued on next page
Signal location
(ppm)
Irradiation at -540 Hz
Extinction (%)
Irradiation at 7110 Hz
Extinction (%) Amino acid
VH
 +
 0
79
10.185 0.71 0.54 9 W
10.075 0.39 0.42 3 W
7.209 0.44 0.37
9 W / 3 W
7.074 0.59 0.44
3.143 0.44 0.29 3 W
3.018 0.41 0.33 9 W
0.819 0.34 0.27 1 V
VH
 +
 5
89
7.455 0.71 0.54 9 W
7.259 0.39 0.42 5 F
7.209 0.44 0.37 9 W
7.074 0.59 0.44 9 W/3 W
3.143 0.44 0.29 3 W
3.018 0.41 0.33 9 W
0.819 0.34 0.27 1 V
FI
 +
 0
79
7.649 0.29 0.22
11 W7.512 0.42 0.20
7.498 0.42 0.20
7.358 0.20 0.15
1 F / 4 F7.346 0.27 0.15
7.334 0.32 0.15
7.257 0.43 0.24
11 W
7.243 0.49 0.24
7.206 0.23 0.17
1 F / 11 W7.177 0.40 0.13
7.164 0.41 0.22
2.746 0.18 0.33 5 D
2.114 0.38 0.08 7 M
2.080 0.23 0.05 9 M
1.935 0.07 0.40 9 M / 12 E
0.882 0.51 0.09
2 I
0.858 0.660 0.06
FI
 +
 5
89
7.663 0.23 0.18
11 W
7.649 0.15 0.24
7.512 0.15 0.24
7.498 0.17 0.12
7.369 0.19 0.14
7.346 0.19 0.14
7.218 0.12 0.12
7.206 0.18 0.15
0.903 0.39 n.a.
2 I
0.862 0.56 n.a.
FI
 +
 6
21
10.123 0.18 0.24
11 W
7.498 0.13 0.10
7.346 0.13 0.10
7.220 0.08 0.10
7.206 0.18 0.15
0.888 0.34 n.a. 02 I
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Table is continued on next page
Signal location
(ppm)
Irradiation at -540 Hz
Extinction (%)
Irradiation at 7110 Hz
Extinction (%) Amino acid
G
L 
+ 
07
9
8.085 0.15 0.22 10Y/9L
7.986 0.22 0.31 11L
7.105 0.24 0.22
10Y
6.818 0.27 0.26
4.205 0.24 0.17 7T / 9L
3.814 0.12 0.10 1G
3.068 0.17 0.10 3H / 12H /10Y
2.918 0.26 0.22 10Y
2.768 0.23 0.18 8N
1.493 0.35 0.16 2L / 9L /11L
1.427 0.24 0.12 6A
1.191 0.25 0.13 4T / 7T
0.886 0.36 0.18 11L
0.867 0.39 0.18 2L / 9L
0.806 0.41 0.18 9L
G
L 
+ 
58
9
8.163 0.13 1.02 4 T
8.119 0.17 0.33 7 T
8.077 0.20 1.14 10 Y / 9 L
7.584 0.08 0.20 8 N
7.121 0.37 0.51
10 Y6.847 0.40 0.49
6.833 0.44 0.47
4.395 0.28 0.29 2 L
4.297 0.40 0.30 7 T
4.246 0.43 0.32 11 L
3.926 0.27 0.21 5 S
3.849 0.22 0.16 1 G
3.217 0.19 0.12 3 H
3.140 0.20 0.20 12 H
3.078 0.36 0.23
10 Y
2.948 0.43 0.36
2.807 0.33 0.21 08 N
1.573 0.48 0.19 2 L
1.503 0.62 0.25
1.455 0.45 0.21 9 L / 11 L
1.443 0.46 0.20 6 A
1.220 0.52 0.21
4 T / 7 T1.208 0.46 0.18
1.197 0.40 0.16
0.925 0.66 0.26 2 L
0.895 0.76 0.30 11 L
0.885 0.67 0.27 2 L
0.845 0.81 0.36
11 L
0.816 0.81 0.32
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Supplementary Table 4.7. Amino acid contact summary of each peptide and antibody
NMR experiment. Signal location represents the x axis position of the signal peak in the proton
spectrum. The next two columns show the relative signal height (in percentage) for each
irradiation side (left at 7110Hz and right at -540 Hz). Amino acid notation is composed of its
position in number followed by its universal one-letter symbol, where 2 L is a leucine in
position 2 in the peptide.
Signal location
(ppm)
Irradiation at -540 Hz
Extinction (%)
Irradiation at 7110 Hz
Extinction (%) Amino acid
G
L 
+ 
62
1
7.857 0.51 0.45
11 L
7.831 0.48 0.50
7.131 0.53 0.47
10 Y
7.117 0.47 0.43
7.034 0.52 0.44 8 N
6.849 0.57 0.50 10 Y
6.835 0.61 0.48 1
4.238 0.44 0.36 11 L
3.791 0.37 0.30 1 G
3.162 0.35 0.25 3 H /  12 H
1.570 0.56 0.32
2 L
1.506 0.53 0.27
1.447 0.51 0.31 11 L / 9 L
1.222 0.49 0.27
4 T/ 7 T
1.188 0.48 0.33
0.916 0.58 0.30 2 L
0.887 0.61 0.32
11 L
0.832 0.65 0.37
Q
S 
+ 
58
9
7.615 0.28 0.24
1 Q / 9 Q/
4 W/ 8 W
(Aromatic)
7.601 0.24 0.14
7.582 0.24 0.22
7.569 0.25 0.19
7.521 0.33 0.16
4 W/ 8 W/
12 W/ 5 F/
NH2 (end)
(Aromatic)
7.500 0.32 0.19
7.480 0.28 0.21
7.466 0.35 0.21
7.311 0.24 0.14
7.254 0.31 0.22
7.234 0.37 0.28
7.217 0.24 0.16
7.175 0.28 0.15
7.128 0.26 0.18
7.117 0.17 0.13
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Final conclusions
This written compilation presents a series of scientific approaches to understand several
aspects of Burkitt lymphoma (BL) pathogenesis, with a focus on paediatric cases.
The first part reports on a new method for gene expression profiling of aggressive
B-cell lymphomas. The innovative aspect of the presented methodology is the fact that
instead of the usual and scarce fresh-frozen biopsy materials the more readily available and
numerous paraffin-embedded biopsy blocks can be used. Together with the latter, the
protocol described avoids amplification bias of genetic material and is able to count
individual molecules in an absolute way, where previously mRNA had to be amplified and
its quality inferred. A further validation of the newly generated B-cell lymphoma classifiers
is manifested in the second publication of this thesis, which focuses on uncommon BCL2-
expressing BL. We describe a good commercially available immunohistochemical marker
for BCL2 and assess the amount of BL cases presenting the protein’s expression. More
related to other lymphomas, BCL2 expression is confirmed in BL, where its presence is not
enough to change the molecular labelling of a BL expressing it. We confirm that a poorer
outcome is not seen in BCL2-expressing BL as in other BCL2-positive lymphoma entities.
B-cell lymphoma immunoglobulin expression bias is reviewed, including previously
unpublished data of such phenomenon in BL. Moreover, a specific mutation occurring in
codon 64 of the heavy chain sequence in BL BcRs is modelled in 3D. The conformational
changes of the antigen-binding site of the antibody upon reversion of said mutation to its
germline sequence are presented. Possible antigenic peptides of the 3 analysed BL mAb are
newly determined and characterised as of putative alimentary or pathogenic origin. By
reversion of the CDR2 mutation it is demonstrated that the stereotyped change present in
BL cases is relevant for antigenic binding localisation.
Burkitt lymphoma survival in the western world is overall 70-80% with today
therapeutic regimens, but relapsed cases tend to have a much worse prognosis, with a five-
year overall survival of 21%-42%[1]. In the last decades a substantial improvement in
outcome has been seen with the implementation of monoclonal antibody therapies (like
rituximab). With outcomes starting to reach a cure plateau and expected to even slightly
improve in the near future with personalised therapy, a fresh interest in prevention and
aetiology in B-cell lymphoma is being developed [2]. Targeted therapies are still a hope for
BL patients in Africa, where intensive chemotherapeutic regimens are hard to implement
[3].
FINAL CONCLUSIONS
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For BL in particular and B-cell lymphomas in general, new efforts in risk
assessment combined with aetiology studies and improved prevention policies could bend
the actual static rate of newly diagnosed lymphatic neoplasms per year.
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Annex
Primer Tables
Amplification primers
Table P1. Amplification primers for the three Burkitt lymphoma cases analysed.
HEAVY CHAINS
MPI-079 (IGV4-39*01; IGHD2-2*02; IGHJ3*01)
VH4-39-for1: 5'-GGTCCAACTCATAAGGGAAATG-3'
VH4-39-for2: 5'-CTTAAATTCAGGTCCAACTCATA-3'
VH4-39-for3: 5'-GGGAAATGCTTTCTGAGAGTCA-3'
JH3-01-rev1: 5'-CTGAAGAGACGGTGACCATTG-3'
MPI-589 (IGV4-39*01; IGHD6-13*01; IGHJ6*04)
VH4-39-for1: 5'-GGTCCAACTCATAAGGGAAATG-3'
VH4-39-for2: 5'-CTTAAATTCAGGTCCAACTCATA-3'
VH4-39-for3: 5'-GGGAAATGCTTTCTGAGAGTCA-3'
JH6-04-rev1: 5'-TCTTACCTGAGGAGACGGTGACCG-3'
JH6-04-rev2: 5'-TCTTACCTGAGGAGACGGTGA-3'
JH6-04-rev3: 5'-TCTTACCTGAGGAGACGGTG-3'
MPI-621 (IGV4-39*07; IGHD4-4*01; IGHJ3*01)
VH4-39-for1: 5'-GGTCCAACTCATAAGGGAAATG-3'
VH4-39-for2: 5'-CTTAAATTCAGGTCCAACTCATA-3'
VH4-39-for3: 5'-GGGAAATGCTTTCTGAGAGTCA-3'
JH3-01-rev1: 5'-CTGAAGAGACGGTGACCATTG-3'
LIGHT CHAINS
MPI-079 (IGLV3-12*01 and IGLV1-51*02)
VL3-12-for1: 5'-GCCTCAGCCATGGCCTGGA-3'
VL1-51-for1: 5'-CAGGACTCGGGACAATCTTCA-3'
JLcons-rev1: 5'-CTAGGACGGTCAGCTTGGTCCC-3'
MPI-589 (IGKV3-20*01)
VK-3-20-for1: 5'- CTGCTCAGTTAGGACCCAGA-3'
JK2-01-rev1: 5'- GTTTGATCTCCAGCTTGGTCCC-3'
MPI-621 (IGLV1-47*02)
VL1-47-for1: 5'-AGGATTCAGGACAATCTCCAGC-3'
VL1-47-for2: 5'-GATTCAGGACAATCTCCAGC-3'
JLcons-rev1: 5'-CTAGGACGGTCAGCTTGGTCCC-3'
ANNEX
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Primer combinations
Table P2. Primer combinations used to produce an amplified IGH cDNA fragment.
Ig subtype primers
Table P3. Primers used to determine the 3 studied BL isotype.
Primer name Sequence
FW 079 amplification 5’-AAGCTGACGTCTGTGACTGC-3’
FW 589+621 amplification 5’-ACACGTCCAAGAACCAGTTC-3’
RW membrane amplification 5’-CTTGAACAAGGTGACGGTGG-3’
RW secretion amplification 5’-AGTAGCAGGTGCCAGCTGTG-3’
FW 079 sequencing 5’-GACACGGCTGTGTATTACTG-3’
FW 589 sequencing 5’-GAGGCTGAGCTCTGTGACC-3’
FW 621 sequencing 5’-TGAAGCTGAACTCTGTGACC-3’
RW membrane sequencing 5’-AGAAGAGGCTCAGGAGGAAG-3’
RW secretion sequencing 5’-CATGACCAGGGACACGTTG-3’
HE
AV
Y
MPI-079
VH4-39-for1 JH3-01-rev1
VH4-39-for2 JH3-01-rev1
VH4-39-for3 JH3-01-rev1
MPI-589
VH4-39-for1 JH6-04-rev1
VH4-39-for2 JH6-04-rev1
VH4-39-for3 JH6-04-rev1
VH4-39-for1 JH6-04-rev2
VH4-39-for2 JH6-04-rev2
VH4-39-for3 JH6-04-rev2
VH4-39-for1 JH6-04-rev3
VH4-39-for2 JH6-04-rev3
VH4-39-for3 JH6-04-rev3
MPI-621
VH4-39-for1 JH3-01-rev1
VH4-39-for2 JH3-01-rev1
VH4-39-for3 JH3-01-rev1
LI
GH
T
MPI-079
VL3-12-for1 JLcons-rev1
VL1-51-for1 JLcons-rev1
MPI-589 VK-3-20-for1 JK2-01-rev1
MPI-621
VL1-47-for1 JLcons-rev1
VL1-47-for2 JLcons-rev1
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Overhang primers
Table P4. Green nucleotides (nt) mark the overhangs to be inserted. Red are new
restriction sites. Blue mark ATG start codons for translation. In orange are added nt to
maintain an appropriate reading frame.
Sequencing primers
Table P5. Primers used for general vector sequencing
MCS mutation primers
Table P6. Multiple cloning site mutation primers
Heavy chain Light chain
079
forward
5'-GCTGAGGAATTCGAGA
GTCATGGATCTCATGTG-3'
5'-GTTGACGAATTCTCAT
CATGACCTGCTCCCCT-3'
079
reverse
3'-ACCAGTGGCAGAGGAG
TCCACGATCGGAGATG-5'
3'-TCGACTGGCAGGATCC
AGTCCTTAAGTCAACC-5'
589
forward
5'-GCTGAGGAATTCGAGA
GTCATGGATCTCATGTG-3'
5'-CGACACGAATTCGGAA
CCATGGAAACCCCAGCG-3'
589
reverse
3'-ACCAGTGGCAGAGAAG
TCCACGATCGGTGAGG-5'
3'-CCTGGTTCGACCTCTAG
TTTGCTTAAGGTGAAC-5'
621
forward
5'-GCTGAGGAATTCGAGA
GTCATGGACCTCCTGT-3'
5'-AAGTGCGAATTCCCAG
CATGGCCGGCTTCCCT-3'
621
reverse
3'-ACCAGTGGCAGAGAAG
TCCACGATCGGTGAGG-5'
3'-CAGTCGCAGGATCCAG
TTCCTCTTAAGTCAACC-5'
Primer name Sequence
Heavy sequencing forward 5’-GCGCCGTTACAGATCCAAGC-3’
Heavy sequencing reverse 5’-ACAGGGGCCAGTGGATAGAC-3’
Light sequencing forward 5’-GTTACAGATCCAAGCTGTGAC-3’
Light sequencing reverse 5’-GAAGGTGGAAACAGGGTGAC-3’
Heavy chains
079 forward 5’-GGTCACCGTCTCCTCAGCTAAAACAACAGC-3’
079 reverse 5’-GCTGTTGTTTTAGCTGAGGAGACGGTGACC-3’
589 and 621 forward 5’-GGTCACCGTCTCTTCAGCTAAAACAACAGC-3’
589 and 621 reverse 5’-GCTGTTGTTTTAGCTGAAGAGACGGTGACC-3’
Light chains
079 forward 5’-CAAGCTGACCGTCCTAGGCCAGCCCAAGTCTTC-3’
079 reverse 5’-GAAGACTTGGGCTGGCCTAGGACGGTCAGCTTG-3’
589 forward 5’-CAAGCTGGAGATCAAAGGCCAGCCCAAGTCTTC-3’
589 reverse 5’-GAAGACTTGGGCTGGCCTTTGATCTCCAGCTTG-3’
621 forward 5’-CAAGGTCAGCGTCCTAGGCCAGCCCAAGTCTTC-3’
621 reverse 5’-GAAGACTTGGGCTGGCCTAGGACGCTGACCTTG-3’
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Buffer and reactions list
PCR reaction set-up
5µl of 5x Kapa HiFi buffer
0.5µl of dNTPs (10mM each)
0.5µl of primer FW (10pmol)
0.5µl of primer RW (10pmol)
0.5µl of Kapa HiFi Polymerase
200ng of cDNA template
Add H2O to 25µl of total volume
Sequencing reaction set-up
4µl of 5x sequencing buffer
2µl of premix
0.5µl of 10pmol/µl forward or reverse primer
40ng of the cleaned PCR sample
Add H2O to 20µl of total volume
Enzimatic restriction reaction
0,3µl of restriction enzyme at 20U/µl
1,5µl of 10x restriction buffer
1µl of 20mg/ml BSA
500ng of plasmid DNA
Add H2O to 15µl
Lysis buffer for protein extraction
100ml of PBS
2ml of triton
0.4ml of 0.25 M EDTA
IgG purification buffers
Binding buffer
20mM of monosodium phosphate (NaH2PO4) at pH7
Elution buffer
100mM of glycine (C2H5NO2) at pH2.7
Neutralisation buffer
1M of TrisHCl at pH9.0
It is used in 1/10 of the final elution volume.
Western blots
Loading dye, 6x
0.35 M Tris-HCl
10.28% SDS
36% glycerol
5% -mercaptoethanol
0.012% bromophenol blue
Temp. Time
96°C 20sec
60°C 4min
10°C ∞
x 27
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10x TBS
24.2gr trizma
80gr NaCl
H2Odest. to 1l, pH7.6
TBST
1x TBS
0.01% tween-20
Transfer buffer
14.4gr glycine
3gr trizma
200ml methanol
H2Odest. to 1l
Blocking buffer
1x TBST
5% milk powder
Stripping buffer
7.57gr Tris
20gr SDS
H2Odest. to 1l, pH 6.7. Store withoutmercaptoethanol.
Add 6.98 ml of -mercaptoethanol when stripping.
Phage display
PEG/NaCl solution
14.6gr NaCl (2.5M final)
20gr PEG 8000 (20% final)
100ml of H2O, autoclave
Iodide buffer
10mM of TrisHCl, pH8
1mM of EDTA
29,92gr of NaI (4M)
Autoclave and store at RT, in the dark
Tris-HCl solution
1M TrisHCl, pH9
IPTG/Xgal
1.25gr IPTG
1gr Xgal
25ml N,N-Dimethylformamide
Filtered through 0.22µm, stored at -20°C
1ml of this stock is used per liter of LB agar plates
Wash solution
1x TBST
Tween quantities: 0.1% for 1st and 0.5% for the 2nd and 3rd pannings
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ELISA
Carbonate buffer, 0.05M
5.3gr of Na2CO3
5.04gr of NaHCO3
100ml H2O
pH 9.3-9.6
Wash buffer
1x PBS
0.05% tween-20
Filtered through 0.22µm membrane
Blocking buffer
1x PBS
0.05% tween-20
5% milk powder
Stopping reagent
H2SO4 in 0.5M
For immunohistochemical stainings
Wash buffer
9,0 gr Tris-Base (Sigma)
68,5 gr Tris HCl (Sigma)
87,8 gr NaCl (Merck)
ad  10 l  dest. H2O
and 5 ml Tween 20(Merck)
Citrate buffer
10mM, pH 6.0
10,5 gr citric acid monohydrate
mix with ca. 65 ml NaOH (2N)
Methanol H2O2
200ml Methanol with 6-8 ml H2O2 dest (1x)
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Vectors
pCR2.1 vector
pmaxGFP vector
ANNEX
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pFUSE-CHIg-mG2a vector
pFUSE-CLIg-ml1 vector
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Material List
Product Type Reference Company Company location Country
10x DPBS M 14200-067 Thermo Fischer Scientific Waltham USA
10X NEBuffer  M B7002S New England Biolabs Ipswich USA
10x TAE buffer for M CL86.1 Carl Roth GmBH Karlsruhe Germany
1-Step™ Ultra TMB-ELISA
Substrate Solution M 34028 Thermo Fischer Scientific Waltham USA
5x sequencing buffer for BigDye
Terminator M 4339843 Thermo Fischer Scientific Waltham USA
6-well culture plates M 83.392 Sarstedt Nümbrecht  Germany
ABI PRISM® Genetic Analyzer E 3500 Life Technologies Carlsbad USA
Agar powder M 05040-1-KG Sigma-Aldrich Saint Louis, MO USA
Agarose (electrophoresis grade) M 15510-027 Thermo Fischer Scientific Waltham USA
Agilent RNA 6000 Nano Kit M 5067-1511 Agilent Technologies Santa Clara, CA USA
Alkaline Phosphatase M M0290S New England Biolabs Ipswich USA
Amaxa electroporator machine E Nucleofector I Lonza Basel Switzerland
Amaxa® Cell Line Nucleofector®
Kit V M VCA-1003 Lonza Basel Switzerland
Amersham Hybond-P PVDF
membrane M 10600021  GE Healthcare Little Chalfont UK
Amicon® Ultra-4 Centrifugal
Filter Units M UFC803024 Merck-Millipore Darmstadt Germany
Ampicilin sodium salt M A9518-5G Sigma-Aldrich Saint Louis, MO USA
Anti-Bcl-2 antibody M Clone 100-D5 Dako, Agilent Technologies Santa Clara, CA USA
Anti-Bcl-2 antibody M Clone E17 Zytomed Berlin Germany
Anti-CD10 M PA0270 Leica Wetzlar Germany
Anti-CD20 M CD20-L26-L-CE Leica Wetzlar Germany
Anti-Ki67 M PA0230 Leica Wetzlar Germany
Anti-lambda light chain antibody M ab74316 Abcam Cambridge UK
Aquatex M 1085620050 Merck Kenilworth, NJ USA
Bacterial culture plates M 821,472,001 Sarstedt Nümbrecht  Germany
BigDye® Terminator v1.1 Cycle
Sequencing Kit M 4337450 Thermo Fischer Scientific Waltham USA
Bio Fotometer 8.5mm E RS323C Eppendorf Hamburg Germany
Bioanalyzer E 2100 Agilent Technologies Santa Clara, CA USA
BioRad Universal Hood for gel
pictures E SN75S BioRad Hercules, CA USA
Blasticidin powder M ant-bl-10p InvivoGen San Diego USA
β-mercaptoethanol M M6250-250ML Sigma-Aldrich Saint Louis, MO USA
Bromophenol blue M 114391-25G Sigma-Aldrich Saint Louis, MO USA
BSA, molecular biology grade M B9000S New England Biolabs Ipswich USA
C-Chip Neubauer Improved M DHC-NO1 PeqLab Erlangen Germany
Cell culture incubator with
copper chambers E Heracell™ 150i Thermo Fischer Scientific Waltham USA
Centrifuge E Varifuge RF Heraeus Hanau Germany
Centrifuge eppendorf
microtubes 0.5ml M 72.735.002 Sarstedt Nümbrecht  Germany
Centrifuge eppendorf
microtubes 1.5ml M 72.690.001 Sarstedt Nümbrecht  Germany
Centrifuge eppendorf
microtubes 2.0 ml M 72.695.200 Sarstedt Nümbrecht  Germany
Centrifuge for 500ml bottles E J-6B Beckman Coulter Brea, CA USA
Citric acid monohydrate M 1.00244.100 Merck Kenilworth, NJ USA
CodeSet, custom M N/A NanoString Technologies Inc.Seattle USA
cOmplete Protease Inhibitor
Cocktail Tablets M 11697498001 Roche Basel Switzerland
Coverslips 22mm, sterile M 83.1840.001 Sarstedt Nümbrecht  Germany
Culture bottle large M 83.3912.002 Sarstedt Nümbrecht  Germany
Culture bottle medium M 83.1813.002 Sarstedt Nümbrecht  Germany
Culture bottle small M 83.1810.002 Sarstedt Nümbrecht  Germany
Culture plates M 83.3902 Sarstedt Nümbrecht  Germany
CutSmart® Buffer M B7204S New England Biolabs Ipswich USA
Cycler 5402 E N/A Eppendorf Hamburg Germany
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Cytospin machine, Shandon E Cytospin3 Thermo Fischer Scientific Waltham USA
DAB+, Liquid M K3468 Dako, Agilent Technologies Santa Clara, CA USA
DAPI M D1306 Thermo Fischer Scientific Waltham USA
Dialysis tubing cellulose M D9527-100FT Sigma-Aldrich Saint Louis, MO USA
Digital Analyzer 2GEN E N/A NanoString Technologies Inc.Seattle USA
Discovery Studio Visualizer S v 4.1.0.14169 Accelrys Software Inc.-Biovia-San Diego, CA USA
DMSO (Dimethyl Sulphoxide) M D2438 Sigma-Aldrich Saint Louis, MO USA
DpnI restriction enzyme M ER1701 Thermo Fischer Scientific Waltham USA
E. coli  K12 ER2738 M N/A New England Biolabs Ipswich USA
EcoRI restriction enzyme M R0101S New England Biolabs Ipswich USA
Ethylenediaminetetraacetic acid
(EDTA) M E9884-500G Sigma-Aldrich Saint Louis, MO USA
ExpressArt FFPE Clear Total
RNAready kit FFPE M 9009-A100 AmpTec Hamburg Germany
EZ-Link™ Micro Sulfo-NHS-LC-
Biotinylation Kit M 21935 Thermo Fischer Scientific Waltham USA
Falcon tubes, 15ml M 62.554.502 Sarstedt Nümbrecht  Germany
Falcon tubes, 50ml M 62.547.004 Sarstedt Nümbrecht  Germany
FBS (Fetal Bovine Serum) M 10270-098 Thermo Fischer Scientific Waltham USA
Fisherbrand™ Filter Cards for M 22-030-410 Thermo Fischer Scientific Waltham USA
Fixogum M 290117000  Marabu Stuttgart Germany
Fluorescent microscope E Axioplan 2 Carl Zeiss Oberkochen Germany
Folded Filters M 10311643 Sigma-Aldrich Saint Louis, MO USA
Glycerol M G5516-500ML Sigma-Aldrich Saint Louis, MO USA
Glycine (C2H5NO2) M 50046 Sigma-Aldrich Saint Louis, MO USA
Goat Anti-Mouse IgG2a heavy
chain (HRP) M ab97245 Abcam Cambridge UK
Goat anti-mouse lambda chain M A90-121A Bethyl Laboratories Inc. Montgomery, TX USA
GraphPad Prism S v 5.03 GraphPad Softeare, Inc. La Jolla, CA USA
Greiner CELLSTAR® 96 well M M3562-60EA Sigma-Aldrich Saint Louis, MO USA
H2SO4 M 258105-500ML- Sigma-Aldrich Saint Louis, MO USA
HEK-293 cells M ACC 305 DSMZ Braunschweig Germany
HiTrap columns, 5ml columns M 29-0588-06 GE Healthcare Little Chalfont UK
HRP anti-M13 monoclonal
conjugate M 27-9421-01 GE Healthcare Little Chalfont UK
HRP-goat anti-rabbit IgG (H+L) M 111-035-003 Jackson ImmunoResearch West Grove, PA USA
HRP-rabbit anti-goat IgG (H+L) M 305-035-003 Jackson ImmunoResearch West Grove, PA USA
HRP-rabbit anti-mouse IgG+IgM
(H+L) M 315-035-044 Jackson ImmunoResearch West Grove, PA USA
IgG2a isotype control M ab18414 Abcam Cambridge UK
IgG2amouse isotype control M 401501 BioLegend Sant Diego, CA USA
IHC Select ® Citrate Buffer pH 6.0 M 21545 Merck Kenilworth, NJ USA
IPTG Dioxane free, 2gr M AM9462 Thermo Fischer Scientific Waltham USA
Isopropanol M I9516 Sigma-Aldrich Saint Louis, MO USA
Kanamycin M K4378 Sigma-Aldrich Saint Louis, MO USA
Kapa HiFi PCR Kit M 07-KK2100-01 Peqlab Erlangen Germany
Lab Vision™ UltraVision™ LP
Detection M TL-060-AL Thermo Fischer Scientific Waltham USA
LB powder M L3022-1KG Sigma-Aldrich Saint Louis, MO USA
Lipofectamine 2000 Reagent M 11668-030 Thermo Fischer Scientific Waltham USA
Luminometer E Synergy HT Biotek Winooski, VT USA
Mab Trap kit, 1ml columns M 17-1128-01 GE Healthcare Little Chalfont UK
Mayer's hemalum solution M 1092490500 Merck Kenilworth, NJ USA
Methanol M 8045 JT Baker Center Valley, PA USA
Microscope slides M 1000612 Marienfeld Lauda Königshofen Germany
Milk Powder, Blotting Grade M 170-6404 BioRad Hercules, CA USA
Millex-GP Syringe Filter Unit, M SLGP033RS Merck-Millipore Darmstadt Germany
Monoclonal Mouse Anti-Human.
CD20 M M075529-2 Dako, Agilent Technologies Santa Clara, CA USA
Monosodium phosphate M S5011-500G Sigma-Aldrich Saint Louis, MO USA
Mounting medium M S3023 Dako, Agilent Technologies Santa Clara, CA USA
Mouse monoclonal anti-beta M A5441-2ml Sigma-Aldrich Saint Louis, MO USA
MultiMark® Multi-Colored M LC5725 Thermo Fischer Scientific Waltham USA
N,N-Dimethylformamide (DMF) M D4551-500ML Sigma-Aldrich Saint Louis, MO USA
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NanoDrop 2000 E ND-2000c-PC Thermo Fischer Scientific Waltham USA
NativeMark™ Unstained Protein
Standard M LC0725 Thermo Fischer Scientific Waltham USA
NativePAGE™ 20x Cathode
Buffer Additive M BN2002 Thermo Fischer Scientific Waltham USA
NativePAGE™ 20x Running M BN2001 Thermo Fischer Scientific Waltham USA
NativePAGE™ Novex® 4-16% Bis-
Tris Protein Gels M BN1002BOX Thermo Fischer Scientific Waltham USA
NativePAGE™ Running Buffer Kit M BN2007 Thermo Fischer Scientific Waltham USA
NativePAGE™ Sample Buffer M BN2003 Thermo Fischer Scientific Waltham USA
Natrium hydroxide 2N M 1091361000 Merck Kenilworth, NJ USA
NeutrAvidin 96-well plate M 15129 Thermo Fischer Scientific Waltham USA
NheI restriction enzyme M R0131S New England Biolabs Ipswich USA
NucleoSEQ® columns M 740523250 Macherey-Nagel Düren Germany
NucleoSpin® Extract II Kit M 636972 Macherey-Nagel Düren Germany
NucleoSpin® Gel and PCR Clean-
up kit M 740.609.250 Macherey-Nagel Düren Germany
Nunc Immobilizer Streptavidin
F96 Clear M 436014 Thermo Fischer Scientific Waltham USA
Nunc MaxiSorp® flat-bottom 96
well plate M 44-2404-21 Affymetrix Santa Clara, CA USA
NuPAGE Bis-Tris Mini 4-12% gels M NP0321BOX Thermo Fischer Scientific Waltham USA
NuPAGE® MES SDS Running
Buffer (20X) M NP0002 Thermo Fischer Scientific Waltham USA
One Shot® TOP10 Chemically
Competent E. coli M C4040-03 Thermo Fischer Scientific Waltham USA
Opti-MEM® I Reduced Serum M 31985-070 Thermo Fischer Scientific Waltham USA
pAdVAntage™ Vector M E1711 Promega Madison USA
Penicillin-Streptomycin M 15140-122 Thermo Fischer Scientific Waltham USA
peqGOLD Plasmid Miniprep Kit II M 12-6945-02 Peqlab Erlangen Germany
Permanent AP Red Kit, colour
development M ZuC001-125 Zytomed Berlin Germany
Pertex M 41-4041-00 Medite Orlando, FL USA
pFUSE2-CLIg-mI1 M pfuse2-mcll1 InvivoGen San Diego USA
pFUSE-CHIg-mG2a M pfuse-mchg2a InvivoGen San Diego USA
PhD12 phage library kit M E8110S New England Biolabs Ipswich USA
Phenol – chloroform – isoamyl
alcohol mixture M 77617-500ML Sigma-Aldrich Saint Louis, MO USA
Pipette tips low protein bind, 0.5-
10ul M 732824 Brand GmBH Wertheim Germany
Pipette tips low protein bind, 50-
1000ul M 732834 Brand GmBH Wertheim Germany
Pipettes, 10ml M 86.1284.001 Sarstedt Nümbrecht  Germany
Pipettes, 25ml M 86.1685.001 Sarstedt Nümbrecht  Germany
Pipettes, 5ml M 86.1253.001 Sarstedt Nümbrecht  Germany
pmaxGFP® M N/A Lonza Basel Switzerland
Polyethylene glycol 8000 (PEG) M 1546605-1G Sigma-Aldrich Saint Louis, MO USA
Polyvalent centrifuge 5430R E N/A Eppendorf Hamburg Germany
PonceauS solution M P7170-1L Sigma-Aldrich Saint Louis, MO USA
Premix Buffer Concentrate M 401446 Thermo Fischer Scientific Waltham USA
PrepStation 2GEN E N/A NanoString Technologies Inc.Seattle USA
Primers (general) M N/A Eurogentec Liège Belgium
Protein glycerol M P049.1 Carl Roth GmBH Karlsruhe Germany
Protein LoBind tubes, 1.5ml M 30108.116 Eppendorf Hamburg Germany
PureLink® Quick Plasmid
Miniprep Kit M K2100-10 Thermo Fischer Scientific Waltham USA
PyMOL S v 1.7.4.5 Schrödinger, LLC New York, NY USA
QIAquick PCR Purification Kit  M 28106 QIAgen Venlo Netherlands
Qubit asssay tubes M Q32856 Thermo Fischer Scientific Waltham USA
Qubit fluorometer E v 2.0 Thermo Fischer Scientific Waltham USA
Qubit® dsDNA BR Assay Kit M Q32850 Thermo Fischer Scientific Waltham USA
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Qubit® Protein Assay Kit M Q33211 Thermo Fischer Scientific Waltham USA
QuikChange II Site-Directed
Mutagenesis Kit M 200523 Agilent Technologies Santa Clara, CA USA
Rabbit anti-bovine IgG, IgM, IgA M SA1-36042 Thermo Fischer Scientific Waltham USA
Rabbit anti-mouse IgG2a heavy
chain, 1ml M 61-0200 Thermo Fischer Scientific Waltham USA
RNAse free tubes, 0.5ml M AM12300 Thermo Fischer Scientific Waltham USA
RNAse free tubes, 1.5ml M AM12400 Thermo Fischer Scientific Waltham USA
RNAse free tubes, 2.0ml M AM12475 Thermo Fischer Scientific Waltham USA
RNeasy Mini Kit M 74104 QIAgen Venlo Netherlands
Rotilabo®-syringe filters PVDF,
sterile M P666.1 Carl Roth GmBH Karlsruhe Germany
RPMI medium M 21875-034 Thermo Fischer Scientific Waltham USA
Scrapers M 83.1831 Sarstedt Nümbrecht  Germany
SimplyBlue SafeStain M LC6060 Thermo Fischer Scientific Waltham USA
SnakeSkin Dialysis Tubing Clips M 68011 Thermo Fischer Scientific Waltham USA
Sodium acetate M S2889-250G Sigma-Aldrich Saint Louis, MO USA
Sodium bicarbonate (NaHCO3) M S6014-500G Sigma-Aldrich Saint Louis, MO USA
Sodium carbonate (Na2CO3) M 223484-500G Sigma-Aldrich Saint Louis, MO USA
Sodium chloride M S3014-5KG Sigma-Aldrich Saint Louis, MO USA
Sodium dodecyl sulfate (SDS) M L3771 Sigma-Aldrich Saint Louis, MO USA
Sodium iodide (NaI) M 383112-500G Sigma-Aldrich Saint Louis, MO USA
Stericup-GV, 0.22 µm M SCGVU05RE Merck-Millipore Darmstadt Germany
SuperScript® First-Strand
Synthesis System for RT-PCR M 11904-018 Thermo Fischer Scientific Waltham USA
Synthetic peptides M N/A Eurogentec Liège Belgium
Syringes, 5ml M 302187 BD Plastipak Plymouth, MI USA
T4 DNA Ligase Reaction Buffer M B0202S New England Biolabs Ipswich USA
T4 ligase M M0202S New England Biolabs Ipswich USA
Target(10x) M S1699 Dako, Agilent Technologies Santa Clara, CA USA
TC-plate 96 well, Suspens. K M 83.3926.500 Sarstedt Nümbrecht  Germany
TE buffer pH8.0 M AM9849 Thermo Fischer Scientific Waltham USA
Tetracyclin M 87128-25G Sigma-Aldrich Saint Louis, MO USA
TissueQuest S v3.0 TissueGnostics Vienna Austria
TOPO TA Cloning® Kit (pCR™2.1
Vector and One Shot® E. coli) M K2000-01 Thermo Fischer Scientific Waltham USA
TransIT®-293 Transfection M MIR 2705 Mirus Madison, WI USA
Triethylamine [(C2H5)3N] M 90335-250ML Sigma-Aldrich Saint Louis, MO USA
Tris M T1503 Sigma-Aldrich Saint Louis, MO USA
Tris-HCl M PHG0002-100G Sigma-Aldrich Saint Louis, MO USA
Triton, for molecular biology M T8787-250ML Sigma-Aldrich Saint Louis, MO USA
Trizma® base M T1503-1KG Sigma-Aldrich Saint Louis, MO USA
Trypan Blue Solution, 50ml M 93595 Sigma-Aldrich Saint Louis, MO USA
Turbo Blotter GB-Set Blotting M 55482300 Sigma-Aldrich Saint Louis, MO USA
Tween-20 M P2287-500ML Sigma-Aldrich Saint Louis, MO USA
Ultra Low IgG FBS (Fetal Bovine
Serum) M 16250-078 Thermo Fischer Scientific Waltham USA
VWR Disposable Spatulas M 231-0103 VWR Tingalpa Australia
X-Gal 99% 5g M 2315.4 Carl Roth GmBH Karlsruhe Germany
Zeocin M R25001 Thermo Fischer Scientific Waltham USA
M, Material; E, Equipment; S, Software
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